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iThe Global SMART Programme
UNODC launched the Global Synthetics Monitoring: 
Analyses, Reporting and Trends (SMART) Programme 
in September 2008. The Programme seeks to enhance 
the capacity of Member States and authorities in 
priority regions, to generate, manage, analyse and 
report synthetic drug information, and to apply 
this scientific evidence-based knowledge to design 
the policies and programmes. The Global SMART 
Programme is being implemented in a gradual phased 
manner, with East Asia being the first focus priority 
region. Operations in Latin America started in 2011. 
This report is the first global situation assessment 
on new psychoactive substances put forward under 
the Global SMART Programme and pursuant to 
Commission on Narcotic Drugs Resolution 55/1 on 
“Promoting international cooperation in responding 
to the challenges posed by new psychoactive 
substances”, which requested the United Nations 
Office on Drugs and Crime to provide an update to 
its 2011 report entitled “Synthetic cannabinoids in 
herbal products”, addressing a wider range of new 
psychoactive substances, in addition to synthetic 
cannabinoids, and to take into consideration the 
creation of a compilation of new psychoactive 
substances encountered by Member States, to serve as 
an early warning advisory.
It constitutes the first step in providing consolidated 
up to-date analysis, based primarily on the information 
shared by Member States and the International 
Collaborative Exercise network of drug analysis 
laboratories. It is hoped that the information on 
new psychoactive substances presented in this report 
will make a practical contribution to addressing the 
significant threat posed by the manufacture, trafficking 
and use of these substances throughout the world, and 
place policymakers in a better position to evaluate the 
drug situation, and to make informed decisions on 
intervention and prevention strategies. 
This report provides an overview of the situation 
throughout the world. It outlines the emergence of 
different groups of new psychoactive substances in the 
regions and  highlights several key issues associated 
with these substances, including reported adverse 
effects associated with their use, the challenges for 
the identification of these substances and their 
subsequent control through legislation. While the 
information presented points towards increasing 
efforts by the countries to address the NPS problem, 
it also highlights the need for continued and joint 
efforts, both at the national as well as regional levels. 
It is hoped that this report will contribute to a better 
understanding of the NPS problem and in developing 
effective strategies to address it.
ii
Abbreviations
2-AI 2-Aminoindane
3-MeO-PCE 3-Methoxyeticyclidine
4-AcO-DiPT 4-Acetoxy-N,N-diisopropyltryptamine
4-AcO-DMT 4-Acetoxy-N,N-dimethyltryptamine
4-FA 4-Fluoroamphetamine
4-FMA 4-Fluoromethamphetamine
4-MeO-PCP 4-methoxyphen cyclidine
5-APB 5-(2-Aminopropyl)benzofuran
5-HTP 5-Hydroxytryptophan
5-IAI 5-Iodo-2-aminoindane
5-MeO-DALT 5-Methoxy-N,N-diallyltryptamine
5-MeO-DMT 5-Methoxy-N,N-dimethyltryptamine 
5-MeO-DPT 5-Methoxy-N,N-dipropyltryptamine
6-APB 6-(2-Aminopropyl)benzofuran
Į-PPP Į-Pyrrolidinopropiophenone
Į-PVP Į-Pyrrolidinopentiophenone
ARQ UNODC Annual Reports Questionnaire
ATS Amphetamine-type stimulants
BCS British Crime Survey (UK)
BZP Benzylpiperazine
‘CP’ compounds cyclohexylphenols or 3-arylcyclohexanols
CSA Controlled Substances Act (USA)
DAINAP Drug Abuse Information Network for Asia and the Pacific
DEA Drug Enforcement Administration (USA)
DET 3-[2-(diethylamino)ethyl]indole
DOB Brolamphetamine
DOC 2,5-dimethoxy-4-chloroamphetamine
DOI 2,5-dimethoxy-4-iodoamphetamine
DOM / STP 2,5-dimethoxy-alpha,4-dimethylphenethylamine
EACD Expert Advisory Committee on Drugs  (New Zealand)
EDND European database on new drugs
EDRS Ecstasy and Related Drugs Reporting System (Australia)
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EMEA European Agency for the Evaluation of Medicinal Products 
ETAI N-Ethyl-5-trifluoromethyl-2-aminoindane
EU European Union 
EUROPOL European Police Office
FTIR Fourier transform infrared spectroscopy 
GC-MS Gas chromatography - mass spectrometry 
GHB Gamma-hydroxybutyrate
HPLC High performance liquid chromatography 
ICE International Collaborative Exercises
INCB International Narcotics Control Board
LC–MS Liquid chromatography–mass spectrometry 
LSD d-lysergic acid
MBZP 1-Benzyl-4-methylpiperazine
iii
mCPP 1-(3-Chlorophenyl)piperazine
MDA 3,4-methylenedioxyamphetamine
MDAI 5,6-Methylenedioxy-2-aminoindane
MDBP Methylenedioxybenzylpiperazines
MDE N-ethyl-Į-methyl-3,4-(methylenedioxy)phenethylamine
MDMA 3,4-methylenedioxymethamphetamine
MDMAI 5,6-Methylenedioxy-N-methyl-2-aminoindane
MDPV 3,4-Methylenedioxypyrovalerone
Mephedrone (4-MMC) 4-methylmethcathinone
MMAI 5-Methoxy-6-methyl-2-aminoindane
NFLIS National Forensic Laboratory Information System 
NMR Nuclear magnetic resonance 
NPS New Psychoactive Substances
np-SAD National Programme on Substance Abuse Deaths (UK)
NTA National Treatment Agency for Substances Misuse (UK)
PCE Eticyclidine
PCP Phencyclidine
pFPP 1-(4-Fluorophenyl)piperazine
PHP/PCPY Rolicyclidine
PMA p-methoxy-alpha-methylphenethylamine
PMMA 1-(4-methoxyphenyl)-2-methylaminopropane
SMART Global Synthetics Monitoring: Analyses, Reporting and Trends
TAI 5-trifluoromethyl-2-aminoindane
TCP Tenocyclidine
TFMPP 1-(3-Trifluoromethylphenyl)piperazine
THC Δ9-tetrahydrocannabinol 
UK United Kingdom
US United States of America
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
YSS Youth Smoking Survey (Canada)
Weights and measurements
kg Kilogram
mt Metric tons
iv
Notes to the reader 
This report has not been formally edited. 
The designations employed and the presentation 
of the material in this publication do not imply the 
expression of any opinion whatsoever on the part of 
the Secretariat of the United Nations concerning the 
legal status of any country, territory, city or area or 
of its authorities, or concerning the delimitation of 
its frontiers or boundaries. Countries and areas are 
referred to by the names that were in official use at the 
time the relevant data were collected.
The following notes describe certain terms, regional 
designations, data sources and timeframes used 
throughout this document.
NPS – New psychoactive substances are substances 
of abuse, either in a pure form or a preparation, that 
are not controlled by the 1961 Single Convention on 
Narcotic Drugs or the 1971 Convention on Psycho-
tropic Substances, but which may pose a public health 
threat. In this context, the term ‘new’ does not neces-
sarily refer to new inventions but to substances that 
have been recently become available.
Data sources – Unless indicated specifically, data 
contained in this report draws upon official sources 
as reported in the UNODC questionnaire on new 
psychoactive substances by Member States and by 
the International Collaborative Exercise network 
of drug analysis laboratories, data reported in the 
UNODC Annual Reports Questionnaire (ARQ) by 
Member States, annual and technical reports of official 
government and inter-governmental entities (e.g. 
Europol, EMCDDA, World Health Organization, 
UNODC reports) and scientific literature. 
Annexes – Any compound or substance reported 
through the UNODC questionnaire on new 
psychoactive substances under control in the 
international drug control conventions or whose name 
was not provided in full or only as an analogue without 
further indication was excluded from the annexes to 
this report. Individual reports on active ingredients 
of plant-based substances were merged with the 
corresponding plant/herb. Substances with several 
positional isomers in which the specific isomer was not 
indicated were merged into the generic compound.      
Data time frame – The statistical data contained in 
this report cover the 2009-2012 period, except in 
instances where a longer historical frame is necessary 
to provide a clear explanation of emergence and use of 
new psychoactive substances. Data for 2012 should be 
considered preliminary as the UNODC questionnaire 
on NPS was circulated in July 2012. Data are subject 
to change for a variety of reasons, such as new or late 
data being added or revisions in data already provided 
by Member States. Thus, some figure may differ from 
previously published figures. All data reported herein 
reflect the most up-to-date and precise information 
available at the time of publication.
Symbols –  In the tables throughout this report arrows 
indicate an increase or decrease in the trend of use or 
availability of a specified new psychoactive substance 
during the previous year - (Ĺ) an increase, (Ļ) a decrease, 
(ļ) a stable and (-) indicates that the information is 
not available, not known, or was not reported. 
Terms – Since there is some scientific and legal 
ambiguity about the distinctions between drug ‘use’, 
‘misuse’ and ‘abuse’, this report uses the neutral terms, 
drug ‘use’ or ‘consumption’. 
Country names and geographical names – In 
various sections, this report uses a number of regional 
designations. These are not official designations. They 
are defined as follows: 
Africa
Algeria, Angola, Benin, Botswana, Burkina Faso, 
Burundi, Cameroon, Cape Verde, Central African 
Republic, Chad, Comoros, Congo, Democratic 
Republic of Congo, Côte d’Ivoire, Djibouti, Egypt, 
Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, 
Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, 
Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, 
Mauritius, Morocco, Mozambique, Namibia, Niger, 
Nigeria, Rwanda, Sao Tome and Principe, Senegal, 
Seychelles, Sierra Leone, Somalia, South Africa, South 
Sudan, Sudan, Swaziland, Togo, Tunisia Uganda, 
United Republic of Tanzania, Zambia and Zimbabwe.
Americas
Antigua and Barbuda, Argentina, Bahamas, Barbados, 
Belize, Bermuda, Bolivia (Plurinational State of ), 
Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, 
Dominica, Dominican Republic, Ecuador, El Salvador, 
vGrenada, Guatemala, Guyana, Haiti, Honduras, 
Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, 
Saint Kitts and Nevis, Saint Lucia, Saint Vincent and 
the Grenadines, Suriname, Trinidad and Tobago, 
United States of America, Uruguay and Venezuela 
(Bolivarian Republic of ).
Asia
Afghanistan, Armenia, Azerbaijan, Bahrain, 
Bangladesh, Bhutan, Brunei Darussalam, Cambodia, 
China, Democratic People’s Republic of Korea, 
Georgia, India, Indonesia, Iran (Islamic Republic 
of ), Iraq, Israel, Japan, Jordan, Kazakhstan, Kuwait, 
Kyrgyzstan, Lao People’s Democratic Republic, 
Lebanon, Malaysia, Maldives, Mongolia, Myanmar, 
Nepal, Oman, Pakistan, Philippines, Qatar, Republic 
of Korea, Saudi Arabia, Singapore, Sri Lanka, Syrian 
Arab Republic, Tajikistan, Thailand, Timor-Leste, 
Turkmenistan, the United Arab Emirates, Uzbekistan, 
Viet Nam and Yemen
Europe
Albania, Andorra, Austria, Belarus, Belgium, Bosnia 
and Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, 
Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, 
Monaco, Montenegro, Netherlands, Norway, Poland, 
Portugal, Republic of Moldova, Romania, Russian 
Federation, San Marino, Serbia, Slovakia, Slovenia, 
Spain, Sweden, Switzerland, the former Yugoslav 
Republic of Macedonia, Turkey, Ukraine and United 
Kingdom of Great Britain and Northern Ireland.
Oceania
Australia, Cook Islands, Fiji, Kiribati, Marshall Is-
lands, Micronesia (Federated States of ), Nauru, New 
Zealand, Palau, Papua New Guinea, Samoa, Solomon 
Islands, Tonga, Tuvalu and Vanuatu.
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Background 
The amphetamine-type stimulants (ATS) market 
has always been characterized by a large variety of 
substances. However, in recent years, new psychoactive 
substances (NPS) have rapidly emerged in this market 
purportedly as “legal” alternatives to internationally 
controlled drugs, causing similar effects to the latter, 
with the potential to pose serious risks to public health 
and safety. The fast-paced nature of this market, the 
increased availability of these substances and the 
reports of increased and emerging use of and trade 
in such substances have drawn concerns among the 
international community as there is the potential for 
transnational organized criminal groups to exploit the 
market for these substances.   
As a response, the Commission on Narcotic Drugs, 
recalling its resolution 48/1 of 11 March 2005 on 
promoting the sharing of information on emerging 
trends in the abuse of and trafficking in substances 
not controlled under the international drug control 
conventions, and noting the increasing number of 
reports about the production of synthetic cannabinoids 
in herbal products, adopted resolution 53/11 of 12 
March 2010, on promoting the sharing of information 
on the potential abuse of and trafficking in synthetic 
cannabinoid receptor agonists. In that resolution, the 
Commission requested the United Nations Office on 
Drugs and Crime to “share information on the issue 
of cannabinoid receptor agonists with the Expert 
Committee on Drug Dependence of the World 
Health Organization to increase its understanding and 
awareness of the issue”. Pursuant to this resolution, 
UNODC prepared the 2011 report “Synthetic 
cannabinoids in herbal products”.1  
The continued high number and wide range of new 
psychoactive substances of diverse origin, effect and 
risk profile, identified as posing serious risks to public 
health, as well as the challenges that identification 
and control of such substances pose to effective 
health and law enforcement regulation, resulted in 
Commission on Narcotic Drugs resolution 55/1, 
which in paragraph 13 requests UNODC “to provide 
an update to its 2011 report entitled ‘Synthetic 
cannabinoids in herbal products’, addressing a wider 
range of new psychoactive substances, in addition to 
synthetic cannabinoids, and to take into consideration 
the creation of a compilation of new psychoactive 
substances encountered by Member States, to serve as 
an early warning advisory”.  
This report was prepared pursuant to resolution 
55/1. Its aim is to provide an overview of the main 
groups of new psychoactive substances present in 
illicit ATS markets, their chemistry, mode of use 
and reported adverse effects associated with their 
use. It reflects the situation as of February 2013 and 
provides information about the emergence of NPS, 
the prevalence of use, the origins of these substances 
and the different approaches in regulation that have 
been taken by some Governments. It finally suggests 
ways that could be potentially used to detect, identify 
and monitor NPS, in order to facilitate States making 
effective evidence-based decisions to counteract the 
challenges posed by such substances.
Methodology 
The information and data presented in this report 
were obtained primarily through an electronic 
questionnaire on NPS, which was sent to all Member 
States as well as to the drug analysis laboratories 
that participate in the UNODC International 
Collaborative Exercises (ICE) in July 2012. The 
questionnaire covered a wide spectrum of issues 
related to NPS, inter alia,  legislation, seizures of 
NPS, substances detected and analyzed, identification 
of NPS, sources, trafficking, distribution and the use 
of NPS. Additional information was obtained from 
Government reports, scientific literature and data 
extracted from the UNODC ICE Portal.
1 8QLWHG1DWLRQV2IÀFHRQ'UXJVDQG&ULPH¶6\QWKHWLFFDQQDELQRLGVLQ
KHUEDOSURGXFWV·9LHQQD
1Introduction
1. INTRODUCTION
1.1 Emergence of new psychoactive sub-
stances
New psychoactive substances that fall outside interna-
tional drug control conventions are not a novel phe-
nomenon. Many of these substances were synthesized 
and patented in the early 1970s or even earlier, but 
only recently their chemistry or process of synthesis 
have been slightly modified to produce effects similar 
to known illicit substances. 
NPS have been known in the market by terms such 
as ‘designer drugs’, ‘legal highs’, ‘herbal highs’, ‘bath 
salts’. The term ‘designer drugs’ had been tradition-
ally used to identify synthetic substances but has re-
cently been broadened to include other psychoactive 
substances that mimic the effects of illicit drugs and 
are produced by introducing slight modifications to 
the chemical structure of controlled substances to cir-
cumvent drug controls. ‘Legal highs’, ‘herbal highs’, 
‘research chemicals’ and ‘bath salts’ are also common 
names used to refer to NPS offered as a legal alter-
native to controlled drugs. These substances are fre-
quently labelled as ‘not for human consumption’. 
Over the last decade these substances have been in-
troduced in ATS markets through various modes of 
distribution, including the Internet, ‘head’ or ‘smart 
shops’ which sell drug paraphernalia, or street-level 
drug traffickers as legal alternatives to illicit drugs, ac-
counting for an increasingly significant share of illicit 
drug markets in some countries  and becoming a mat-
ter of great concern and a threat to public health.  
Ketamine is one of the oldest NPS. Its abuse was rec-
ognized in the United States since the beginning of 
the 1980s and started to be noticed in Europe in the 
1990s.2 Other NPS such as those belonging to the fam-
ily of phenethylamines and piperazines appeared in the 
market through the 1990s and at the beginning of the 
2000s respectively.3 From 2004 onwards synthetic can-
nabinoids such as ‘spice’, started to be seen in the mar-
ket, followed by synthetic cathinones and other emerg-
ing groups of NPS, as identified in this report.
 'H¿QLWLRQ DQG FDWHJRULHV RI QHZ
psychoactive substances 
For the purposes of this document, NPS are defined as 
“substances of abuse, either in a pure form or a prepa-
ration, that are not controlled by the 1961 Conven-
tion on Narcotic Drugs or the 1971 Convention on 
Psychotropic Substances, but which may pose a public 
health threat”. In this context, the term ‘new’ does not 
necessarily refer to new inventions but to substances 
that have recently become available. 
The information and analysis of NPS presented throu-
ghout this report is based on the identification of six 
main groups of substances present in this market, i.e. 
synthetic cannabinoids, synthetic cathinones, ketamine, 
phenethylamines, piperazines, plant-based substances, 
and a seventh group of miscellaneous substances that 
contain recently identified NPS which do not fit into 
the aforementioned groups.
Given the almost infinite possibilities of altering struc-
2 European Monitoring Center for Drugs and Drug Addiction, ‘Report 
on the risk assessment of  ketamine in the framework of  the joint ac-
tion on new synthetic drugs’, Belgium, 2002
3 )RU LQVWDQFH%HQ]\OSLSHUD]LQH %=3ZDV ÀUVW VROG FRPPHUFLDOO\ DV
an alternative and a legal drug in New Zealand around the year 2000. 
Bassindale, T., ‘Benzylpiperazine: the New Zealand legal perspective’, 
'UXJ7HVWLQJDQG$QDO\VLV%=3ZDVÀUVWQRWHGLQ
Europe around 2004
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tures of chemicals, the list of substances mentioned in 
each of the NPS groups is not exhaustive but offers 
some guidance on the most common substances as re-
ported by respondents to the UNODC questionnaire 
on NPS. 
Substances that are not covered in this report include 
substances that are subject to international control un-
der the 1961 Convention on Narcotic Drugs or under 
the 1971 Convention. Benzodiazepines,  for instance, 
or any other prescription drugs that are prone to 
abuse, such as opioids, central nervous system depres-
sants and stimulants are not the subject of this report. 
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2. MAIN NEW PSYCHOACTIVE SUB-
STANCES ENCOUNTERED IN ILLICIT 
ATS MARKETS AND THEIR EFFECTS
Many of the substances that are available on the mar-
ket for NPS contain unfamiliar molecules that may 
or may not share similar risk effects and profiles to 
the illicit substances they are designed to mimic. As a 
result, they may pose serious challenges to researchers 
and policy-makers that try to assess the risk of harm 
and to take appropriate measures to control them. 
Research on most NPS is very limited. There are no 
comprehensive scientific studies on their toxicity 
and most studies are based on work in animals, fa-
tal poisonings in humans or clinical observations in 
intoxicated patients. Toxicity, abuse liability and risks 
associated with long-term use in particular remain un-
known. Most NPS have little or no history of medical 
use.
2.1. Synthetic cannabinoids
Background
The appearance of ‘herbal highs’ in the market is not 
a new phenomenon. Such products usually consisted 
of plant mixtures with little psychoactive effects. Since 
2004, however, the composition of these herbal prod-
ucts seems to have substantially changed to include 
potent new psychoactive compounds known as syn-
thetic cannabinoids. 
Research on the mechanism of cannabis activity dates 
back several decades when molecules with similar be-
haviour to Δ9-tetrahydrocannabinol (THC) were first 
examined. A synthetic analogue of THC , ‘HU-210’, 
was first synthesized in Israel in 19884  and is consid-
ered to have a potency of at least 100 times more than 
THC. Due to its similar chemical structure to THC, 
‘HU-210’ is regarded as a ‘classical cannabinoid’ and 
has been found in synthetic cannabinoids sold in the 
United States and other countries. 
Non-classical cannabinoids include cyclohexylphe-
nols or 3-arylcyclohexanols (‘CP’compounds). ‘CP’ 
compounds were developed as potential analgesics by 
a pharmaceutical company in the 1980s. Respondents 
to the UNODC questionnaire on NPS have reported 
4 Mechoulam, R., Lander, N., Breuer, A., Zahalka, J., ‘Synthesis of  the 
individual, pharmacologically distinct, enantiomers of  a tetrahydro-
cannabinol derivative’, Tetrahedron: Asymetry, 1990, 1 (5), 315-18
O
OH
H
H
A
O
OH
H
H
OH
B
Chemical structure of classical cannabinoids: Δ9-tetrahy-
drocannabinol (A), and of the synthetic cannabinoid 
HU-210 (B). The differences between the synthetic 
cannabinoid and the controlled substance tetrahydrocan-
nabinol are highlighted in red.
4Global SMART Programme 2013
the emergence of CP-47,497 and CP-47,497-C8 in 
numerous countries in all regions except Africa since 
2009.   
Other structurally dissimilar varieties of synthetic 
cannabinoids unrelated to THC have also emerged on 
the market. These include aminoalkylindoles, such as 
naphtoylindoles (e.g. JWH-018), phenylacetylindoles 
(e.g. JWH-250), and benzoylindoles (e.g. AM-2233).5 
JWH-018, arguably the best known synthetic can-
nabinoid, belongs to the group of aminoalkylindoles 
and is considered to be three times as potent as THC. 
The JWH-compounds had been previously developed 
as test compounds in the research of receptor-drug in-
teractions by Professor John William Huffman6 and 
his team in the United States. 
While cannabis and THC are controlled under the in-
ternational drug control treaties, none of the synthetic 
cannabinoids are under international control. However, 
several have been subject to control measures at the na-
tional level. Respondents to the 2012 UNODC survey 
on NPS identified JWH-018 as the most widespread 
synthetic cannabinoid, followed by JWH-073, JWH-
250 and JWH-081, all of which are aminoalkylindoles.
5 8QLWHG1DWLRQV2IÀFHRQ'UXJVDQG&ULPH¶6\QWKHWLFFDQQDELQRLGV
in herbal products’, Vienna, 2011, 5; see also Hudson, S., Ramsey, J., 
¶7KHHPHUJHQFHDQGDQDO\VLVRI V\QWKHWLFFDQQDELQRLGV·'UXJ7HVW-
ing and Analysis, 2011, 3, 466–478      
6 John W. Huffman is a US chemist and a retired professor of  organic 
FKHPLVWU\DW&OHPVRQ8QLYHUVLW\LQWKH8QLWHG6WDWHVZKRVHUHVHDUFK
led to the synthesis of  non-cannabinoid cannabimimetrics in the 
V'U+XIIPDQ·VUHVHDUFKJURXSIRFXVHVRQWKHV\QWKHVLVRI DQD-
ORJXHVDQGPHWDEROLWHVRI 7+&ZLWKWKHDLPWRGHYHORSQHZSKDU-
PDFHXWLFDOSURGXFWVIRUPHGLFDOWUHDWPHQW¶-RKQ+XIIPDQ·&OHPVRQ
8QLYHUVLW\ KWWSZZZFOHPVRQHGXFKHPLVWU\SHRSOHKXIIPDQ
html; accessed in: October 2012)   
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Generic chemical structure of non-classical cannabinoids and aminoalkylindoles: generic chemical structure of synthetic 
non-classical cannabinoids (A), and three groups of aminoalkylindoles, i.e. naphthoylindoles (B), phenacetylindoles (C), 
and benzoylindoles (D). Many cannabinoid derivatives and analogues could be synthesized by the addition of a halogen, 
alkyl, alkoxy or other substituent to one of the aromatic ring systems. Other small changes, such as variations of the length 
and configuration of the alkyl chain, can also be made to synthesize other compounds.
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Description 
Most synthetic cannabinoids are functionally similar to 
THC. Synthetic cannabinoids are usually available in 
powder form and are sold as ‘Spice Gold’, ‘Spice Silver’, 
‘Spice Diamond’,  ‘K2’, ‘Bliss’, ‘Black Mamba’, ‘Bombay 
Blue’, ‘Blaze’, ‘Genie’, ‘Zohai’, ‘JWH -018, -073, -250’, 
’Kronic’, ‘Yucatan Fire’, ‘Skunk’, ‘Moon Rocks’, ‘Mr. Smi-
ley’. They are usually smoked, but oral use has also been 
reported. Labels on packages and actual constituents of 
the product are often mismatched. 
Reported adverse effects 
While side effects of cannabis are well documented,7 
data on human toxicity related to the use of synthetic 
cannabinoids remains limited. As with other NPS, 
products sold as synthetic cannabinoids often contain 
several chemicals in different concentrations, mak-
ing it very difficult to determine substance-specific 
effects. Available knowledge on the toxicity of these 
compounds comes from scientific reports and clinical 
observations.
Health-related problems associated with the use of 
synthetic cannabinoids include cardiovascular prob-
lems and psychological disorders,8 and it appears that 
there may be carcinogenic potential with some of the 
metabolites of the substances contained in these prod-
ucts.9
A study published in 2011 on the severe toxicity fol-
lowing synthetic cannabinoid ingestion suggested that 
JWH-018 could lead to seizures and tachyarrhythmia 
(irregular heartbeat).10 In a recent review of clinical re-
ports, addiction and withdrawal symptoms similar to 
those seen with cannabis abuse were also linked to the 
use of synthetic cannabinoids.11 An analysis of synthetic 
cannabinoids in ‘spice-like’ herbal blends highlighted 
the increasing number of reports on suicides associated 
with preceding use of these products.12
2.2. Synthetic cathinones 
Background 
Cathinone and its derivatives are closely related to the 
phenethylamine family (which includes amphetamine 
and methamphetamine), but with a lower potency 
than the latter.13 They are characterised by the presence 
of a β-keto group on the side chain of the phenethyl-
amines. Cathinone, the principal active ingredient in 
the leaves of the khat plant (catha edulis), can be con-
sidered as the prototype from which a range of syn-
thetic cathinones have been developed.
Synthetic cathinones appeared in drug markets in 
the mid 2000s. In 2005, methylone, an analogue of 
MDMA, was the first synthetic cathinone reported to 
the European Monitoring Centre on Drugs and Drug 
Addiction (EMCDDA). In 2007, reports of 4-methyl-
methcathinone (mephedrone) use emerged, first in Is-
rael and then in other countries and regions, including 
Australia, Scandinavia, Ireland and the United King-
dom.14 Mephedrone was reportedly first synthesized in 
1929.15
Typically, synthetic cathinones have an amphetamine-
type analogue, i.e. cathinone, ephedrone, and methy-
lone are structurally related to amphetamine, meth-
amphetamine and MDMA respectively. However, 
little is known about the mechanism of action and the 
potential harms of mephedrone, but it has been sug-
gested that mephedrone is likely to act in a similar way 
to other stimulants (e.g. cocaine, amphetamine and 7 )RUH[DPSOH LQ+DOO:6RORZLM1 ¶$GYHUVHHIIHFWVRI  FDQQDELV·
7KH/DQFHW   $VKWRQ&+ ¶$GYHUVH HIIHFWVRI 
cannabis and cannabinoids’, British Journal of  Anaesthesia, 1999, 83 
(4), 637-49
8 Müller, H., Huttner, H.B., Köhrmann, M., Wielopolski, J.E., Kornhu-
EHU-DQG6SHUOLQJ:¶3DQLFDWWDFNDIWHUVSLFHDEXVHLQSDWLHQWZLWK
$'+'·3KDUPDFRSV\FKLDWU\0LU$2EDIHPL
$<RXQJ$ DQG.DQH& ¶0\RFDUGLDO LQIDUFWLRQ DVVRFLDWHGZLWK
use of  the synthetic cannabinoid K2’, Jounal of  Pediatrics, 2011, 128, 
6, 1622-1627; Every-Palmer, S., ‘Synthetic cannabinoid JWH-018 and 
SV\FKRVLVDQH[SORUDWLYHVXG\·'UXJDQG$OFRKRO'HSHQGHQFH
117 (2-3), 152-157
9 /LQ&<:KHHORFN$00RULQ'%DOGZLQ50/HH0*7DII
$3ORSSHU&%XFNSLWW$DQG5RKGH$¶7R[LFLW\DQGPHWDEROLVP
RI PHWK\OQDSKWKDOHQHVFRPSDULVRQZLWKQDSKWKDOHQHDQG- Nitro-
naphthalene’, Toxicology, 2009, 260, 16-27
10 /DSRLQW--DPHV/30RUDQ&/1HOVRQ/6+RIIPDQ56	
0RUDQ -+ ¶6HYHUH WR[LFLW\ IROORZLQJ V\QWKHWLF FDQQDELQRLG LQJHV-
WLRQ·&OLQLFDO7R[LFRORJ\3KLODGHOSKLD
11 9DUGDNRX , 3LVWRV & 6SLOLRSRXORX &+ ¶6SLFH GUXJV DV D QHZ
WUHQGPRGHRI DFWLRQLGHQWLÀFDWLRQDQGOHJLVODWLRQ·7R[LFRORJ\/HW-
ter, 2010, 197, 157-162
12 Ludger, E., Krueger, K., Lindigkeit, R., Schiebel, HM., Beuerle, T., 
¶6\QWKHWLFFDQQDELQRLGVLQ¶¶VSLFHOLNH··KHUEDOEOHQGVÀUVWDSSHDUDQFH
RI  -:+DQG UHFXUUHQFHRI  -:+RQ WKH*HUPDQPDUNHW·
Forensic Science International, 2012, 222 (1), 216-222
13 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ ¶6\Q-
WKHWLFFDWKLQRQHV·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
14 .HOO\-3¶&DWKLQRQHGHULYDWLYHV$UHYLHZRI WKHLUFKHPLVWU\SKDU-
PDFRORJ\DQGWR[LFRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
453  
15 Saem de Burnaga Sanchez, J., ‘Sur un homologue de l’ephedrine’, Bul-
OHWLQGHOD6RFLpWp&KLPLTXHGH)UDQFH
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MDMA).16 Up to 2010, methylone and mephedrone 
(4-methylmethcathinone) were identified as the most 
common substances of use in this group in Europe.17
 
Other synthetic cathinones recently identified in the 
drug market are analogues of pyrovalerone (3,4-meth-
ylenedioxypyrovalerone and naphyrone). For instance, 
3,4-methylenedioxypyrovalerone (MDPV), first syn-
thesized in 1969,18 emerged in 2007 as a new psycho-
active substance in Germany.19 In 2008, it was first re-
ported to the European Early Warning System by the 
United Kingdom and by Finland, after being associ-
ated with adverse health effects.20 Initially unregulated, 
many countries, including countries of the European 
Union as well as Australia, Israel and the United States 
have introduced control measures over the substance. 
Other synthetic cathinones, inter alia, flephedrone and 
naphyrone also became available in the drug market as 
NPS from 2008 onwards.21
Responses to the UNODC questionnaire on NPS in-
dicated that other synthetic cathinones, including 
methylone, butylone, 4-methylethcathinone, 4-flu-
oromethcathinone, naphyrone, 3-fluoromethcathi-
none, methedrone, and, to a lesser extent, 3,4-di-
methyl-methcathinone, α-pyrrolidinopentiophenone 
(α-PVP), buphedrone, pentedrone and α-pyrrolidi-
nopropiophenone (α-PPP), have increasingly been 
used as NPS from 2010 onwards.
While some synthetic cathinones such as methylone 
had been patented as antidepressant and antiparkinso-
nian agents,22 very few have been exploited clinically 
predominantly on account of their abuse and depen-
dence potential. For instance, whereas diethylcathinone 
(amfepramone) is used as an appetite suppressant, py-
rovalerone, first synthesized in 1964 and marketed for 
use as an appetite suppressant and in the treatment of 
chronic fatigue, was later withdrawn due to abuse and 
dependency in users.23 Apart from cathinone, the only 
16 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJVDQG'UXJ$GGLFWLRQ ¶5LVN
DVVHVVPHQW UHSRUWRI DQHZSV\FKRDFWLYH VXEVWDQFHPHWK\OPHWK-
cathinone (mephedrone)’, 2010  
17 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJVDQG'UXJ$GGLFWLRQ ¶6\Q-
WKHWLFFDWKLQRQHV·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
18 ¶%RHKULQJHU ,QJHOKHLP 3DWHQW IRU 0'39· KWWSFDWEXOOFRPDO-
DPXW%LEOLRWKHN%RHKULQJHUB0'39B3DWHQWKWP
19 ,Q0'39ZDVÀUVWLGHQWLÀHGLQDVHL]XUHLQ*HUPDQ\:HVWSKDO
F., Junge, T., Rosner, P., Sonnichsen, F., Schuster, F., ‘Mass and NMR 
spectroscopic characterization of  3,4-methylenedioxypyrolvalerone: a 
GHVLJQHUGUXJZLWKDS\UUROLGLQRSKHQRQHVWUXFWXUH·)RUHQVLF6FLHQFH
International, 2009, 190, 1-8
20 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQDQG(X-
URSHDQ3ROLFH2IÀFH¶(0&''$²(XURSRO$QQXDOUHSRUWRQWKH
LPSOHPHQWDWLRQ RI &RXQFLO'HFLVLRQ -+$· /LVERQ 
21 .HOO\-3¶&DWKLQRQHGHULYDWLYHV$UHYLHZRI WKHLUFKHPLVWU\SKDUPD-
FRORJ\DQGWR[LFRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
22 -DFRE36KXOJLQ$73DWHQW:2&$
Neurobiological Technologies Inc, USA
23 0HOW]HU 3 %XWOHU ' 'HVFKDPSV -5 0DGUDV %.
‘(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) ana-
logues: a promising class of  monoamine uptake inhibitors’, Journal of  
0HGLFLQDO&KHPLVWU\RWKHUFDWKLQRQHGHULYDWLYHV
such as amfepramone and bupropion are or have also been used as 
active pharmaceutical ingredients.
Chemical structures of cathinone (A), mephedrone (B), MDMA (C) and methylone (D). Differences between controlled 
substances (i.e. cathinone and MDMA) and synthetic derivatives of cathinones (i.e. mephedrone and methylone) are 
highlighted in red.  The molecular structure of generic cathinone derivatives is represented in structure (E). The ‘R’ groups 
indicate locations of the molecule where modifications can occur to produce a wide range of cathinone derivatives.
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cathinone derivatives under international drug control 
are amfepramone, methcathinone and pyrovalerone.24
Description 
Synthetic cathinones are frequently found in products 
sold as ‘research chemicals’, ‘plant food’, ‘bath salts’ 
or ‘glass cleaner’ and are usually sold in powder, pill 
or capsule form. Mephedrone (‘m-cat’, ‘meph’, ‘drone’ 
or ‘miaow’) and methylone (‘explosion’ or ‘top cat’) are 
usually available as white or brown powders or in the 
form of pills that are often sold as ‘ecstasy’. Most syn-
thetic derivatives are ingested but may be injected. 
Mephedrone is commonly nasally insufflated, inject-
ed, ingested by swallowing a powder wrapped in paper 
(‘bombing’), or mixed in a drink. 
Reported adverse effects 
Few reports on the toxicity of synthetic cathinones ex-
ist to date. Much of the current knowledge on health-
related effects comes from user reports and clinical 
observations. Further research is needed to provide 
evidence of short and long-term health risks and the 
addiction potential associated with the use of these 
substances.
Whereas cardiac, psychiatric, and neurological signs 
are some of the adverse effects reported by synthetic 
cathinone users, agitation, ranging from mild agita-
tion to severe psychosis, is the most common symp-
tom identified from medical observations.25 Studies of 
patients under the apparent influence of mephedrone 
have also shown that synthetic cathinones present 
similar sympathomimetic effects (including tachycar-
dia and hypertension as well as psychoactive effects) 
to similar amphetamine derivatives.26 In a student 
survey, more than half of those who had taken me-
phedrone reported adverse effects associated with the 
central nervous system, nasal/respiratory system and 
cardiovascular system.27 The first fatality related to 
the sole use of mephedrone, confirmed by toxicologi-
cal analysis, was reported in Sweden in 2008.28 Most 
fatalities associated with the use of mephedrone in-
volved the use of other substances.29 Deaths associated 
with the use of other synthetic cathinones include two 
deaths related to methedrone30 and two other deaths 
related to butylone.31
The Finnish Poisons Information Centre reported 33 
calls regarding exposures to MDPV during the pe-
riod of January 2008 to October 2009. Post mortem 
toxicological analysis confirmed 6 deaths related to 
MDPV between 2009 and 2010, although in most of 
the cases the presence of other drugs was also detect-
ed.32 A report from the United States provided details 
on the case of 35 patients who visited an Emergency 
Department over a 3-month-period after ingesting, 
inhaling or injecting substances sold as ‘bath salts’ and 
asserted that these products could contain stimulant 
compounds such as MDPV or mephedrone. One 
person was dead upon arrival at the emergency de-
partment. The toxicological analysis revealed a high 
level of MDPV, along with cannabis and prescription 
drugs, but the autopsy results revealed MDPV toxicity 
to be the primary factor contributing to death.33
24 &DWKLQRQHDQGPHWKFDWKLQRQHDUHOLVWHGLQ6FKHGXOH,RI WKH8QLW-
HG 1DWLRQV &RQYHQWLRQ RQ 3V\FKRWURSLF 6XEVWDQFHV $PIHSUDPRQH
DQGS\URYDOHURQHDUHOLVWHGLQ6FKHGXOH,9RI WKHVDPH&RQYHQWLRQ
25 3URVVHU-0DQG1HOVRQ/6¶7KHWR[LFRORJ\RI EDWKVDOWVDUHYLHZ
of  synthetic cathinones’, The Journal of  Medical Toxicology, 2012, 8 
(1), 33-42  
26 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ ¶6\Q-
WKHWLFFDWKLQRQHV·'UXJ3URÀOHVZZZHPFGGDHXURSDHX7KHWHUP
sympathomimetic refers to a pharmacologic agent that mimics the 
effects of  stimulation of  organs and structures by the sympathetic 
nervous system. It functions by occupying adrenergic receptor sites 
and acting as an agonist or by increasing the release of  the neurotrans-
mitter norepinephrine at postganglionic nerve endings.   
27 'DUJDQ3,$OEHUW6:RRG'0¶0HSKHGURQHXVHDQGDVVRFLDWHG
adverse effects in school and college/university students before the 
UK legislation change’, Oxford Journal of  Medicine, 2010, 103 (10), 
875-9
28 *XVWDYVVRQ ' (VFKHU & ¶0HSKHGURQH ² LQWHUQHW GUXJ ZKLFK
VHHPVWRKDYHFRPHDQGVWD\)DWDOFDVHVLQ6ZHGHQKDYHGUDZQDW-
WHQWLRQWRSUHYLRXVO\XQNQRZQVXEVWDQFH·/DNDUWLGQLQJHQ
(43), 2769-71
29 7KHGHDWKRI D\HDUROGPDQLQWKH8.ZDVFDXVHGE\DFRPELQD-
tion of  mephedrone and heroin. Other cases reported from Scotland 
UHYHDOHG WKHSUHVHQFHRI RWKHU VXEVWDQFHVDORQJZLWKPHSKHGURQH
6HH'LFNVRQ$-9RUFH63/HYLQH%3DVW05 ¶0XOWLSOHGUXJ
toxicity caused by the coadministration of  4-methylmethcathinone 
(mephedrone) and heroin’, Journal of  Analytical Toxicology, 2010, 34 
7RUUDQFH+&RRSHU*¶7KHGHWHFWLRQRI PHSKHGURQH
(4-methylmethcathinone) in 4 fatalities in Scotland’, Forensic Science 
International, 2010, 202 (1-3), 62-3  
30 :LNVWU|P07KHODQGHU*1\VWU|P,DQG.URQVWUDQG5¶7ZR
IDWDO,QWR[LFDWLRQVZLWKWKH1HZ'HVLJQHU'UXJ0HWKHGURQH0H-
thoxymethcathinone)’, Journal of  Analytical Toxicology, 2010, 34, 
594-98
31 &DUWHU15XWW\*10LOUR\&0)RUUHVW$5:¶'HDWKVDV-
VRFLDWHGZLWK0%'%PLVXVH·-RXUQDORI /HJDO0HGLFLQH
168–70
32 )LQODQG1DWLRQDO ,QVWLWXWH IRU+HDOWKDQG:HOIDUH ¶0'39 LQ)LQ-
ODQG·KWWSHZVGZLYLVSEH3XEOLFDWLRQVRQQHZ
SV\FKRDFWLYHVXEVWDQFHV0'390'39IDFWVIURP
Finland.pdf)  
33 8QLWHG6WDWHV&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ$WODQWD
¶(PHUJHQF\ 'HSDUWPHQW YLVLWV DIWHU XVH RI  D GUXJ VROG DV ´EDWK
salts”--- Michigan, November 13, 2010--March 31, 2011’ ( http://
ZZZFGFJRYPPZUSUHYLHZPPZUKWPOPPDKWP
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2.3. Ketamine
Background
Ketamine is closely related to the internationally con-
trolled drug phencyclidine (also known as PCP or 
‘angel dust’) which is listed in Schedule II of the 1971 
Convention (see section 2.7.2).
Phencyclidine was investigated as an intravenous an-
aesthetic in the 1950s but was later withdrawn due to 
undesired hallucinogenic and delirium effects.34 Fol-
lowing the withdrawal of phencyclidine, ketamine was 
synthesized as an anaesthetic in 1962, patented in 1963 
in Belgium and three years later in the United States. In 
the early 1970s, ketamine was marketed as a medical 
alternative to phencyclidine. 
The use of ketamine as a new psychoactive substance 
dates back to the 1980s and 1990s. At the international 
level, ketamine was subject to a series of risk assess-
ments. The Expert Committee on Drug Dependence 
of the WHO pre-reviewed ketamine in 2003 and con-
ducted critical review in 2006. After reviewing the in-
formation contained before it, the Committee conclud-
ed that “this information was not sufficient to warrant 
scheduling”.35 It also requested an updated version of 
the critical review to be presented at the next meeting of 
the Committee which was held in 2012. At that meet-
ing, the Committee decided that “bringing ketamine 
34 (XURSHDQ0RQLWRULQJ&HQWHUIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI NHWDPLQHLQWKHIUDPHZRUNRI WKHMRLQWDF-
WLRQRQQHZV\QWKHWLFGUXJV·%HOJLXP
35 :RUOG+HDOWK2UJDQL]DWLRQ¶:+2([SHUW&RPPLWWHHRQ'UXJ'H-
SHQGHQFH7KLUW\IRXUWK5HSRUW·*HQHYD
under international control is not appropriate.”36 At 
the level of European Union, in 2000, growing con-
cern over the use of ketamine as a NPS prompted a 
risk assessment in the framework of the joint action on 
new synthetic drugs.37 The European Commission con-
cluded that it was not appropriate to introduce control 
measures and recommended further monitoring of the 
use of ketamine.
Description 
Ketamine and phencyclidine have similar modes of 
action, affecting a range of central neurotransmitters. 
Ketamine is frequently sold as ‘ecstasy’ in illicit ATS 
markets. Street names for ketamine include ‘K’, ‘spe-
cial K’, ‘kit kat’, ‘tac’, ‘tic’, ‘cat valium’, ‘cat tranquilizer’, 
‘vitamin K’, ‘ket’, ‘super K’.38
Pharmaceutical preparations of ketamine are usu-
ally found in liquid form, but powder and capsules 
are also available. The powder prepared by evapora-
tion of the original solution is often nasally insufflated 
(‘bumping’), smoked or swallowed.
 
Reported adverse effects 
Ketamine appears to stimulate the cardiovascular sys-
tem, producing changes in the heart rate and blood 
pressure. As such, tachycardia is one of the most com-
mon symptoms identified in recreational users. 
Findings of neurotoxicity in animal studies have raised 
concerns on the consumption of ketamine by recre-
ational users, for a number of reasons: unlike when it 
is clinically administered, substance users will not take 
ketamine in combination with protective agents. More-
over, substances which may increase the neurotoxic po-
tency of ketamine might be co-administered (including 
PCP, tiletamine as well as alcohol). Furthermore, recre-
ational use usually implies repeated exposure, whereas 
clinical use is mostly incidental.39
36 :RUOG+HDOWK2UJDQL]DWLRQ¶:+2([SHUW&RPPLWWHHRQ'UXJ'H-
SHQGHQFH7KLUW\ÀIWK5HSRUW·*HQHYD
37 (XURSHDQ0RQLWRULQJ&HQWHUIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI NHWDPLQHLQWKHIUDPHZRUNRI WKHMRLQWDF-
WLRQRQQHZV\QWKHWLFGUXJV·%HOJLXP
38 (XURSHDQ0RQLWRULQJ&HQWHUIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI NHWDPLQHLQWKHIUDPHZRUNRI WKHMRLQWDF-
WLRQRQQHZV\QWKHWLFGUXJV·%HOJLXP
39 -DQVHQ./¶.HWDPLQH&DQFKURQLFXVHLPSDLUPHPRU\"·,QWHUQD-
tional Journal of  the Addictions, 1990, 25, 133-139, in World Health 
2UJDQL]DWLRQ¶:+2([SHUW&RPPLWWHHRQ'UXJ'HSHQGHQFH7KLU-
W\ÀIWK0HHWLQJ·
Chemical structures of phencyclidine (A) (controlled 
substance) and ketamine (B).  A significant portion of the 
molecule is common to both compounds (the phenylcy-
clohexyl), while the differences between them are highlight-
ed in red. 
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Chemical structure of amphetamine (A), two substituted 
phenethylamines: 2C-B (B) and Bromo-Dragonfly (C), 
and the generic structure of phenethylamines (D). The 
differences between amphetamine and two of the pheneth-
ylamine derivatives (i.e. 2C-B (internationally controlled 
substance) and Bromo-Dragonfly) are highlighted in red. 
The eight positions of the phenethylamine core that can be 
modified to generate a wide range of substituted pheneth-
ylamine derivatives are also highlighted in structure (D).
B
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Side effects related to the use of ketamine in conjunc-
tion with other drugs include hypertension and pul-
monary oedema. Psychological dependence in some 
users has also been identified. Adverse effects in long-
term users of ketamine have been reported albeit scarce. 
These included persistent impairment of attention and 
recall, and a subtle visual anomaly. Other reported ef-
fects include anxiety, changes of perception, an impair-
ment of motor function and rhabdomyolysis.
Between 1987 and 2000, 12 fatal cases in which ket-
amine was identified were reported, but only three of 
them involved ketamine alone. Chronic ketamine use 
has been reported to result in potential lasting memo-
ry and cognitive dysfunction.40
2.4. Phenethylamines 
Background 
Phenethylamines refer to a class of substances with 
documented psychoactive and stimulant effects 
and include amphetamine, methamphetamine and 
MDMA, all of which are controlled under the 1971 
Convention.41 The phenethylamines also include ring-
substituted substances such as the ‘2C series’, ring-
substituted amphetamines such as the ‘D series’ (e.g. 
DOI, DOC), benzodifurans (e.g. Bromo-Dragonfly, 
2C-B-Fly) and others (e.g. p-methoxymethamphet-
amine (PMMA)).
Seizures of phenethylamines were first reported 
from the United States and European countries and 
since 2009 substances such as 2C-E, 2C-I, 4-FA and 
PMMA have been commonly reported by several 
countries in different regions. Other phenethylamines 
increasingly reported in the UNODC questionnaire 
on NPS since 2011 include 4-FMA, 5-APB, 6-APB 
and 2C-C-NBOMe.
A number of studies have reported the synthesis of 
some phenethylamines and amphetamine substitutes. 
In the 1980s and 1990s, Alexander Shulgin, a bio-
chemist and pharmacologist, reported the synthesis 
of numerous new psychoactive compounds.42 This 
included the ‘D series’ (e.g. DOC, DOI) and the ‘2C 
series’ (e.g. 2C-T-7, 2C-T-2) of phenethylamines.
Simple variations on the mescaline molecule (a natu-
ral phenylethylamine) led to the synthesis of powerful 
hallucinogenic substances, e.g. 4-bromo-2,5-dime-
thoxyphenethylamine (2C-B), synthesized by Shulgin 
in 1974. The ‘2C’ series  differs from the ‘D’ series 
only by a slight modification in the chemical struc-
ture, and their psychoactive effects have been reported 
to be dose dependant, ranging from mere stimulant 
40 2NRQ7DFDVHEDVHGUHYLHZ¶.HWDPLQHDQLQWURGXFWLRQIRUWKHSDLQ
and palliative medicine physician’, Pain Physician, 2007, 10, 493-500
41 +LOO 6/ 7KRPDV 6+ ¶&OLQLFDO WR[LFRORJ\ RI  QHZHU UHFUHDWLRQDO
GUXJV·-RXUQDO&OLQLFDO7R[LFRORJ\
42 Alexander Shulgin research institute, ‘Alexander ‘Sasha’ Shulgin’ (http://
ZZZVKXOJLQUHVHDUFKRUJKRPHDERXWDOH[DQGHUVDVKDVKXOJLQ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effect at lower doses, with hallucinogenic and entacto-
genic effects at higher doses.44
Over two decades later, a new generation of phenethyl-
amines was researched by Professor David Nichols and 
his research team at Purdue University in the United 
States. The team found the potency of synthetic ana-
logues of mescaline such as 2C-B and DOB, to exceed 
that of many naturally occurring hallucinogens.45 Sever-
al substances were synthesized, including a wide range of 
benzodifuranyl substances, later known as the ‘FLY’.46 
Benzodifurans, such as ‘FLY’ (tetrahydrobenzodifura-
nyl) and ‘Dragonfly’ (benzodifuranyl aminoalkanes) 
are potent hallucinogens. Bromo-Dragonfly is the most 
common and potent substance in this sub-group.     
Other phenethylamines such as PMMA, first synthe-
sized in 1938,47 are also sold in the drug market as a sub-
stitute for ‘ecstasy’. PMMA, in combination with PMA 
(a substance listed in Schedule I of the 1971 United 
Nations Convention on Psychotropic Substances), has 
been frequently found in tablets that carry a similar logo 
to ‘ecstasy’.48
Whereas some phenethylamines such as 2C-B, brolam-
phetamine (DOB), STP/DOM, MDE, 4-MTA, are 
listed in Schedules I and II of the 1971 Convention, 
most of the new substances such as the 2C series, the 
D-Series and ‘others’ such as PMMA are not under in-
ternational control. Some phenethylamine derivatives 
are controlled in some countries.
Description
Street names for some phenethylamines include ‘Euro-
pa’ for 2C-E; ‘4-FMP’, ‘para-fluoroamphetamine’, ‘RDJ’ 
for 4-FA; and ‘4-MMA’, ‘Methyl-MA’  for PMMA. 
Phenethylamines are usually available in form of pills, 
but FLY compounds are commonly sold in powder 
form, while oral doses (on a slip of blotter paper) are 
usually available for ‘D substances’. Ingestion is the 
most common route of administration of phenethyl-
amines.  
Reported adverse effects
Phenethylamines included in the ‘D series’ are de-
scribed to be longer lasting, more potent and report-
edly more liable to induce vasoconstriction than other 
members of the phenethylamine family.49
Reported adverse effects associated with the use of the 
‘D series’ derivatives include agitation, tachycardia, my-
driasis, hallucinations, severe limb ischemia, seizures, 
liver and renal failure.50 Bromo-Dragonfly has also been 
associated with a number of deaths in Scandinavia.51 A 
43 p-methoxy-alpha-methylphenethylamine (PMA) is controlled in Schedule 
,RI WKH8QLWHG1DWLRQV&RQYHQWLRQRQ3V\FKRWURSLF6XEVWDQFHV
44 Huang, H.H. and Bai, Y.M. ‘Persistent psychosis after ingestion of  a 
VLQJOHWDEOHWRI ¶&%··-RXUQDO3URJUHVVLQ1HXUR3V\FKRSKDUPD-
FRORJ\	%LRORJLFDO3V\FKLDWU\LV
45 0RQWH$3:DOGPDQ 650DURQD/HZLFND':DLQVFRWW'%
1HOVRQ'/6DQGHUV%XVK(1LFKROV'( ¶'LK\GUREHQ]RIXUDQ
analogues of  hallucinogens. 4. Mescaline derivatives’, Journal of  Me-
GLFLQDO&KHPLVWU\²
46 &ROOLQV0¶6RPHQHZSV\FKRDFWLYHVXEVWDQFHVSUHFXUVRUFKHPLFDOV
DQGV\QWKHVLVGULYHQHQGSURGXFWV·'UXJ7HVWLQJDQG$QDO\VLV
3 (7-8), 404-16
47 *OHQQRQ5$,VPDLHO$(00DUWLQ%3RII'DQG6XWWRQ0
‘A preliminary behavioral investigation of  PMMA, the 4-methoxy ana-
log of  methamphetamine’, Pharmacology Biochemistry and Behavior, 
1988, 31 (1), 9-13
48 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI 300$LQWKHIUDPHZRUNRI WKHMRLQWDFWLRQ
RQQHZV\QWKHWLFGUXJV·
49 +LOO6DQG7KRPDV6+¶&OLQLFDOWR[LFRORJ\RI QHZHUUHFUHDWLRQDO
GUXJV·&OLQLFDO7R[LFRORJ\
50 .LQJ·V &ROOHJH /RQGRQ ,QVWLWXWH RI  SV\FKLDWU\ 3V\FKRQDXW :HE
0DSSLQJ5HVHDUFK*URXS ¶%URPR'UDJRQÁ\ UHSRUW·/RQGRQ8.
 KWWSGRFXPHQWVUHSRUWV%URPRGUDJRQÁ\
SGIDFFHVVHGLQ6HSWHPEHU:RRG'0/RRNHU--6KDLNK
/%XWWRQ -3XFKQDUHZLF]0'DYLHV6/LGGHU65DPVH\G -
+ROW':'DUJDQ3,¶'HOD\HGRQVHWRI VHL]XUHVDQGWR[LFLW\DVVR-
FLDWHGZLWKUHFUHDWLRQDOXVHRI %URPRGUDJRQ)/<·-RXUQDORI 0HGL-
cal Toxicology, 2009, 5, 226
51 Andreasen, M.F., Telving, R., Birkler, R., Schumacher, B. and Jo-
KDQQVHQ 0 ¶$ IDWDO SRLVRQLQJ LQYROYLQJ %URPR'UDJRQÁ\· $Q-
QDOHVGH7R[LFRORJLH$QDOLWLTXH3HUVRQQH0+XOWHQ3
¶%URPR'UDJRQÁ\DOLIHWKUHDWHQLQJGHVLJQHUGUXJ·-RXUQDO&OLQLFDO
Toxicology, 2008, 46, 379-80   
Chemical structures of other synthetic phenethylamines: 
PMA (A) and PMMA (B). Structure (B) shows how the 
derivative PMMA is produced by introducing a small modifi-
cation in the structure of PMA (internationally controlled 
substance).43
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52 0L\DMLPD00DWVXPRWR7DQG,WR6 ¶&7LQWR[LFDWLRQDFXWH
SV\FKRVLVFDXVHGE\DGHVLJQHUGUXJ·-RXUQDO3V\FKLDWU\DQG&OLQLFDO
Neurosciences, 2008, 62, 243
53 &XUWLV%.HPS3+DUW\/&KRL&DQG&KULVWHQVHQ'¶3RVWPRU-
WHPLGHQWLÀFDWLRQDQGTXDQWLWDWLRQRI GLPHWKR[\QSURS\OWKLR-
SKHQHWK\ODPLQHXVLQJ*&06'DQG*&13'·-RXUQDORI $QDO\WLFDO
Toxicology, 2003, 27, 493-98
54 /LQJ/+0DUFKDQW&%XFNOH\1$3ULRU0,UYLQH5-¶3RLVRQLQJ
ZLWKWKHUHFUHDWLRQDOGUXJSDUDPHWKR[\DPSKHWDPLQH¶GHDWK··0HGLFDO
-RXUQDORI $XVWUDOLD'H/HWWHU($&RRSPDQ9$
&RUGRQQLHU-$DQG3LHWWH0+¶2QHIDWDODQGVHYHQQRQIDWDOFDVHV
of  4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological 
ÀQGLQJV·,QWHUQDWLRQDO-RXUQDORI /HJDO0HGLFLQH(O-
OLRW63¶)DWDOSRLVRQLQJZLWKDQHZSKHQHWK\ODPLQHPHWK\OWKLRDP-
phetamine (4-MTA)’, Journal of  Analytical Toxicology, 2000, 24, 85-9; 
)HOJDWH+()HOJDWH3'-DPHV5$6LPV'1DQG9R]]R'&¶5H-
cent paramethoxyamphetamine deaths’,  Journal of  Analytical Toxicol-
RJ\/DPEHUWK3*'LQJ*.1XUPL/$¶)DWDO
SDUDPHWKR[\DPSKHWDPLQH 30$SRLVRQLQJ LQ WKH$XVWUDOLDQ&DSLWDO
Territory’, Medical Journal of  Australia, 2008, 188, 426
55 'UXJ7HVWLQJDQG$QDO\VLV>(GLWRULDO@ ¶$EULHI KLVWRU\RI ¶QHZSV\-
choactive substances’’, 2011, 3, 401-403
case of acute psychosis after ingestion of 2C-T-4 was 
reported in Japan.52 Three fatal cases associated with 
the use of 2C-T-7 have been identified, two of which 
involved poly-drug use.53
 
PMA, PMMA and 4-methylthioamfetamine have been 
more often associated with incidental deaths than other 
phenethylamines. PMA and PMMA are known to have 
a particularly high toxicity but there is no data available 
on fatalities associated with their use. Clinical obser-
vations have reported severe hyperthermia following 
the use of these substances.54 Studies in animals have 
suggested that some metabolites may be exposed to in-
creased toxicity from 4-MTA.
2.5. Piperazines 
Background
Piperazines have been described as ‘failed pharmaceu-
ticals’, as some had been evaluated as potential thera-
peutic agents by pharmaceutical companies but never 
brought to the market.55 While the best known pipera-
zine that has been used as a new psychoactive substance 
56 8QLWHG1DWLRQV2IÀFHRQ'UXJVDQG&ULPH¶812'&TXHVWLRQQDLUH
RQ136·VXEPLWWHGE\0HPEHU6WDWHVDQGDQHWZRUNRI GUXJDQDO\VLV
laboratories in 2012. 
57 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI %=3LQWKHIUDPHZRUNRI WKH&RXQFLOGHFL-
VLRQRQQHZSV\FKRDFWLYHVXEVWDQFHV·5LVN$VVHVVPHQWV,VVXH/LV-
bon, 2009, 23
58 $´SSUR[LPDWHO\WRPLOOLRQWDEOHWVKDGEHHQPDQXIDFWXUHGE\9L-
WDÀW1XWULWLRQ/WG IRU 6WDUJDWH ,QWHUQDWLRQDO RQHRI  WKHPDMRUGLV-
WULEXWRUVLQ1HZ=HDODQGVLQFHµ1HZ=HDODQG([SHUW$GYLVRU\
&RPPLWWHHRQ'UXJV($&' ¶$GYLFHWRWKH0LQLVWHURQ%HQ]\OSL-
SHUD]LQH%=3·,QGXVWU\ÀJXUHVSRLQWHGRXWWKDWPLOOLRQGRV-
HVZHUHVROGRYHUDQ\HDUSHULRG6WDUJDWH,QWHUQDWLRQDO¶3DUW\SLOOV
VXFFHVVIXOVDIHW\UHFRUG·KWWSZZZVWDUJDWHLQWHUQDWLRQDORUJ
SUHVVBB3DUW\3LOOV6XFFHVVIXO6DIHW\5HFRUGGRF
pdf; accessed in: September 2012)
59 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶5HSRUW
RQWKHULVNDVVHVVPHQWRI %=3LQWKHIUDPHZRUNRI WKH&RXQFLOGHFL-
VLRQRQQHZSV\FKRDFWLYHVXEVWDQFHV·5LVN$VVHVVPHQWV,VVXH/LV-
bon, 2009, 23
60 %\LWZDVHVWLPDWHGWKDWDOPRVWRI LOOLFLWWDEOHWVVROGLQWKH
EU, as part of  the illicit ecstasy market, contained m&33SHUFHQWDJH
WKDWLQFUHDVHGXSWRLQVRPH0HPEHU6WDWHVDWWKHHQGRI 
DQGEHJLQQLQJRI (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG
'UXJ $GGLFWLRQ ¶%=3 DQG RWKHU SLSHUD]LQHV· 'UXJ 3URÀOHV ZZZ
emcdda.europa.eu; accessed in: September 2012)
is 1-benzylpiperazine (BZP), during the last decade 
other compounds such as 1-(3-chlorophenyl) pipera-
zine (mCPP), 1-(3-trifluoromethylphenyl) piperazine 
(TFMPP) and, to a lesser extent, 1-Benzyl-4-methyl-
piperazine (MBZP) and 1-(4-Fluorophenyl)piperazine 
(pFPP) have been identified on the market.56 
BZP was initially developed as a potential antidepres-
sant drug, but was found to have similar properties 
to amphetamine and therefore liable to abuse. In the 
1980s, it was used in Hungary to manufacture pibera-
line, a substance marketed as an antidepressant, but later 
withdrawn.57 In the late 1990s, BZP emerged in New 
Zealand as a ‘legal alternative’ for MDMA and metham-
phetamine.58 In Europe, its use was first reported in Swe-
den in 1999, but it only became widespread as a NPS 
from 2004 onwards until controls over the substance 
were introduced in 2008, in the European Union.59
MCPP, reportedly more widespread than BZP in some 
regions of the world,60 was developed during the late 
Chemical structures of  BZP (A), mCPP (B) and  TFMPP (C).
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1970s and is used as an intermediate in the manufacture 
of several antidepressants, e.g. trazodone and nefazodo-
ne.61 TFMPP is almost always seen in combination with 
BZP to produce the entactogenic62 effects of MDMA.63
Neither BZP nor any other piperazines are under in-
ternational control, although several (BZP, TFMPP, 
mCPP, MDBP) were pre-reviewed by the WHO Ex-
pert Committee on Drug Dependence in 2012. Several 
countries have introduced national control measures 
over piperazines.
Description
Piperazines are frequently sold as ‘ecstasy’. Some of the 
generic names for these substances include, ‘pep pills’, 
‘social tonics’ or simply ‘party pills’. The latter term was 
used to commercialize BZP in New Zealand.64 Other 
street names include Jax, A2, Benny Bear, Flying Angel, 
Legal E or Legal X, and Pep X, Pep Love or Nemesis.65 
MCPP is known as 3CPP, 3C1-PP or CPP.  
Piperazines are usually available in the form of pills 
(regularly pressed with logos similar to ecstasy pills), 
capsules or loose powders, and are mainly consumed 
by ingestion. Liquid forms are rarely seen, but injec-
tion, smoking and snorting is also possible. 
Reported adverse effects 
Information on the toxicological aspects of many pi-
perazines listed in this group remain limited. Further 
research is required to provide evidence on short and 
long term health-effects associated with the use of 
these substances. Current knowledge comes from user 
reports, studies in animals, limited human studies, and 
clinical observations. 
Piperazines have been found to act as stimulants as a 
result of dopaminergic, noradrenergic, and predomi-
nantly serotoninergic effects produced in the brain. BZP 
produces toxic effects similar to amphetamine and other 
sympathomimetics, although, according to animal stud-
ies, its effects are less potent than amphetamine, meth-
amphetamine and MDMA.66 TFMPP, used in conjunc-
tion with BZP, has been reported to produce some of 
the effects of MDMA, but with a lower potency,67 while 
mCPP has been indicated to produce similar stimulant 
and hallucinogenic effects as MDMA.68
In New Zealand, toxic seizures and respiratory acidosis 
after the use of BZP alone or in conjunction with oth-
er drugs were reported from three patients.69 Another 
study of 61 patients reported toxic effects of BZP, with 
two cases presenting life-threatening toxicity.70 Hyper-
61 )RQJ0+*DUDWWLQL6&DFFLD6¶P&KORURSKHQ\OSLSHUD]LQHLVDQ
active metabolite common to the psychotropic drugs trazodone, eto-
peridone and mepiprazole’, Journal of  Pharmacy and Pharmacology, 
1982, 34, 674-5
62 ´(QWDFWRJHQV HYRNHPDLQO\ SOHDVDQW HPRWLRQDO HIIHFWV RI  UHOD[DWLRQ
feelings of  happiness, increased empathy, and closeness to others”. 
'RZQLQJ-¶7KHSV\FKRORJLFDODQGSK\VLRORJLFDOHIIHFWVRI 0'0$
RQQRUPDOYROXQWHHUV·-RXUQDO3V\FKRDFWLYH'UXJV
*UHHU*57ROEHUW5¶6XEMHFWLYHUHSRUWVRI WKHHIIHFWVRI 0'0$
LQDFOLQLFDOVHWWLQJ·-RXUQDO3V\FKRDFWLYH'UXJV/L-
HVWHU 0%*URE &6%UDYR*/:DOVK51 ¶3KHQRPHQRORJ\
DQG VHTXHODH RI  PHWK\OHQHGLR[\PHWKDPSKHWDPLQH· -RXUQDO RI 
1HUYRXVDQG0HQWDO'LVHDVH+HUPOH/6SLW]HU
0%RUFKDUGW'.RYDU.$*RX]RXOLV( ¶3V\FKRORJLFDOHIIHFWV
RI 0'(LQQRUPDOVXEMHFWV$UHHQWDFWRJHQVDQHZFODVVRI SV\FKRDF-
WLYHDJHQWV"·1HXURSV\FKRSKDUPDFRORJ\&RKHQ56
¶6XEMHFWLYH UHSRUWVRQ WKHHIIHFWVRI  WKH0'0$´(FVWDV\´H[SHUL-
ence in humans’, Progress in Neuro-Psychopharmacology	%LRORJLFDO3V\-
FKLDWU\LV   9ROOHQZHLGHU);*DPPD$/LHFKWL
M., Huber,T., ‘Psychological and cardiovascular effects and short-term 
VHTXHODHRI 0'0$´HFVWDV\´ LQ0'0$QDLYHKHDOWK\YROXQWHHUV·
1HXURSV\FKRSKDUPDFRORJ\DVFLWHG LQ*RX]RXOLV
0D\IUDQN ( ¶'LIIHUHQWLDO DFWLRQV RI  DQ HQWDFWRJHQ FRPSDUHG WR D
VWLPXODQWDQGDKDOOXFLQRJHQLQKHDOWK\KXPDQV·7KH+HIIWHU5HYLHZ
of  Psychedelic Research, 2001, 2, 64-72
63 :LONLQV&*LUOLQJ06ZHHWVXU3+XFNOH7+DXNDX-¶/HJDO3DUW\
3LOOXVHLQ1HZ=HDODQG3UHYDOHQFHRI 8VH$YDLODELOLW\+HDOWK+DUPV
DQG¶*DWHZD\(IIHFWV·RI %HQ]\OSLSHUD]LQH%=3DQG7ULÁXRURSKHQ\O-
PHWK\OSLSHUD]LQH 7)033·1DWLRQDO+RXVHKROG 6XUYH\ &HQWUH IRU
Social and Health Outcomes Research and Evaluation (SHORE), 
0DVVH\8QLYHUVLW\1HZ=HDODQG
64 Stargate International, ‘Party pills: successful safety record’ (http://
ZZZVFRRSFRQ]VWRULHV326KWP
65 8QLWHG6WDWHV'UXJ(QIRUFHPHQW$GPLQLVWUDWLRQ¶1%HQ]\OSLSHUD]LQH
VWUHHW1DPHV%=3$/HJDO(RU/HJDO;·(XURSHDQ0RQL-
WRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ ¶5HSRUWRQ WKHULVNDV-
VHVVPHQWRI %=3 LQ WKH IUDPHZRUNRI  WKH&RXQFLO GHFLVLRQRQQHZ
psychoactive substances’, Risk Assessments Issue 8, Lisbon, 2009; World 
+HDOWK2UJDQL]DWLRQ¶1EHQ]\OSLSHUD]LQH%=3SUHUHYLHZUHSRUW([-
SHUW&RPPLWWHHRQ'UXJ'HSHQGHQFH7KLUW\ÀIWK0HHWLQJ·
66 (OOLRWW6¶&XUUHQWDZDUHQHVVRI SLSHUD]LQHVSKDUPDFRORJ\DQGWR[L-
FRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
67 %DXPDQQ0&ODUN5'%XG]\QVNL$*3DUWLOOD-6%ORXJK%(
5RWKPDQ5%¶(IIHFWVRI ¶/HJDO;·SLSHUD]LQHDQDORJVRQGRSDPLQH
DQGVHURWRQLQUHOHDVHLQUDWEUDLQ·$QQDOVRI WKH1HZ<RUN$FDGHP\
RI 6FLHQFHV%DXPDQQ0&ODUN5'%XG]\Q-
VNL $* 3DUWLOOD -6 %ORXJK %( 5RWKPDQ5% ¶16XEVWLWXWHG
piperazines abused by humans mimic the molecular mechanism of  
PHWK\OHQHGLR[\PHWKDPSKHWDPLQH0'0$RU¶(FVWDV\··1HX-
ropsychopharmacology, 2005, 30 (3), 550-60
68 7DQFHU0(-RKDQVRQ&(¶7KHVXEMHFWLYHHIIHFWVRI 0'0$DQG
m&33LQPRGHUDWH0'0$XVHUV·'UXJDQG$OFRKRO'HSHQGHQFH
FLWHGLQ(OOLRWW6 ¶&XUUHQWDZDUHQHVVRI SLSHUD]LQHV
SKDUPDFRORJ\DQG WR[LFRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
430-8)
69 *HH 3 5LFKDUGVRQ 6:ROWHUVGRUI: DQG0RRUH* ¶7R[LF HI-
fects of  BZP-based herbal party pills in humans: a prospective study 
LQ&KULVWFKXUFK1HZ=HDODQG·1HZ=HDODQG0HGLFDO-RXUQDO
118, U1784
70 *HH 3 5LFKDUGVRQ 6:ROWHUVGRUI: DQG0RRUH* ¶7R[LF HI-
fects of  BZP-based herbal party pills in humans: a prospective study 
LQ&KULVWFKXUFK1HZ=HDODQG·1HZ=HDODQG0HGLFDO-RXUQDO
118, U1784
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thermia, rhabdomyolysis and renal failure associated 
with BZP ingestion have also been reported.71 In the 
United Kingdom, self-terminating grand mal seizures72 
after the use of BZP have also been reported.73
Between 2004 and 2008, six fatal cases involving pi-
perazines use were reported in Europe. Two of the cases 
involved the use of BZP in conjunction with TFMPP 
and none referred to the use of piperazines alone.74 
BZP and TFMPP were also associated with 19 fatali-
ties between 2007 and 2010.75 While reported effects 
of mCPP include the serotonin syndrome, no fatal poi-
sonings from mCPP have been reported so far.76 Simi-
larly, toxic effects from the use of TFMPP alone have 
not been documented.77
2.6. Plant-based substances 
2.6.1. Khat
Background
The khat shrub (Catha edulis) of the celastraceae fam-
ily is a plant native to the horn of Africa and the Ara-
bian peninsula. Khat chewing is a social custom in 
the communities living in these areas. The psychoac-
tive effects resulting from the release of cathinone and 
cathine alkaloids after chewing of khat are well-docu-
mented.78 The khat shrub became known to Europe-
ans in the late 18th century and in the 19th century, 
and the active constituents of the plant were isolated 
in the 19th and 20th century. A ‘katin’ alkaloid was 
identified first in 1887, ‘cathine’ in 1930 and ‘cathi-
none’ in 1975.79
In Europe and North America, khat was considered 
to be traditionally used by migrant communities from 
Ethiopia, Kenya, Somalia and Yemen, but in recent 
years its use has spread beyond these communities. 
Respondents to the UNODC questionnaire on NPS 
from Bahrain, Canada, Finland, Ireland, Italy, New 
Zealand, Norway, Oman, United States and Hong 
Kong (China) reported that khat emerged on their 
markets in 2009, and was the second most popular 
plant based substance, after salvia divinorum, reported 
by Member States from 2009 to 2012.       
Catha edulis is not under international drug control, 
but cathinone and cathine are listed in Schedules I 
and III, respectively, of the 1971 Convention. Khat is 
under national control in several countries. 
Description  
Street names for khat include ‘qat’, ‘gat’, ‘chat’, ‘miraa’, 
‘murungu’ and ‘Arabian or Abyssinian tea’. Due to the 
degradation of cathinone, khat leaves need to be con-
sumed soon after harvesting and therefore fresh leaves 
of khat are the preferred form of use, but dried leaves 
(‘graba’) are also available. Khat is usually consumed 
by chewing the leaves and shoots of the plant, but in-
fusions are also possible. Recently, alcoholic extracts of 
khat sold as ‘herbal highs’ have been reported.80 
Reported adverse effects
It has been estimated that a typical chewing session of 
khat results in the absorption of its active constituents 
with an activity equivalent to that of approximately 5 
mg of amphetamine.81 The pharmacological effects of 
71 *HH3 -HUUDP7%RZLH' ¶0XOWLRUJDQ IDLOXUH IURPEHQ]\OSL-
SHUD]LQH LQJHVWLRQ²OHJDO KLJK RU OHWKDO KLJK"· &OLQLFDO 7R[LFRORJ\
(Philadelphia), 2010, 48, 230-3
72 $´ JHQHUDOL]HG WRQLFFORQLF VHL]XUH LV D VHL]XUH LQYROYLQJ WKH HQWLUH
ERG\,WLVDOVRFDOOHGDJUDQGPDOVHL]XUH7KHWHUPV´VHL]XUHµFRQ-
YXOVLRQµ RU ´HSLOHSV\µ DUH PRVW RIWHQ DVVRFLDWHG ZLWK JHQHUDOL]HG
tonic-clonic seizures”. United States, National Library of  Medicine 
KWWSZZZQOPQLKJRYPHGOLQHSOXVHQF\DUWLFOHKWP
73 :RRG'0%XWWRQ-/LGGHU65DPVH\-+ROW':'DUJDQ3,
¶'LVVRFLDWLYHDQGV\PSDWKRPLPHWLFWR[LFLW\DVVRFLDWHGZLWKUHFUHDWLRQDO
XVHRI WULÁXRURPHWK\OSKHQ\OSLSHUD]LQH7)033DQGEHQ]\O-
piperzine (BZP)’, Journal of  Medical Toxicology, 2008, 4, 254-7
74 (OOLRWW66PLWK&¶,QYHVWLJDWLRQRI WKHÀUVWGHDWKVLQWKH8.LQ-
YROYLQJ WKHGHWHFWLRQDQGTXDQWLWDWLRQRI  WKHSLSHUD]LQHV%=3DQG
3-TFMPP’, Journal of  Analytical Toxicology, 2008, 32, 172; Wik-
VWURP0+ROPJUHQ3$KOQHU-¶$1%HQ]\OSLSHUD]LQHDQHZ
GUXJRI DEXVHLQ6ZHGHQ·-RXUQDORI $QDO\WLFDO7R[LFRORJ\
%DOPHOOL&.XSIHUVFKPLGW+5HQWVFK.DQG6FKQHHPDQQ0
‘Fatal brain edema after ingestion of  ecstasy and benzylpiperazine’, 
'HXWVFKH0HGL]LQLVFKH:RFKHQVFKULIW
75 (OOLRWW6¶&XUUHQWDZDUHQHVVRI SLSHUD]LQHVSKDUPDFRORJ\DQGWR[L-
FRORJ\·'UXJ7HVWLQJDQG$QDO\VLV$GHWDLOHGGHVFULS-
tion of  fatal and non-fatal cases related to the use of  BZP is available 
LQ:RUOG+HDOWK2UJDQL]DWLRQ¶1EHQ]\OSLSHUD]LQH%=3SUHUHYLHZ
UHSRUW([SHUW&RPPLWWHHRQ'UXJ'HSHQGHQFH7KLUW\ÀIWK0HHW-
ing’, 2012
76 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ ¶%=3
DQGRWKHUSLSHUD]LQHV·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
77 (OOLRWW6¶&XUUHQWDZDUHQHVVRI SLSHUD]LQHVSKDUPDFRORJ\DQGWR[L-
FRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
78 6DZDLU)$$O0XWZDNHO$$O(U\DQL.$O6XUK\$0DUX\DPD
6&KHQJ-$O6KDUDEL$DQG6DNX7¶+LJKUHODWLYHIUHTXHQF\RI 
RUDOVTXDPRXVFHOOFDUFLQRPDLQ<HPHQTDWDQGWREDFFRFKHZLQJDV-
its aetiological background’, International Journal of  Environmental 
Health Research, 2007, 17, 185-95
79 See Szendrei, K., ‘The chemistry of  khat’, Bulletin on Narcotics, 1980, 
32, 3, 5-35 for further information. 
80 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶NKDW·
'UXJ3URÀOHVZZZHPFGGDHXURSDHX
81 'KDLIDODK,DQG6DQWDY\-¶.KDWKDELWDQGLWVKHDOWKHIIHFW$QDWXUDO
amphetamine’, Biomedical Papers, 2004, 148, 11-5
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khat resemble those of amphetamine use, and includes 
increased alertness, euphoria, hyperthermia, anorexia, in-
creased respiration rate, heart rate and blood pressure.82
Fatalities associated with the sole consumption of khat 
have not yet been reported. However, prolonged use 
of khat has been linked to adverse effects that range 
from psychiatric disturbances (from psychosis to de-
pression) to damage of major organs of the body, as 
well as to similar neurological disorders to those as-
sociated with amphetamine and cocaine use.83
2.6.2. Kratom 
Background
Mitragyna speciosa Korth (of the Rubiaceae family) is a 
large tree found in tropical and sub-tropical regions of 
South-East Asia. In Thailand, the tree known  as ‘Kra-
tom’ is found throughout the country but predomi-
nantly in the southern region, although the growing 
and harvesting is prohibited. 
Kratom contains many alkaloids including mitragynine, 
mitraphylline, and 7-hydroxymitragynine. Traditional-
ly, kratom had been used in Malaysia and Thailand by 
labourers and farmers to enhance productivity, but also 
as a substitute to opium and in traditional medicine, 
allegedly due to its morphine-like pharmacological ef-
fects. However, its use as a new psychoactive substance 
in the global market has been recently reported. 
In the early 2000s, products labelled as ‘kratom acetate’ or 
‘mitragynine acetate’ became available in Europe, although 
it was found that neither of them contained mitragynine. 
Caffeine and synthetic O-desmethyltramadol (an active 
metabolite of tramadol) were found in products under 
the name ‘krypton’.84 More recently, products containing 
kratom have been sold as ‘incense’ for their psychoactive 
effects, but concentrations of the active components mi-
tragynine and 7-hydroxymitragynine in these products 
differ depending on the variety of the plant used, the en-
vironment and the time of harvesting.
Internet surveys conducted by the EMCDDA in 2008 
and 2011 revealed that kratom is one of the most 
widely offered NPS.85 Respondents to the UNODC 
questionnaire on NPS reported kratom among the 
top three plant-based substances, along with khat and 
salvia divinorum.86 As kratom is often not monitored 
in national drug abuse surveys, there is little informa-
tion on prevalence of its use.
Neither kratom nor any of its active alkaloids are list-
ed under the 1961 and 1971 Conventions, but several 
countries have adopted control measures on kratom, 
mitragynine and 7-hydroxymitragynine.
Description
Street names for kratom include ‘thang’, ‘kakuam’, 
‘thom’, ‘ketum’ and ‘biak’. Kratom leaves are usually 
consumed fresh, although dried leaves in powder form 
are also available. The fresh leaves are chewed while 
the powder form is often either swallowed or brewed 
into tea. Dried leaves are rarely smoked.
Reported adverse effects 
In spite of the increasing use of this substance, scientific 
literature about the effects and toxicity of kratom alone 
remains very scarce.
Kratom is a central nervous system stimulant, from 
which over 40 alkaloids have been isolated. In low doses 
it is reported to have stimulant effects (used to combat 
fatigue during long hours of work), while at high doses, 
it can have sedative-narcotic effects.87 In 1921, the ma-
jor alkaloid found in this plant, ‘Mitragynine’, was first 
isolated. Mitragynine has an opioid agonistic activity 
and its derivative 7-hydroxymitragynine (7-OH-mi-
tragynine) is reported to be more potent than mitragy-
nine or morphine.88
82 .HOO\-3¶&DWKLQRQHGHULYDWLYHVDUHYLHZRI WKHLUFKHPLVWU\SKDUPD-
FRORJ\DQGWR[LFRORJ\·'UXJ7HVWLQJDQG$QDO\VLV
83 Hoffman, R. and Al’absi, M., ‘Khat use and neurobehavioural func-
tions: suggestions for future studies’, Journal of  Ethnopharmacol-
ogy, 2010, 132, 554; Morrish, P.K., Nicolaou, N., Brakkenberg, P. 
DQG6PLWK3(¶/HXNRHQFHSKDORSDWK\DVVRFLDWHGZLWKNKDWPLVXVH·
Journal of  Neurology, Neurosurgery, and Psychiatry, 1999, 67, 556; 
2GHQZDOG0¶&KURQLFNKDWXVHDQGSV\FKRWLFGLVRUGHUVDUHYLHZRI 
the literature and future prospects’,  Sucht, 2007, 53, 9-22
84 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJV DQG'UXJ$GGLFWLRQ ¶NUD-
WRP·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
85 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJV DQG'UXJ$GGLFWLRQ ¶NUD-
WRP·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
86 8QLWHG1DWLRQV2IÀFHRQ'UXJVDQG&ULPH¶812'&TXHVWLRQQDLUH
RQQHZSV\FKRDFWLYHVXEVWDQFHV·VXEPLWWHGE\0HPEHU6WDWHVDQGD
QHWZRUNRI GUXJDQDO\VLVODERUDWRULHVLQ
87 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJV DQG'UXJ$GGLFWLRQ ¶NUD-
WRP·'UXJ3URÀOHVZZZHPFGGDHXURSDHX
88 .LNXUD+DQDMLUL5.DZDPXUD00DUX\DPD7.LWDMLPD07DND\D-
PD+DQG*RGD<¶6LPXOWDQHRXVDQDO\VLVRI PLWUDJ\QLQHK\GUR[\PL-
WUDJ\QLQHDQGRWKHUDONDORLGVLQWKHSV\FKRWURSLFSODQW´ NUDWRPµMitragy-
na speciosaE\/&(6,06·)RUHQVLF7R[LFRORJ\
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Nine fatal cases of intoxication associated with the use of 
‘krypton’, a mixture of mitragynine and O-desmethyltra-
madol, have been described in scientific literature. How-
ever, these fatalities have been attributed to the addition 
of O-desmethyltramadol to the dried kratom leaves.89
2.6.3. Salvia divinorum
Background
Salvia divinorum (of the mint family Lamiaceae), is a 
psychoactive plant indigenous to forest areas in Oxa-
ca, Mexico. It was traditionally used by the Mazatec 
Indians for religious practices and medical purposes, 
although there is no approved medicinal use for salvia 
divinorum or its active ingredient salvinorin A. The 
use of salvia divinorum as a new psychoactive sub-
stance dates back to the 1990s but respondents to the 
UNODC questionnaire on NPS identified this plant 
as the most common plant-based substance in 2009, 
and the third, after khat and kratom, in 2012. 
Neoclerodane diterpene (i.e. salvinorin A) is the active 
component responsible for the psychoactive effects of 
the plant in the 1980s. The concentration of salvino-
rin A in salvia divinorum leaves varies and depends on 
the stage of development of the plant and the type of 
preparation.
Neither salvia divinorum nor salvinorin A are under 
international control. However, due to the increasing 
use of this plant as a new psychoactive substance, the 
plant and its active constituent salvinorin A are in-
creasingly controlled in several countries under differ-
ent regulatory frameworks. 
Description 
Street names for salvia divinorum include ‘Maria Pas-
tora’, ‘Sage of the Seers’, ‘Diviner’s Sage’, ‘Salvia’, ‘Sally-D’, 
‘Magic Mint’, ‘Purple Sticky’, ‘Shepherdess’s Herb’.90
Salvia divinorum is usually sold as seeds or leaves, but 
a liquid extract purported to contain salvinorin A and 
a combination of dried leaves and extracts of salvino-
rin A (known as ‘the fresh-man selection’ or the ‘starter 
pack’) are also available on the market.91 Recent studies 
of products containing salvia divinorum have shown a 
mismatch between the label and the actual constituent 
of the products. Vitamin E and caffeine have also been 
reported as adulterants.
Salvia divinorum is traditionally consumed by sucking 
and chewing the fresh leaves from a cigar-like roll or al-
ternatively the fresh leaves are crashed to make a drink-
able infusion. Many users reportedly inhale vaporized sal-
vinorin A extract, or smoke the dried leaves of the plant. 
Smoking of the dry leaves is reported to produce short 
but intense hallucinations, and the effects of salvinorin A 
have been compared to those of LSD or DOB.92
Reported adverse effects
Animal studies have shown low toxicity and low addic-
tive potential for salvia divinorum.93 Like other plant-
based substances, there are limited scientific studies in 
humans that report acute or chronic toxicity associated 
with its use, but clinical observations have indicated last-
ing psychosis in vulnerable individuals. Thus far, there 
are no reports on fatalities from use of salvia divinorum. 
However, toxicological analyses have proved difficult as 
salvinorin A and other diterpenoids of the plant are not 
detected by conventional drug screening methods.94
2.7. Miscellaneous substances
2.7.1. Aminoindanes 
Background 
In the 1970s, aminoindanes were reported to possess 
significant bronchodilating and analgesic properties, but 
recent research has indicated that they also have potent 
effects on serotonin release and re-uptake.95 These sub-
89 .URQVWUDQG55RPDQ07KHODQGHU* DQG(ULNVVRQ$ ¶8QLQ-
WHQWLRQDOIDWDOLQWR[LFDWLRQVZLWKPLWUDJ\QLQHDQG2GHVPHWK\OWUDPDGRO
from the herbal blend krypton’, Journal of  Analytical Toxicology,  2011, 
35 (4), 242-7
90 8QLWHG6WDWHV'UXJ(QIRUFHPHQW$GPLQLVWUDWLRQ‘Salvia divinorum and 
VDOYLQRULQ $·  KWWSZZZGHDGLYHUVLRQXVGRMJRYGUXJVBFRQ-
FHUQVDOYLDBGSGI(XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ
Addiction, ‘Salvia divinorum’'UXJ3URÀOHVZZZHPFGGDHXURSDHX
91 %DEX.00F&XUG\&5DQG%R\HU(:¶2SLRLGUHFHSWRUVDQG
legal highs: Salvia divinorumDQG.UDWRP·&OLQLFDO7R[LFRORJ\3KLOD-
delphia), 2008, 46 (2), 146-52
92 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ‘Salvia 
divinorum’'UXJ3URÀOHVZZZHPFGGDHXURSDHX
93 0RZU\00RVKHU0DQG%ULQHU:¶$FXWHSK\VLRORJLFDQGFKURQ-
LFKLVWRORJLFFKDQJHVLQUDWVDQGPLFHH[SRVHGWRWKHXQLTXHKDOOXFLQR-
JHQVDOYLQRULQ$·-RXUQDORI 3V\FKRDFWLYH'UXJV
94 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ‘Salvia 
divinorum’'UXJ3URÀOHVZZZHPFGGDHXURSDHX
95 Solomons, E. and Sam, J, ‘2-aminoindans of  pharmacological inter-
HVW· -RXUQDO RI 0HGLFLQDO &KHPLVWU\     -RKQVRQ
M.P., Frescas, S.P., et al., ‘Synthesis and pharmacological examination of  
1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-meth-
yl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine 
0'0$·-RXUQDORI 0HGLFLQDO&KHPLVWU\
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stances have been sold as NPS for their ability to produce 
empathogenic and entactogenic effects of serotonin re-
leasing drugs, such as MDMA.96
2-Aminoindane (2-AI) is a rigid analogue of amphet-
amine. Its basic ring structure can be modified to produce 
diverse chemical substances such as 5-Iodo-2-aminoin-
dane (5-IAI) and 5,6-methylenedioxy-2-aminoindane 
(MDAI). Analogues of aminoindanes are prepared us-
ing indanone, indene or after intramolecular cyclization 
of the acyl chloride derivative of 3-phenyl-2-propanoic 
acid.97 Other aminoindanes sold as NPS include ETAI 
(N-Ethyl-5-trifluoromethyl-2-aminoindane) and TAI 
(5-trifluoromethyl-2-aminoindane)98 which are ana-
logues of fenfluramine and norfenfluramine, substances 
used as appetite suppressants.99
MDAI, 5-IAI and 2-AI were reported by respondents to 
the UNODC questionnaire on NPS as the most com-
mon substances within this group. None of the aminoin-
danes are under international control. 
Description
Street names of MDAI include ‘MDAI gold’, while 2-AI has 
been found in party pills known as ‘Pink Champagnes’.100 
Aminoindanes are commonly found in powder form and 
crystals and are usually ingested, but snorting is also possible. 
Reported adverse effects
Research conducted in animals and in in vitro cell cultures 
indicates that aminoindanes are relatively benign at rec-
reational doses; however, the effects on humans have not 
yet been reported.101 MDAI and 5-IAI are reported to be 
highly potent selective serotonin releasing agents. Animal 
studies have shown that these analogues did not present 
any long-term neurotoxicity at the levels administered,102 
but slight neurotoxicity on rodents was shown after ad-
ministration of very high doses of 5-IAI.103 
2.7.2. Phencyclidine-type substances
Background 
Another group of NPS that has recently appeared in 
the market include phencyclidine-type substances. 
Phencyclidine (PCP) and ketamine (see section 2.3) 
show structural similarity and are classified as arylcy-
cloalkylamines.104
PCP was first synthesized in the 1950s and sold until 
1967 as an injectable anaesthetic in the United States 
under the trade names Sernyl and Sernylan. It was 
withdrawn from the market due to intensely negative 
psychological effects, such as dysphoria, confusion, 
96 0RQWH $30DURQDOHZLFND' HW DO ¶6\QWKHVLV DQG SKDUPDFRORJLFDO
examination of  benzofuran, indan, and tetralin analogs of  3,4-(methylene-
GLR[\DPSKHWDPLQH·-RXUQDORI 0HGLFLQDO&KHPLVWU\
97 6DLQVEXU\3'.LFPDQ$7HWDO¶$PLQRLQGDQHVWKHQH[WZDYHRI 
¶OHJDOKLJKV·"·'UXJ7HVWLQJDQG$QDO\VLV
98 Ibid
99 )HQÁXUDPLQH3RQGLPLQDQGIHQÁXUDPLQH5HGX[ZHUHDS-
proved for the treatment of  obesity by the United States Food and 
'UXJ$GPLQLVWUDWLRQ LQ  DQG  UHVSHFWLYHO\ %RWK IHQÁXUD-
PLQHVZHUHZLWKGUDZQIURPWKHPDUNHWLQEHFDXVHYDOYXODUKHDUW
GLVHDVH9+'ZDVGLVFRYHUHGLQVRPHSDWLHQWVUHFHLYLQJWKHVHGUXJV
&RQQROO\+0&UDU\-/0F*RRQ0'+HQVUXG''(GZDUGV
%6DQG6FKDII+9¶9DOYXODUKHDUWGLVHDVHDVVRFLDWHGZLWKIHQÁXUD-
PLQHSKHQWHUPLQH·1HZ(QJODQG-RXUQDORI 0HGLFLQH
&RQQROO\+0 DQG0F*RRQ0' ¶2EHVLW\ GUXJV DQG WKH
KHDUW·&XUUHQW3UREOHPVLQ&DUGLRORJ\:HLVVPDQ
N. J., ‘Appetite suppressants and valvular heart disease’, The American 
Journal of  the Medical Sciences, 2001, 321 (4), 285-91
100 .DYDQDJK396KDUPD-HWDO¶+HDGVKRS´OHJDOKLJKVµDFWLYHFRQ-
VWLWXHQWV ,GHQWLÀFDWLRQ FKDUW 0D\  SUHEDQ·'HSDUWPHQW RI 
3KDUPDFRORJ\DQG7KHUDSHXWLFV6FKRRORI 0HGLFLQH7ULQLW\&HQWUH
IRU+HDOWK6FLHQFHV6W-DPHV·V+RVSLWDO'XEOLQ
101 6DLQVEXU\3'.LFPDQ$7HWDO¶$PLQRLQGDQHVWKHQH[WZDYHRI 
¶OHJDOKLJKV·"·'UXJ7HVWLQJDQG$QDO\VLV
102 Johnson, M.P., Frescas, S.P., et al., ‘Synthesis and pharmacological 
examination of  1-(3-methoxy-4-methylphenyl)-2-aminopropane and 
5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylene-
GLR[\PHWKDPSKHWDPLQH 0'0$· -RXUQDO RI  0HGLFLQDO &KHPLV-
WU\0RQWH$30DURQDOHZLFND'HWDO¶6\QWKHVLV
and pharmacological examination of  benzofuran, indan, and tetralin 
analogs of  3,4-(methylenedioxy)amphetamine’, Journal of  Medicinal 
&KHPLVWU\0DURQD/HZLFND'5KHH*6HWDO¶5H-
inforcing effects of  certain serotonin-releasing amphetamine deriva-
tives’, Pharmacology Biochemistry and Behavior, 1996, 53, 99-105
103 1LFKROV' -RKQVRQ03DQG2EHUOHQGHU5 ¶LRGRDPLQRLQ-
dan, a nonneurotoxic analog of  para-iodoamphetamine’, Pharmacol-
RJ\%LRFKHPLVWU\	%HKDYLRU
104 Baldridge, E.B., Bessen, H.A., ‘Phencyclidine’, Emergency Medicine 
&OLQLFVRI 1RUWK$PHULFD     %DOVWHU5/ ¶7KH
behavioral pharmacology of  phencyclidine’, in H.Y. Meltzer (Eds.), 
3V\FKRSKDUPDFRORJ\7KHWKLUGJHQHUDWLRQRI SURJUHVV1HZ<RUN
1987, 1573–9; The structure-activity relationships among arylcycloal-
N\ODPLQHVFDQEHIXUWKHUFRQVXOWHGLQ0DQDOODFN'7'DYLHV-:
%HDUW306DXQGHUV05DQG/LYLQJVWRQH'-¶$QDO\VLVRI WKHELR-
logical and molecular properties of  phencyclidine-like compounds by 
chemometrics’, Arzneimittelforschung, 1993, 43 (10), 1029-32
Chemical structures of Amphetamine (A) and 2-AI (B). 
The differences between amphetamine (internationally 
controlled substance) and 2-AI are highlighted in red.
NH2
A
NH2
B
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delirium, and psychosis.105  Its use as a recreational 
drug started in the mid-1960s, but its unpredictable 
dysphoric reactions made the drug infamous. 
PCP-type substances appeared for the first time in Eu-
rope as ‘research chemicals’ in 2010, when the United 
Kingdom reported 3-methoxyeticyclidine (3-MeO-
PCE) to the European Early Warning System.106 In 
2011, 4-methoxyphencyclidine  (4-MeO-PCP) was 
identified in Norway, Russian Federation and the 
United Kingdom.107 Respondents to the UNODC 
questionnaire on NPS reported 4-MeO-PCP as the 
most common PCP-type substance.
PCP and phenylcyclohexyl analogues, including eticy-
clidine (PCE), rolicyclidine (PHP, PCPY), tenocycli-
dine (TCP) are controlled in Schedule I of the 1971 
Convention but derivatives such as 3-MeO-PCE and 
4-MeO-PCP are not under international control.
 
Description
3-MeO-PCE and 4-MeO-PCP are frequently sold as 
research chemicals and usually in powder form.
Reported adverse effects
There is very limited information on the PCP ana-
logues. Acute PCP intoxication results in a wide range 
of behavioural/psychological effects, from mild neu-
rologic and physiologic abnormalities, stupor or light 
coma to deep coma. Manifestations of behavioural 
toxicity resemble psychiatric syndromes. PCP has also 
been claimed to cause violent behaviour.108
2.7.3. Tryptamines 
Background 
Tryptamine, the prototype of the tryptamines group, is 
a primary amine alkaloid. Some tryptamines are natural 
neurotransmitters while most are psychoactive halluci-
nogens found in plants, fungi and animals.109 Natural 
tryptamines include serotonin, melatonin, bufotenin,110 
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 
and dimethyltryptamine (DMT). Other tryptamines 
have been synthesized for pharmaceutical purposes to 
combat medical conditions (e.g. sumatriptan and zolmi-
triptan to treat migraine), but they have also been used 
as NPS.
The use of psilocybin,111 a natural hallucinogen found 
in certain species of mushrooms that contain the 
tryptamine structure, became widespread in the late 
1950s in the United States, but synthetic tryptamines 
appeared on illicit drug markets only throughout the 
1990s. The use of tryptamines remains limited but ap-
pears to have increased over the past five years. For 
example, the Drug Enforcement Administration of 
the United States reported that the estimated number 
of tryptamine reports to State and local laboratories 
in the United States rose from 42 reports in 2006 to 
474 reports in 2010. Respondents to the UNODC 
questionnaire on NPS reported the incidence of both 
natural and synthetic tryptamines including, 5-MeO-
DMT, 5-MeO-DPT, AMT, 4-AcO-DMT, 4-AcO-
DiPT, and 5-HTP. 
Psilocin, psilocybin, DET, DMT, and etryptamine are 
the only tryptamines under international control (listed 
in Schedule I of the 1971 Convention). Some others 
are restricted at the national level in several countries.
105 3HDUOVRQ*' ¶3V\FKLDWULF DQGPHGLFDO V\QGURPHV DVVRFLDWHGZLWK
SKHQF\FOLGLQH 3&3DEXVH·  -RKQV+RSNLQVPHGLFDO MRXUQDO 
6PLWK-%¶6LWXDWLRQDOVSHFLÀFLW\RI WROHUDQFHWRHIIHFWV
RI SKHQF\FOLGLQHRQUHVSRQGLQJRI UDWVXQGHUÀ[HGUDWLRDQGVSDFHG
responding schedules’, Psychopharmacology, 1991, 103, 121-8
106 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQDQG(X-
URSHDQ3ROLFH2IÀFH ¶(0&''$²(XURSRO $QQXDO UHSRUW RQ
WKH LPSOHPHQWDWLRQ RI &RXQFLO'HFLVLRQ -+$$QQH[ 
³1HZSV\FKRDFWLYHVXEVWDQFHVUHSRUWHGWRWKH(0&''$DQG(X-
URSROIRUWKHÀUVWWLPHLQXQGHUWKHWHUPVRI &RXQFLO'HFLVLRQ
2005/387/JHA’, Lisbon, 2011    
107 8QLWHG1DWLRQV2IÀFHRQ'UXJVDQG&ULPH¶812'&TXHVWLRQQDLUH
RQQHZSV\FKRDFWLYHVXEVWDQFHV·VXEPLWWHGE\0HPEHU6WDWHVDQGD
QHWZRUNRI GUXJDQDO\VLVODERUDWRULHVLQ
108 *RUHOLFN'$DQG%DOVWHU5/¶3KHQF\FOLGLQH3&3·LQ)(%ORRP
	5/.XSIHU (GV3V\FKRSKDUPDFRORJ\7KHIRXUWKJHQHUDWLRQ
RI  SURJUHVV 1HZ <RUN   %UHFKHU 0 :DQJ %:
Wong, H. and Morgan, J.P., ‘Phencyclidine and violence: clinical and 
OHJDO LVVXHV· -RXUQDO RI  &OLQLFDO 3V\FKRSKDUPDFRORJ\   
'DJKHVWDQL $1 DQG 6FKQROO 6+ ¶3KHQF\FOLGLQH DEXVH
DQGGHSHQGHQFH·7UHDWPHQWVRI 3V\FKLDWULF'LVRUGHUV$WDVNIRUFH
report of  the American Psychiatric Association, American Psychiatric 
$VVRFLDWLRQ:DVKLQJWRQ'&
109 &ROOLQV0¶6RPHQHZSV\FKRDFWLYHVXEVWDQFHVSUHFXUVRUFKHPLFDOV
DQGV\QWKHVLVGULYHQHQGSURGXFWV·'UXJ7HVWLQJDQG$QDO\VLV
3 (7-8), 404-16
110 %XIRWHQLQ D WU\SWDPLQH FORVHO\ UHODWHG WR VHURWRQLQZDV RULJLQDOO\
found by Wieland in the 1930s. Wieland, H., Konz, W. and Mittash, 
+¶'LH.RQVWLWXWLRQYRQ%XIRWHQLQXQG%XIRWHQLGLQhEHU.U|WHQ
*LIWVWRIIH9,,· -XVWXV /LHELJV$QQDOHQ GHU&KHPLH   
1-25
111 7KHVWUXFWXUHVRI SVLORFLQDQGSVLORF\ELQZHUHFRQÀUPHGE\$OEHUW
Hoffmann et al. in 1959. Hoffmann, A., Heim. R., Brack, A. and Ko-
bel, H., ‘Experientia’, 1958, 14, 107-9; Hoffmann, A., Heim, R., Brack, 
A., Kobel, H., Frey, A., Ott, H., Petrzilka, T. and Troxler, F., ‘Psilo-
F\ELQXQG3VLORFLQ]ZHLSV\FKRWURSH:LUNVWRIIHDXVPH[LNDQLVFKHQ
5DXVFKSLO]HQ·+HOYHWLFD&KLPLFD$FWD
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Description
Street names for some tryptamines include ‘Foxy-Me-
thoxy’ (5-MeO-DIPT);  ‘alpha-O’, ‘alpha’ and ‘O-DMS’ 
(5-MeO-AMT); ‘5-MEO’ (5-MeO-DMT). Natural 
tryptamines are commonly available in preparations 
of dried or brewed mushrooms, while tryptamine de-
rivatives are sold in capsule, tablet, powder or liquid 
form. Tryptamines are generally swallowed, sniffed, 
smoked or injected. 
Reported adverse effects 
Toxicological studies on tryptamines remain limited. 
Reported adverse effects related to the use of ‘foxy me-
thoxy’ include restlessness, agitations, gastrointestinal 
distress, and muscle tension.112 Rhabdomyolosis after 
ingestion of ‘Foxy’ has also been described in a case 
study.113 Other fatalities associated with the use of 
‘Foxy’ and other tryptamines have also been described 
in scientific literature.114
112 $ODWUDVK*0DMKDLO16DQG3LOH-&¶5KDEGRP\RO\VLVDIWHULQJHV-
WLRQRI ´)R[\µDKDOOXFLQRJHQLFWU\SWDPLQHGHULYDWLYH·0D\R&OLQLF
Proceedings, 2006, 81 (4), 550-1
113$ODWUDVK*0DMKDLO16DQG3LOH-&¶5KDEGRP\RO\VLVDIWHULQJHV-
WLRQRI ´)R[\µDKDOOXFLQRJHQLFWU\SWDPLQHGHULYDWLYH·0D\R&OLQLF
Proceedings, 2006, 81 (4), 550-1
114 Einosuke, T., Tooru, K., Munehiro, K., Hitoshi, T. and Katsuya, H., ‘A 
IDWDO SRLVRQLQJZLWK PHWKR[\11GLLVRSURS\OWU\SWDPLQH )R[\·
Forensic Science International, 2006, 163, 152–4; Sklerov, J., Levine, 
%0RRUH.$.LQJ7DQG)RZOHU'¶$IDWDOLQWR[LFDWLRQIROORZ-
ing the ingestion of  5-methoxy-N,N-dimethyltryptamine in an aya-
huasca preparation’, Journal of  Analytical Toxicology, 2005, 29 (8), 
838-41
Chemical structures of DMT (A), 5-MeO-DMT (B) and the generic structure of tryptamine derivatives (C). The structural 
differences between 5-MeO-DMT and the related DMT (internationally controlled substance) is highlighted in red. (C) 
Represents the generic structure of tryptamine derivatives, showing five of the positions that have been modified so far to 
produce synthetic tryptamines.
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3. THE GLOBAL SPREAD OF NEW 
PSYCHOACTIVE SUBSTANCES
3.1. Emergence of new psychoactive 
substances
Prior to the present report, no information was avail-
able on the global spread of NPS, due to the absence 
of a global early warning system which monitors 
the appearance of new substances. The UNODC 
questionnaire on NPS, which was used to collect 
information on this issue, received more than 240 
responses from 80 countries and territories, indicat-
ing a high level of interest in the subject.115 Most 
questionnaires were received from countries in Eu-
rope (33), which might be due to the high degree of 
awareness of the problem in that region, followed 
by Asia (23 countries and territories), Americas (12 
countries), Africa (10 countries) and Oceania (2 
countries). 
All 80 countries and territories from all regions 
provided data on the emergence of NPS, with 70 
countries and territories116 (87%) indicating that 
NPS had appeared on their drugs market, compared 
to 10 countries117 (13%) which reported otherwise. 
Responses indicate a worldwide spread of NPS, with 
countries and territories reporting their appearance 
in Europe (31 countries or 94% of respondents), 
followed by Asia (19 countries and territories or 
86% of respondents), the Americas (11 countries or 
92% of respondents), Africa (7 countries or 70% 
of respondents) and Oceania (2 countries or all re-
spondents). 
With respect to the global emergence by NPS 
groups, ketamine as well as plant-based substances 
were reported by 44 respondents (83%), followed 
by piperazines with 41 respondents (77%) and syn-
thetic cannabinoids with 40 respondents (75%). The 
least reported NPS group were phenethylamines, re-
ported by 32 respondents (60%).
115 Multiple responses were received from some countries, as question-
naires were frequently circulated to various authorities working on 
this issue. In the analysis of  the data, only respondents that provided 
full identifying information (institutions, country/territory) were con-
sidered.
116 Countries and territories reporting emergence of  NPS: Albania, 
Andorra, Angola, Argentina, Australia, Bahrain, Belgium, Bosnia 
and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, 
Cape Verde, Chile, China, Colombia, Costa Rica, Croatia, Ecuador, 
Egypt, Finland, France, Georgia, Germany, Ghana, Greece, Hong 
Kong SAR, Hungary, Indonesia, Ireland, Israel, Italy, Japan, Jordan, 
Latvia, Lebanon, Liechtenstein, Lithuania, Luxembourg, Malaysia, 
Malta, Mexico, Republic of  Moldova, Mongolia, Netherlands, New 
Zealand, Norway, Oman, Panama, Philippines, Poland, Portugal, Ro-
mania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, 
South Africa, Spain, Switzerland, Thailand, Togo, Turkey, United 
Arab Emirates, United Kingdom, United States of  America, Uru-
guay, Viet Nam, Zimbabwe.
117  Countries, which reported that NPS had not emerged: Armenia, 
Azerbaijan, the former Yugoslav Republic of  Macedonia, Mauritius, 
Monaco, Nepal, Nigeria, Seychelles, Turkmenistan and Venezuela 
(Bolivarian Republic of).
Global emergence of new psychoactive 
substances
Source: UNODC quesonnaire on NPS, 2012
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Global emergence by new psychoactive substances group
Source: UNODC quesonnaire on NPS, 2012
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All NPS groups have emerged in all regions, except 
Africa where, so far, no synthetic cathinones and 
phenethylamines have been reported.
The appearance of the NPS groups over time shows 
that all groups appeared before 2008, with ketamine 
being the most widely reported NPS (79%), followed 
Regional emergence of new psychoactive substances 
Source: UNODC quesonnaire on NPS, 2012
7
11
19
31
2
3
1
4
2
0
0
5
10
15
20
25
30
35
Africa Americas Asia Europe Oceania
No
 o
f c
ou
nt
rie
s a
nd
 te
rr
ito
rie
s
yes no
22
Global SMART Programme 2013
ÇÇÇÇÇÇÇÇ Ç Ç
ÇÇ Ç
ÇÇ
Ç
ÇÇÇ
Ç
Ç Ç Ç ÇÇ
ÇÇÇÇÇÇÇÇ Ç Ç
ÇÇ Ç
ÇÇ
Ç
ÇÇÇ
Ç
Ç Ç Ç ÇÇ
ÇÇÇÇÇÇÇÇ Ç Ç
ÇÇ Ç
ÇÇ
Ç
ÇÇÇ
Ç
Ç Ç Ç ÇÇ
ÇÇÇÇÇÇÇÇ Ç Ç
ÇÇ Ç
ÇÇ
Ç
ÇÇÇ
Ç
Ç Ç Ç ÇÇ
Map 2: Global emergence of  the new psychoactive substances group
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by phenethylamines (75%) and piperazines (66%). 
Synthetic cathinones made their largest first appear-
ance on the market in 2009. Synthetic cannabinoids, 
on the other hand, rarely known before 2008, became 
more widespread until 2010, the year when their ap-
pearance was most frequently reported. 
Appearance of new psychoactive substances groups up to 2012
Source: UNODC quesonnaire on NPS, 2012
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Synthetic cathinones 
Finland, Germany, Hungary, Netherlands and Norway as 
well as Japan and Hong Kong (China) reported the ap-
pearance of synthetic cathinones for the first time before 
2008 and Israel for 2009. In comparison to synthetic can-
nabinoids, synthetic cathinones first appeared in Australia 
before 2008, and then in 2008 in New Zealand. In Can-
ada and Mexico, synthetic cathinones appeared before 
2008, followed by the United States in 2009. The highest 
number of countries, 14 all from Europe 118, first reported 
synthetic cathinones in 2009. In 2011, this class of sub-
stances was also reported by Brazil, Greece, Luxem-
bourg, Moldova, Mongolia, Singapore and Turkey. 
Synthetic cannabinoids 
Canada, Japan, Liechtenstein, Mexico and Togo re-
ported that synthetic cannabinoids appeared on their 
markets before 2008, while New Zealand reported 
their first appearance in 2008. In Europe, synthetic 
cannabinoids started to emerge on a larger scale in 
2008 and 2009, with seven countries reporting every 
year first appearances In the Americas, synthetic can-
nabinoids were reported in 2009 from Chile and the 
United States. In Europe, the appearance of synthetic 
cannabinoids reached its peak in 2010 when ten coun-
tries reported these substances (Belgium, Bulgaria, 
Croatia, Lithuania, Luxembourg, Malta, Netherlands, 
Slovakia, Spain and Turkey). Outside Europe, Austra-
lia, Egypt, Israel and Hong Kong SAR reported their 
first emergence in 2010.  Greece, Moldova, Mongolia 
and Singapore reported first appearance of synthetic 
cannabinoids in 2011.
Source: UNODC questionnaire on NPS, 2012
Before 2008 2008 2009 2010 2011 2012
Africa 1 - - 1 - -
Americas 2 - 2 - - -
Asia 1 - - 2 2 -
Europe 1 7 7 10 2 -
Oceania - 1 - 1 - -
Map 3: Emergence of synthetic cannabinoids by region up to 2012
118 Belgium, Bulgaria, Croatia, France, Ireland, Italy, Latvia, Malta, Po-
land, Portugal, Romania, Russian Federation, Switzerland and the 
United Kingdom.
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Plant-based substances 
Twenty-three countries from all regions reported the 
emergence of plant-based substances before 2008.119 
In 2008, seven European countries (Belgium, Bul-
garia, Latvia, Luxembourg, Poland, Portugal and Slo-
vakia) reported plant-based substances. In Asia, first 
reports of the appearance of plant-based substances 
were made by Hong Kong (China) in 2009, Lebanon 
in 2010 and Mongolia in 2011. In 2012, this NPS 
group emerged in Bahrain and Liechtenstein as well 
as in Costa Rica and Chile. In Europe, at least one 
country reported the first appearance of a plant-based 
substance every year.
The African countries which responded to the ques-
tionnaire did not report the appearance of synthetic 
cathinones.
Ketamine, phenethylamines and piperazines emerged 
in all regions before 2008. These substance groups are 
the most widespread, having appeared in almost all 
countries and territories which responded to the sur-
vey. Only a few respondents reported the appearance 
of ketamine after 2008, including Slovakia which re-
ported its first appearance in 2009, Bulgaria and New 
Zealand (2010), and Ecuador and Panama (2011). 
Phenethylamines first appeared in most countries and 
regions (except Africa) before 2008.  Bulgaria, Ireland, 
Latvia and Turkey reported their first appearance in 
2009, while Mongolia and New Zealand reported first 
appearance of phenethylamines in 2011. Most regions 
reported the emergence of piperazines before 2008. 
Source: UNODC questionnaire on NPS, 2012
Map 4: Emergence of synthetic cathinones by region up to 2012
Before 2008 2008 2009 2010 2011 2012
Africa - - - - - -
Americas 2 - 1 - 1 -
Asia 2 1 - - 2 -
Europe 5 1 14 2 4 -
Oceania 1 1 - - - -
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119 Australia, Brazil, Canada, Croatia, Egypt, Finland, France, Georgia, 
Germany, Ireland, Italy, Japan, Malta, Mexico, Netherlands, Norway, 
Romania, Russian Federation, Singapore, Switzerland, Thailand, Unit-
ed Kingdom and the United States.
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The data confirmed that all NPS groups - synthet-
ic cannabinoids, synthetic cathinones, ketamine, 
phenethylamines, piperazines, plant-based substances 
and miscellaneous substances - have emerged globally, 
except for phenethylamines and synthetic cathinones 
which were not reported from Africa. However, it 
should be noted that Africa is the region with the few-
est respondents to the questionnaire – responses were 
received from only 10 countries (Angola, Cape Verde, 
Egypt, Ghana, Mauritius, Nigeria, Seychelles, South 
Africa, Togo, Zimbabwe). Less than 20% of African 
countries and territories submitted UNODC’s Annu-
al Reports Questionnaire (ARQ) for 2010.120
120 Under the United Nations drug control Conventions, Member States 
are formally required to provide national drug control related infor-
mation annually to the Secretary-General of  the United Nations. The 
Commission on Narcotic Drugs, the main drug control policy making 
body in the United Nations, developed the Annual Reports Question-
naire (ARQ) to collect this information.
Before 2008 2008 2009 2010 2011 2012
Africa 1 - - - - -
Americas 4 - - - - 2
Asia 4 - 1 - 1 1
Europe 13 7 2 1 3 1
Oceania 1 - 1 - - -
Source: UNODC questionnaire on NPS, 2012
Map 5: Emergence of plant-based substances by region up to 2012
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3.2 Legal situation 
3.2.1 The international drug control system
NPS fall outside the global drug control system and 
are therefore neither included in the schedules of the 
1961 Convention nor in those of the 1971 Conven-
tion. However, some Governments have adopted na-
tional or regional responses to address this issue in a 
need to meet the increasing concerns on the risks that 
these substances pose to public health and to address 
other various aspects of this problem. 
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As provided for in the 1961 Convention and the 1971 
Convention, whenever a Party or the World Health 
Organization (WHO) has information relating to a 
substance not yet under international control which 
in its opinion requires that substance to be added to 
any of the schedules of the Conventions, “it shall no-
tify the Secretary-General and furnish him with the 
information in support of that notification”, accord-
ing to article 3(1) of the 1961 Convention and article 
2 (1) of the 1971 Convention.121 
The notification is subsequently transmitted to the 
Parties, to the Commission on Narcotic Drugs and to 
the World Health Organization. An assessment of the 
substance is then carried out by WHO and based on 
the results of the assessment and the recommendations 
on control measures, if any, the Commission may de-
cide that the substance shall be added to, transferred 
from one schedule to another, or removed from any of 
the schedules of the respective Convention. The deci-
sions of the Commission are subject to review by the 
Economic and Social Council upon the request of a 
Party. The Expert Committee on Drug Dependence 
of WHO has reviewed several NPS, for example BZP 
or ketamine.
3.2.2. Regional responses: the European Union
So far, the only regional response system to the emer-
gence of NPS is the European Early Warning Sys-
tem (EWS) of the European Union (EU). In 1997, a 
mechanism for rapid exchange of information on ‘new 
synthetic drugs’, the assessment of their risks and the 
application of existing control measures on psychotro-
pic substances to ‘new synthetic drugs’ was adopted 
by the Council of the European Union (Joint Action 
97/396/JHA). Building upon this decision, Council 
Decision 2005/387/JHA was adopted in 2005 which 
applies to all NPS. 
Council Decision 2005/387/JHA122 provides for an 
assessment of the risks associated with NPS in order 
to permit the measures applicable in the EU Mem-
ber States for control of narcotic and psychotropic 
substances to be applied also to NPS. According to 
article 4 (1) (2) of the Council Decision, each EU 
Member State shall ensure that information on the 
manufacture of, trafficking in, use of, and of prepara-
tions containing NPS is shared through its Europol 
National Unit and its representative in the Reitox 
Network.123 This information is collected by Europol 
and the EMCDDA and subsequently shared with all 
EU Member States, the European Commission and 
the European Agency for the Evaluation of Medicinal 
Products (EMEA). According to article 5 (1), a ‘Joint 
Report’ shall be prepared by Europol and the EMCD-
DA, if either of them or the Council of the European 
Union consider that further information on the new 
psychoactive substance reported is needed.124 This re-
port is then submitted to the Council of the European 
Union, the EMEA and the European Commission. If 
considered necessary by the Council of the European 
Union, a ‘Risk Assessment Report’ is prepared by the 
Scientific Committee of the EMCDDA. This report, 
as provided for in article 6 (4), shall include a com-
plete assessment of the health and social risks caused 
by the use of, the manufacture of, and trafficking in 
the new psychoactive substance, information on any 
control measure in place in EU Member States and 
on any assessment of the NPS in the United Nations 
System, the level of involvement of organized crime, 
options for control, the possible consequences of con-
trol measures, and the chemical precursors used for 
the manufacture of the substance. 
For the purposes of bringing NPS under control, ar-
ticle 8 (1) (2) of the Council Decision 2005/387/JHA 
states that within six weeks from the date on which the 
European Commission receive the Risk Assessment 
Report, it shall present an initiative to the Council 
of the European Union to place the new psychoactive 
substance under control. If the European Commis-
sion deems it not necessary to present an initiative on 
submitting the new psychoactive substance to control 
measures, such an initiative may be presented by one 
or more EU Member States. It is for the Council of 
the European Union to decide whether to submit the 
121 The wording is identical in both Conventions.
122 Council Decision 2005/387/JHA of  10 May 2005 on the informa-
tion exchange, risk-assessment and control of  new psychoactive sub-
stances. Council of  the European Union (http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=CELEX:32005D0387:EN:NOT)
123 Reitox is the European information network on drugs and drug ad-
diction created at the same time as the EMCDDA. The abbreviation 
‘Reitox’ stands for the French ‘Réseau Européen d ғInformation sur 
les Drogues et les Toxicomanies’. European Monitoring Centre on 
Drugs and Drug Addiction, Reitox Network  (http://www.emcdda.
europa.eu/about/partners/reitox-network)
124 The report contains preliminary information on the description of  
the substance, manufacture, risks associated to its use, involvement 
RI RUJDQL]HGFULPHLQWKHPDQXIDFWXUHDQGWUDIÀFNLQJXVHUSURÀOH
control status of  the substance at the national level in EU Member 
States and on whether or not the substance is under assessment by the 
United Nations. Article 5 (2) Council Decision 2005/387/JHA of  10 
May 2005 on the information exchange, risk-assessment and control 
of  new psychoactive substances, Council of  the European Union
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new psychoactive substance to control measures. If so, 
article 9 (1) of the Council Decision provides that EU 
Member States shall endeavour to take as soon as pos-
sible, but no later than one year from the date of that 
decision, the necessary measures, in accordance with 
their national law, to ‘submit’ the new psychoactive 
substance to control measures and criminal penalties 
as provided under their legislation by virtue of their 
obligations under the international drug control trea-
ties. As stated in article 9 (3), the obligations set forth 
in the Council Decision do not preclude the possibil-
ity of individual Member States to maintain or intro-
duce any national control measures on NPS. Up to 
2012, eleven NPS125 have been included in the Risk 
Assessment Reports prepared by EMCDDA in the 
framework of the Council Decision 2005/387/JHA 
and the Joint Action 97/396/JHA, 8 of the eleven 
substances126 have been subjected to to control mea-
sures following a decision of the Council of the Eu-
ropean Union. At the time of preparing this report, 
a new risk assessment on 4-methylamphetamine was 
being conducted by the EMCDDA.127 
3.2.3 National responses to new psychoactive sub-
stances
Outside Europe, several approaches have been taken to 
control NPS at the national level. The cases of Japan, 
New Zealand, the Republic of Korea, and the United 
States are provided below for illustrative purposes.
In Japan, NPS have been available over the Inter-
net since 2004 and marketed directly in the country 
around 2009. For the purposes of control, NPS were 
defined as “new narcotic or psychotropic drugs, in 
pure form or in preparation, that are not controlled by 
the 1948 Cannabis Control Law, the 1951 Stimulants 
Control Law, the 1953 Narcotics and Psychotropics 
Control Law  and the 1964 Opium Law, but which 
may pose a public health threat”. The Tokyo Metro-
politan Government responded to this challenge in 
2005 by granting the Governor new legislative powers 
that allow the adoption of ordinances to ban activities 
related to the supply and production of NPS of con-
cern to the Tokyo Administration. Subsequently, at 
the national level, the Pharmaceutical Affairs Law was 
amended in 2007 to allow control over NPS as “des-
ignated substances” prohibiting their advertising, sale, 
supply and production. Penalties for the violation of 
this law include imprisonment of up to 5 years and/
or fines up to 5 million Japanese Yen. The simple pos-
session (for personal use) of a “designated substance” 
does not constitute an offense. As at November 2012, 
90 NPS are controlled under the Pharmaceutical Af-
fairs Law since it came into force in 2007.   
In New Zealand, the increasing use of benzylpipera-
zine (BZP)128 raised concern among authorities and 
society about the nature and possible adverse effects 
associated with this substance, and called for a legisla-
tive response. However, BZP was not listed under the 
Misuse of Drugs Act 1975 since and it had been mar-
keted as a dietary supplement, it was neither subject 
to a pre-market approval nor to any control on sale or 
distribution. 
According to the Misuse of Drugs Act 1975, it is for 
the Expert Advisory Committee on Drugs (EACD) to 
advise the Minister of Health of New Zealand on drug 
classification of any substance.129 In 2004, the classifi-
cation of BZP was considered, but given the scarcity of 
information on toxicological aspects and on the long-
terms effects caused by the substance, the issuance of 
an advice under the terms set forth in the Act130 was 
precluded. The Committee concluded that “there is 
no current schedule of the Misuse of Drugs Act 1975 
under which BZP could reasonably be placed”,131 and 
recommended that further research be conducted into 
the potential harms associated with the use of BZP, 
and to examine options for new categories of classifi-
125 European Monitoring Centre for Drugs and Drug Addiction, ‘MBDB, 
4-MTA, GHB, ketamine, PMMA, 2C-I, 2C-T-2, 2C-T-7, TMA-2, 
BZP and mephedrone’, May 2012 (http://www.emcdda.europa.eu/
html.cfm/index16776EN.html)
126  PMMA, 2C-I, 2C-T-2, 2C-T-7, TMA-2, BZP, mephedrone and 
4-MTA. 
127 European Monitoring Centre for Drugs and Drug Addiction, ‘2012 
Annual report on the state of  the drugs problem in Europe’, Lisbon, 
2012
128 The New Zealand Ministry of  Health estimated that 1.5 to 2 million 
doses had been sold by one distributor in New Zealand between 2001 
and 2003.    
129 Section 5AA of  the Misuse of  Drugs Act 1975
130 According to Section 4B of  the Misuse of  Drugs Act 1975, the Ex-
pert Advisory Committee on Drugs must give advice on: “(a) the 
likelihood or evidence of  drug abuse, including such matters as the 
prevalence of  the drug, levels of  consumption, drug seizure trends, 
and the potential appeal to vulnerable populations; and (b) the spe-
FLÀFHIIHFWVRI WKHGUXJLQFOXGLQJSKDUPDFRORJLFDOSV\FKRDFWLYHDQG
toxicological effects; and (c) the risks, if  any, to public health; and (d) 
the therapeutic value of  the drug, if  any; and (e) the potential for use 
of  the drug to cause death; and (f) the ability of  the drug to create 
physical or psychological dependence; and (g) the international clas-
VLÀFDWLRQDQGH[SHULHQFHRI  WKHGUXJ LQRWKHU MXULVGLFWLRQVDQG K
any other matters that the Minister considers relevant.
131  New Zealand, Expert Advisory Committee on Drugs (EACD), ‘Ad-
vice to the Minister on: Benzylpiperazine (BZP)’, 2004 (http://www.
ndp.govt.nz/moh.nsf/pagescm/569/$File/eacdbzp.pdf)
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cation through which some level of control and regu-
lation could be incorporated, without prohibiting ac-
cess to these substances completely.132 Following these 
recommendations, the Misuse of Drugs Amendment 
Act, passed in 2005, created a new schedule for ‘re-
stricted substances’. The substances listed therein were 
then subject to control of manufacture and sale but 
not prohibited. BZP was the first substance initially 
placed under this schedule, and as such, sale restric-
tions of BZP to minors were enforced as well as con-
trols on the advertisement and labelling of the prod-
uct, but the possession of the drug was still legal.  
After the initial scheduling of BZP, the publication 
of further studies on the toxicology of BZP and ad-
verse effects associated with the use of this substance 
resulted in an interim report presented to the EACD, 
which in response, and based on the new evidence, is-
sued a follow-up report on BZP in 2006, and advised 
the Health Minister that this substance posed a ‘mod-
erate risk of harm’. BZP was then removed from the 
‘restricted substances’ schedule, and in 2008, it was 
placed in Schedule 3 (Class C ‘Controlled Drugs’),133 
along with other substances that pose a moderate risk 
of harm, such as cannabis and other piperazines.134 At 
the time of writing, NPS legislation is being drafted 
in New Zealand.
In the Republic of Korea, drugs are controlled under 
the ‘Act on the Control of Narcotics’. In 2000,  the 
three major drug laws to control narcotics, psychotro-
pic substances, opium and cannabis, i.e. the Narcotics 
Act, the Cannabis Control Act, and the Psychotro-
pic Substances Control Act, were combined into this 
single Act. 
Several NPS, listed as “psychotropic drugs”, had been 
subject to control under the Act on the Control of 
132  New Zealand, Expert Advisory Committee on Drugs (EACD), ‘Ad-
vice to the Minister on: Benzylpiperazine (BZP)’, 2004 (http://www.
ndp.govt.nz/moh.nsf/pagescm/569/$File/eacdbzp.pdf)
133 Under the Misuse of  Drugs Act 1975, a ‘controlled drug’ means any 
VXEVWDQFH SUHSDUDWLRQPL[WXUH RU DUWLFOH VSHFLÀHGRU GHVFULEHG LQ
Schedule 1, Schedule 2, or Schedule 3; and includes any controlled 
drug analogue. Controlled drug analogue means any substance, such 
DVWKHVXEVWDQFHVVSHFLÀHGRUGHVFULEHGLQ3DUWRI 6FKHGXOHWKDW
has a structure substantially similar to that of  any controlled drug; but 
GRHVQRWLQFOXGH³DDQ\VXEVWDQFHVSHFLÀHGRUGHVFULEHGLQ6FKHG-
ule 1 or Schedule 2 or Parts 1 to 6 of  Schedule 3; or (b) any pharmacy-
only medicine or prescription medicine or restricted medicine within 
the meaning of  the Medicines Act 1981. (Misuse of  Drugs Act 1975, 
Section 2(1)).  Schedule 3 Part 1 clause 2 was added on 1 April 2008, 
E\VHFWLRQRI WKH0LVXVHRI 'UXJV&ODVVLÀFDWLRQRI %=3$PHQG-
ment Act 2008 (2008 No 5)
134 Section 3A (C) of  the Misuse of  Drugs Act 1975
Narcotics since the mid 2000s.135 However, the dra-
matic increase in the volume of newly detected NPS 
since 2008, prompted an additional Government’s re-
sponse to strength control over the rapid emergence of 
NPS. In September 2011 a new ‘temporary scheduling 
system’, added to the Act on the Control of Narcotics, 
entered into force. Under the Act, the Korean Food 
and Drug Administration may temporarily sched-
ule NPS for a year. The synthetic cathinone MDPV 
(3,4-Methylenedioxypyrovalerone) was the first drug 
subject to temporary schedule at the end of 2011. 
In the United States, the Controlled Substances Act 
(CSA)136 contains the federal drug policy under which 
the manufacture, importation, possession, use and 
distribution of certain substances is regulated. For 
purposes of control, the CSA places all substances 
into one of five schedules, based upon the substance’s 
medicinal value, harmfulness, and potential for abuse 
or dependence. The initial list contained in the Act 
has been complemented by legislative amendments,137 
but the Act also provides a mechanism for substances 
to be controlled, added to a schedule, removed from 
control, reschedule, or transferred from one schedule 
to another.138 Temporary scheduling of new substanc-
es to avoid imminent hazard to public safety is also 
possible under the CSA.139 In 2011, several synthetic 
cannabinoids (JWH-018; JWH-073; JWH-200; 
CP-47,497; CP-47,497 C8 homologue)140 and some 
synthetic cathinones (mephedrone; methylone; and 
(MDPV))141 were subject to temporary control.   
135 See Article 2(4) (a-b) of  the Act on the Control of  Narcotics for the 
GHÀQLWLRQRI SV\FKRWURSLFGUXJV136UHJDUGHGDVSV\FKRWURSLFGUXJV
and subject to control include, among others,  JWH-018 & its ana-
logues, CP-47497 & C6, C8, C9, BZP, 2C-D, 2C-E, MeOPP, HU-210, 
4-Acetoxy-DiPT, mCPP, TFMPP, Psilocybin, phencyclidine analogues.
136 The CSA was enacted into law as part of  the Comprehensive Drug 
Abuse Prevention and Control Act of  1970
137  For instance, the Drug Prohibition Act of  2000 amended the Con-
trolled Substances Act to direct the emergency scheduling of  gamma 
hydroxybutyric acid
138  Section 811, Controlled Substances Act of  1970 
139 Section 811 (h), Controlled Substances Act of  1970. Based on an in-
terim ruling, new substances can be temporarily scheduled up to 12 
months (with the possibility of  six months extension), after which they 
can be permanently scheduled, if  there is an evaluation and recom-
mendation in favour by the Secretary of  Health and Human Services.
140 United States, Drug Enforcement Administration, ‘Schedules of  
FRQWUROOHG VXEVWDQFHV WHPSRUDU\ SODFHPHQW RI  ÀYH V\QWKHWLF FDQ-
nabinoids into Schedule I, Final order’, 21 CFR Part 1308 [Docket 
No. DEA-345F] (http://www.deadiversion.usdoj.gov/fed_regs/
rules/2011/fr0301.htm)
141 United States, Drug Enforcement Administration, ‘Schedules of  con-
trolled substances: temporary placement of  three synthetic cathinones 
into Schedule I’, 21 CFR Part 1308 [Docket No. DEA-357] (http://
www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr1021_3.htm)
30
Global SMART Programme 2013
In addition to the CSA, the United States has a Con-
trolled Substances Analogue Enforcement Act, i.e. 
‘Federal Analogue Act’, to control substances not 
specifically listed in the CSA. The enactment of the 
Federal Analogue Act in 1986 was a response to the 
spread of fentanyl derivatives, Į-prodine derivatives, 
phenethylamines related to MDMA, amphetamines 
and other compounds designed to produce similar ef-
fects to the controlled drugs they mimic.142
Under section 802 (32)(A) of the CSA, “controlled 
substance analogue” is defined as a substance (i) whose 
chemical structure is substantially similar to the struc-
ture of a scheduled substance; (ii) whose effects are 
substantially similar to or greater than the effects of a 
controlled substance or, (iii) the substance is thought 
to have such an effect. The use of analogue control op-
erates on a substance by substance basis, and therefore 
each new substance needs to be assessed individually 
and a Court should decide whether the substance is or 
not controlled. Courts in the United States have in-
terpreted the law as meaning that both requirements 
(similarity in the structure and the effects), must be 
fulfilled. 
The Federal Analogue Act served as a model for oth-
er analogue systems adopted during the 1980s (in 
Canada, New Zealand and parts of Australia), and it 
has been suggested that it might have been effective 
in addressing the proliferation of synthetic drugs at 
that time. While the implementation of the new stan-
dards-based model closed some of the loopholes of the 
CSA, such as the slow and costly process to issue indi-
vidual prohibitions for each illicit chemical, its imple-
mentation has revealed some theoretical and practical 
problems.143 For instance, the lack of clarity of the 
statutory definition of an analogue drug was raised in 
a Court Case in 1995, but the Court ruled in favour 
of the Analogue Act, and deemed it not to be consti-
tutionally vague.144 Moreover, it has been argued that 
some unique entities, which are unlike any controlled 
drug (in terms of chemical structure), i.e. plant-based 
psychoactive substances such as salvia divinorum and 
kratom (mitragyna speciosa), are beyond the scope 
of analogue control.145 For these and other reasons, 
some analysts have considered the analogue system as 
an ‘imperfect law’,146 and other legislative approaches 
have been suggested to address the problem of NPS, 
such as the inclusion of the most problematic groups 
of NPS in the CSA,147 or mixing rules and standards 
in the Federal Analogue Act.148
3.2.4 Other regulatory frameworks 
The international drug control system laid down in the 
United Nations drug control Conventions was founded 
on the basis of concern of public health and social prob-
lems resulting from the abuse of certain psychotropic 
substances and from the addiction to narcotic drugs, 
and the need to prevent and combat abuse of such 
substances and the illicit trafficking to which it gives 
rise. For this purpose, State parties to the Conventions 
agreed to take the necessary legislative and administra-
tive measures to limit exclusively to medical and sci-
entific purposes the production, manufacture, export, 
import, distribution of, trade in, use and possession of 
such drugs, and to treat as a punishable offence, when 
committed intentionally, any action contrary to a law 
or regulation adopted in pursuance of its obligations 
under the Conventions.
Since the adoption of the Conventions, confronted 
with the challenges posed by NPS and considering that 
traditional drug control systems require time and ba-
sic scientific data on the harms posed by NPS to react, 
countries have explored different approaches to regula-
tion that give more flexibility to existing drug control 
systems at the national level or appeal to other regula-
tory frameworks.
Several countries have amended their legislation to 
control the manufacture, trafficking, possession, sale 
142 King, L.A., Nutt, D., Singleton, N., and Howard, R., ‘Analogue con-
WUROV$QLPSHUIHFWODZ·,QGHSHQGHQW6FLHQWLÀF&RPPLWWHHRQ'UXJV
United Kingdom Drug Policy Commission, 2012
143 Kau, G., ‘Flashback to the federal analogue act of  1986: mixing rules 
and standards in the cauldron’, University of  Pennsylvania Law Re-
view, 2008, 156, 1078-115
144 United States court of  Appeals, United States vs. Allen McKin-
ney, 1995 (http://law.justia.com/cases/federal/appellate-courts/
F3/79/105/555999/)
145 King, L.A., Nutt, D., Singleton, N., and Howard, R., ‘Analogue con-
WUROV$QLPSHUIHFWODZ·,QGHSHQGHQW6FLHQWLÀF&RPPLWWHHRQ'UXJV
United Kingdom Drug Policy Commission, 2012
146 Wong, L., Dormont, D. and Matz, H.J., ‘United States Controlled Sub-
VWDQFH$QDORJXH$FW OHJDO DQG VFLHQWLÀFRYHUYLHZRI  DQ LPSHUIHFW
law’, presented to Advisory Council on Misuse of  Drugs, 2010
147 For instance, in 2011 a bill was presented in the United States Con-
gress to include two groups of  new psychoactive substances (i.e. 
cathinone derivatives and cannabinoids antagonists) in Schedule I 
of  the Controlled Substances Act, without relying on the Analogue 
Act. United States Congress.  ‘H.R. 1254--112th Congress: Synthetic 
Drug Control Act of  2011’, GovTrack.us (database of  federal legis-
lation), 2011, (http://www.govtrack.us/congress/bills/112/hr1254; 
accessed in: October 2012
148 Kau, G., ‘Flashback to the federal analogue act of  1986: mixing rules 
and standards in the cauldron’, University of  Pennsylvania Law Re-
view 2008, 156, 1078-115
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and use of NPS in the same fashion as with substances 
controlled under the Conventions, where prohibited 
substances are listed individually. However, the inclu-
sion of new substances is often a lengthy process that 
requires in most cases a health risk assessment (based 
on scientific data and human experience data that in 
the case of NPS is often scarce), followed by legislative 
amendments that usually take several months. For these 
reasons, some countries have adopted a generic or an 
analogue system to complement and to give more flex-
ibility to the individual listing system, which allows the 
control of groups of substances or similar substances to 
those individually listed, without the need to appeal to 
a legislative reform. For instance, in 2010, the generic 
system was introduced in the United Kingdom to ban 
synthetic cathinones, and was introduced in Hungary 
in 2012 to ban NPS temporarily.149 In 2009, synthetic 
cannabinoids were defined as a group of substances 
controlled in Luxemburg and in 2010, Italy developed 
a group definition of synthetic cannabinoids and later a 
group definition of cathinones.150 Ireland also has a ge-
neric system to control NPS.  Norway and the United 
States have an analogue system in place but the defini-
tion of ‘analogue’ differs in the two countries.
Governments have also used ‘emergency scheduling’ 
to introduce temporary bans on NPS while the leg-
islative process is being completed and/or a rigorous 
assessment of the risks is conducted. For instance, in 
Denmark an Executive Order on Euphoriant Sub-
stances can enter into force in two to three days, in 
Germany the Federal Ministry of Health may publish 
a regulation in the Federal Law Gazette (with no ref-
erence to the Council of Ministers or the Bundesrat) 
through a process that takes a few weeks, and in Spain, 
the Minister for Health and Consumer Affairs can 
prepare an Order that is published in the Spanish Of-
ficial Journal (with no reference to the Parliament) and 
the entire process takes between five and 15 days.151 
Australia, China, Croatia, Bahrain, Ghana, Hungary, 
Ireland, Italy, Netherlands, Russian Federation, Saudi 
Arabia, United Kingdom and United States reported 
in the UNODC questionnaire on NPS having used 
emergency scheduling to temporarily ban NPS.
In addition, alternative, effective and proportionate 
ways to respond in an equally fast and flexible way to 
the emergence of NPS has been reflected in the use of 
other regulatory frameworks. For instance, medicine 
legislation has been used in at least eight countries, in-
cluding Finland and the Netherlands.152 Respondents 
to the UNODC questionnaire on NPS from Albania, 
Bahrain, Brunei Darussalam, Bulgaria, and Thailand 
reported the use of Poison Acts. The use of consumer 
safety regulations was reported from Bahrain, Bul-
garia, Croatia, Hungary, Israel, Italy, Nepal, Poland, 
Portugal, Romania, Russian Federation, Togo and the 
United Kingdom. Unlike traditional drug control sys-
tems, where the manufacture, trafficking, possession, 
sale and use of NPS is usually banned and subject to 
criminal provisions, control measures of NPS under 
other regulatory frameworks tend to be limited in 
scope, focusing primarily on the control of the sale 
of NPS.
The different approaches to regulation are varied 
among nations, and while some may be considered 
more advantageous or effective than others, there are 
no perfect systems. However, monitoring has proved 
useful in providing timely information to make ev-
idence-based decisions that respond to the rapid 
changes that encompass the supply and demand of 
NPS. 
149 8QLWHG.LQJGRP+RPH2IÀFHFLUFXODU¶$FKDQJHWRWKH
Misuse of  Drugs Act 1971: Control of  mephedrone and other cathi-
none derivatives’, 2010; Hungary adopted the same approach after the 
Government Decree 66/2012 came into effect on April 2012, where-
by a temporary ban on new psychoactive substances was introduced.
150 European Monitoring Centre for Drugs and Drug Addiction, ‘2012 
Annual report on the state of  the drugs problem in Europe’, Lisbon, 
2012
151 Kelleher, C., Christie, R., Lalor, K., Fox, J., Bowden, M. and O’Donnell, 
C., ‘An Overview of  New Psychoactive Substances and the Outlets 
Supplying Them’, National Advisory Committee on Drugs, Centre 
for Social and Educational Research, Dublin Institute of  Technol-
ogy, Dublin, 2011 (http://www.nacd.ie/images/stories/docs/publi-
cationa/head_report2011_overview.pdf) 
152 Mephedrone was controlled through medicine legislation in Finland 
and the Netherlands before it was subject to a risk assessment in the 
framework of  the Council Decision on new psychoactive substances 
of  the European Union; BZP has also been controlled under medi-
cine legislation in Spain. Austria, Germany, Hungary and the United 
Kingdom, have also used medicine legislation to control synthetic 
cannabinoids. Winstock, A. and Wilkins, C., ‘“Legal highs” The chal-
lenge of  new psychoactive substances’, Transnational Institute, Series 
on Legislative Reform of  Drug Policies, 2011, 16, 1-16
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4. USE OF NEW PSYCHOACTIVE 
SUBSTANCES
4.1. Global use estimates 
The extent of global use of NPS remains unknown. 
Thus far, there are no estimates on the prevalence of 
use of NPS in the general population, but rather lim-
ited data collected in few countries, with respect to 
specific substances and subpopulations. 
Concern about the increasing use of NPS and their 
potential adverse effects has led to a growing need for 
monitoring these substances and several countries have 
opted for the inclusion of NPS in national drug sur-
veys. Some limitations of these surveys include the lack 
of common definitions and of representative samples, 
the large and increasing number of substances regard-
ed as NPS, and the differences in legislation among 
countries. 
4.2. Regional use estimates
In the framework of the European Union, the at-
titude of youth towards drugs is regularly examined 
by the Eurobarometer, which analyses public opinion 
in Member States of the European Union. Drug use 
surveys have been conducted among young people in 
EU Member States in 2002, 2004 and 2008 (Euroba-
rometer No. 172, 158, and 233). These surveys have 
studied the attitude of young people toward licit and 
illicit substances including heroin, cocaine, ecstasy, 
cannabis, alcohol and tobacco. In 2011, responding to 
recent developments in the EU drug market, the Euro-
barometer “Youth attitudes on Drugs” (No. 330) asked 
young people for the first time about their experiences 
and attitudes towards new psychoactive substances or 
‘legal highs’. For the purposes of the survey, NPS were 
understood as “a large number of new unregulated 
compounds that imitate the effects of illicit drugs (so-
called new psychoactive substances or ‘legal highs’)”. 
The sample size for the 2011 survey included over 
12,000 randomly selected young people (aged 15-24) 
across the 27 EU Member States, who were inter-
viewed by telephone. Youths were asked about their 
perceptions on the availability of NPS, perceived 
health risks associated to their use, attitudes towards 
banning or regulating NPS and about the effectiveness 
of alternative drug policies.     
  
Overall, 5% of the participants reported having used 
NPS.153 Ireland (16%), Poland (9%), Latvia (8.8%) and 
the United Kingdom (8%), were at the higher end of 
the country ranking, while Italy (0.8%), Finland (1%) 
and Greece (1.6%) were found at the lower end.154
With respect to the supply of NPS, 54% of the respon-
dents who had used NPS reported that they had been 
offered the substance by friends, 37% had been offered 
the substances during a party or in a club, 33% had 
purchased them from a specialized shop, and less than 
7% had bought them over the Internet. Older respon-
dents were more likely than their younger counterparts 
to have been offered such substances at a party or in a 
club (41% of 22-24 year-olds vs. 32% of 15-18 year-
olds), whereas those who had completed their higher 
education (41% vs. 27% among those who had only 
completed their primary education at the time of the 
survey) were more likely to have purchased the sub-
stances from a specialized shop. 
153 The wording of  the question was as follows: In certain countries some 
new substances that imitate the effects of  illicit drugs are being sold as 
legal substances in the form of  -for example -powders, tablets/pills or 
herbs. Have you ever used such substances? European Commission, 
Youth attitudes on drugs, Flash Eurobarometer 330, 2011, 18
154 European Commission, ‘Youth attitudes on drugs’, Flash Euro-
EDURPHWHU   KWWSHFHXURSDHXSXEOLFBRSLQLRQÁDVK
ÁBBHQSGI
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Young people who reported having used NPS were also 
less likely to recognize the seriousness of the risks as-
sociated with regular and occasional use of various il-
licit and licit substances. Sixty percent of those who had 
never used NPS thought that using ecstasy occasionally 
posed a high risk to a person’s health and 26% saw a 
medium risk. By comparison, only 40% of those who 
had used NPS perceived the health risks caused by oc-
casional ecstasy use as high, and 34% as medium. A 
similar pattern follows the perception of the risks as-
sociated to cannabis use.155
With respect to responding to NPS, only 1% - 4% of 
the interviewees considered that no action was need-
ed. However, preferences on whether to ban all NPS, 
to ban only those that pose serious risks to someone’s 
health or to regulate them, varied across EU Member 
States.
While there are some limitations of the results, includ-
ing the small sample size in each State (in most EU 
countries the target sample size was 500 respondents, 
but in Estonia, Cyprus, Luxembourg, Malta and Slo-
venia the sample size was 250 respondents) to assess 
actual use and the lack of a common understanding on 
what constitutes a new psychoactive substance, the sur-
vey nevertheless provides a glimpse into the use of these 
substances by young people. 
4.3. National use estimates
Apart from the above-mentioned regional estimates, 
national surveys in a general population and/or sub-
populations have also been conducted in few coun-
tries to estimate the use of NPS. It should be noted, 
however, that often only a limited number of NPS (or 
even just a single one) is included in these estimates.
In Australia, information on the prevalence of use of 
NPS has been included since 2010 in the Drug Trends 
in Ecstasy and Related Drug Markets (EDRS) report. 
The 2011 report presents the most recent findings on 
the markets for ecstasy and related drugs156 based on 
data collected in all states and territories in Australia 
from surveys with regular ecstasy users, surveys with 
key experts who have contact with regular ecstasy users 
and the analysis of existing data sources that contain 
information on ecstasy and related drugs. Although 
the results from the regular ecstasy users surveys are 
155 European Commission, ‘Youth attitudes on drugs’, Flash Euro-
EDURPHWHU   KWWSHFHXURSDHXSXEOLFBRSLQLRQÁDVK
ÁBBHQSGI
156 “The term ‘ecstasy and related drugs’ includes drugs that are rou-
tinely used in the context of  entertainment venues and other recre-
ational locations including nightclubs, dance parties, pubs and music 
festivals. ERD include ecstasy (MDMA, 3,4-methylenedioxymetham-
SKHWDPLQHPHWKDPSKHWDPLQH FRFDLQH /6' GO\VHUJLF DFLG NHW-
DPLQH0'$PHWK\OHQHGLR[\DPSKHWDPLQHDQG*+%JDPPD
K\GUR[\EXW\UDWHµ6LQGLFLFK1 DQG%XUQV/ ¶$XVWUDOLDQ WUHQGV LQ
HFVWDV\DQGUHODWHGGUXJPDUNHWVÀQGLQJVIURPWKHHFVWDV\DQG
UHODWHGGUXJVUHSRUWLQJV\VWHP('56·$XVWUDOLDQ'UXJ7UHQGV6H-
ULHV1R1DWLRQDO'UXJDQG$OFRKRO5HVHDUFK&HQWUH8QLYHUVLW\
RI 1HZ6RXWK:DOHV6\GQH\KWWSQGDUFPHGXQVZHGXDX
VLWHVQGDUFFPVPHGXQVZHGXDXÀOHVQGDUFUHVRXUFHV1DWLRQDOB
('56BÀQDOSGI
European Union: lifetime prevalence of NPS use in EU Member States
Source: Flash Eurobarometer 330. Youth Atudes on Drugs. Analycal report. May 2011. 
Base: all respondents, % by country
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not representative of ecstasy users and their other drug 
use in the general population, the data provided is in-
dicative of patterns of drug use. In the 2011 EDRS 
survey, 574 regular ecstasy users were interviewed. 
Participants were recruited primarily through street 
press adverts and word-of-mouth.
According to the findings for 2011, ketamine use re-
mained limited to Victoria, New South Wales and the 
Australian Capital Territory, with 16% of the national 
sample reporting recent use, 157 a significant increase 
from 2010 (12%). A small proportion of regular ec-
stasy users reported the use of some NPS, for example, 
synthetic cannabinoids (‘spice’), synthetic cathinones 
(mephedrone, methylone, MDPV), phenethylamines 
(2C-I, 2C-E, 2,5-dimethoxy-4-iodoamphetamine 
(DOI)), piperazines (BZP), tryptamines and plant-
based substances (datura). While in 2011, lifetime 
and recent use of ‘spice’ was low among the sample 
(1% and <1% respectively), five per cent of the na-
tional sample believed that they have used other form 
of synthetic cannabinoids.158  
In 2011, ketamine, DMT (an internationally con-
trolled substance) and mephedrone were the sub-
stances with the highest rate of lifetime prevalence. 
From 2010 to 2011, there was a significant decrease 
in recent use of mephedrone (16% vs. 14%). Regular 
ecstasy users reported in 2011 lifetime and recent use 
of methylone at 7% and 5% , while only a small num-
ber (2%) reported lifetime and recent use of MDPV 
in the same year. The use of phenethylamines showed 
significant increases in 2011, however the number re-
porting use remained low. Both lifetime (12%) and 
recent use (5%) of  2C-I (compared to 6% and 2% 
in 2010) increased as did lifetime (8%) and recent use 
(4%) of 2C-E (compared to 3% and 2% in 2010). 
Six per cent of the participants reported having tried 
a 2C-class drug (apart from those mentioned above) 
and thirty participants of the entire sample (5%) re-
ported lifetime use of ‘other’ 2C-class drugs, including 
2C-B-Fly, 2C-P, 2C-T-2, 2C-T-7. There was a decline 
in the number of users that reported recent use of 
BZP (2% vs. 4.5% in 2010). To a lesser extent, recent 
use of the plant based substance datura was reported 
by three of the participants (1%).159
157 5HFHQWXVHLQWKH('56UHSRUWUHIHUVWRSUHYDOHQFHRI XVHLQWKHSDVW
six months.
158 6LQGLFLFK1DQG%XUQV/ ¶$XVWUDOLDQWUHQGV LQHFVWDV\DQGUHODWHG
GUXJPDUNHWVÀQGLQJV IURP WKHHFVWDV\DQG UHODWHGGUXJV UH-
SRUWLQJV\VWHP('56·$XVWUDOLDQ'UXJ7UHQGV6HULHV1R1D-
WLRQDO'UXJDQG$OFRKRO5HVHDUFK&HQWUH8QLYHUVLW\RI 1HZ6RXWK
:DOHV6\GQH\KWWSQGDUFPHGXQVZHGXDXVLWHVQGDUFFPV
PHGXQVZHGXDXÀOHVQGDUFUHVRXUFHV1DWLRQDOB('56B
ÀQDOSGI
159 6LQGLFLFK1DQG%XUQV/ ¶$XVWUDOLDQWUHQGV LQHFVWDV\DQGUHODWHG
GUXJPDUNHWVÀQGLQJV IURP WKHHFVWDV\DQG UHODWHGGUXJV UH-
SRUWLQJV\VWHP('56·$XVWUDOLDQ'UXJ7UHQGV6HULHV1R1D-
WLRQDO'UXJDQG$OFRKRO5HVHDUFK&HQWUH8QLYHUVLW\RI 1HZ6RXWK
:DOHV6\GQH\KWWSQGDUFPHGXQVZHGXDXVLWHVQGDUFFPV
PHGXQVZHGXDXÀOHVQGDUFUHVRXUFHV1DWLRQDOB('56B
ÀQDOSGI
Australia: prevalence of drug and NPS use among regular ecstasy users (REU), 2010 - 2011
Source: data from the 2011 EDRS report 
Fields displayed as 0.00% indicate that data is not available
Spice Mephedrone Methylone MDPV Ketamine 2C-I 2C-E DOI PMA BZP Datura DMT 5-MeO -DMT
Recent use prevalence 2010 0.0% 16.0% 0.0% 1.0% 12.0% 2.0% 2.0% 1.0% 1.0% 4.5% 1.0% 7.0% 1.0%
Recent use prevalence 2011 1.0% 14.0% 5.0% 2.0% 16.0% 5.0% 4.0% 1.0% 1.0% 2.0% 1.0% 14.0% 2.0%
Lifeme prevalence 2010 0.0% 18.0% 0.0% 1.0% 36.0% 6.0% 3.0% 2.0% 4.0% 5.0% 3.0% 13.0% 2.0%
Lifeme prevalence 2011 1.0% 23.0% 7.0% 2.0% 42.0% 12.0% 8.0% 3.0% 3.0% 6.0% 7.0% 27.0% 6.0%
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In Canada, the use of NPS was recently included in 
the biennial ‘Youth Smoking Survey’ (YSS) conducted 
since 2002. The YSS helps schools and government 
agencies across Canada assess youth substances use and 
related health behaviours. The 2010-11 school-based 
survey included a representative sample of 50,949 (rep-
resenting approximately 3 million youth) secondary 
school students from all provinces of Canada except 
New Brunswick.160 Survey results showed a higher last 
year prevalence of the use of NPS (salvia divinorum 
(3.4%), ketamine (1.6%), and ‘other illicit drugs’161 
(9.7%)) than for other illicit drugs, such as cocaine 
(2.3%) and heroin (1.1%).162 Cannabis remained the 
top illicit drug of choice (21.2%). 
Questions on NPS were included for the first time in 
the Drug Prevalence Survey 2010/11 on drug use in 
Ireland and Northern Ireland. This survey included 
a sample of 7,669 people aged 15-64 (5,134 in Ire-
land and 2,535 in the United Kingdom (Northern 
Ireland)). In Ireland, NPS included ‘herbal smoking 
mixtures/incense, party pills or herbal highs, bath salts, 
plant feeders or other powders, kratom (krypton), sal-
via divinorum, magic mint, divine mint or sally D and 
other NPS mentioned by the respondent’, while in 
Northern Ireland, NPS (called ‘legal highs’) comprised 
‘party pills, herbal highs, party powders, kratom and 
salvia divinorum’. Limitations of this survey include 
the lack of coverage of some groups with high drug use 
prevalence (e.g. the homeless, those in prison), refusal 
to participate in the survey or under-reporting of drug 
use, and, in some cases, the small sample size.
According to the 2010/11 results from the survey, life-
time and last year prevalence of NPS use in Northern 
Ireland were 2.4% and 1.0%, respectively. Both lifetime 
and last year use were higher among men (3.0%) than 
women (1.8%) and significantly higher for young adults 
(aged 15-34) than for older adults (aged 35-64) (4.8% 
vs. 0.6%). There was a separate question on the use of 
mephedrone in Northern Ireland and responses showed 
similar percentages of use to NPS in both lifetime (2.0% 
vs. 2.4%) and last year prevalence (1.1% vs. 1.0%). In 
Ireland, there is no data available on lifetime prevalence 
of NPS but last year prevalence among adults was 3.5%. 
Cannabis remains the most commonly used illicit drug 
in both Northern Ireland and in Ireland. However, in 
Ireland, after cannabis, NPS and cocaine (including 
crack) were the most frequently reported substances.163
In New Zealand, the most recent national survey data 
on the use of NPS is available from the New Zealand 
Drug Use Survey 2007/2008, which measured self-re-
ported alcohol and drug use in the adult population. 
The survey collected information on 6,784 New Zea-
landers aged 16–64 years, including 1,825 Maori and 
817 Pacific respondents.164 According to the results of 
this survey, lifetime and last year use of BZP (reported at 
13.5% and at 5.6% respectively) was even higher than 
the use of amphetamines (7.2% and 2.1% respectively) 
or cocaine (3.6% and 0.6%). BZP users were signifi-
cantly more likely to be male, aged between 18-34, and 
160 &DQDGD +HDOWK &DQDGD ¶6XPPDU\ RI  UHVXOWV RI   <RXWK
6PRNLQJ 6XUYH\· &RQWUROOHG 6XEVWDQFHV DQG 7REDFFR'LUHFWRUDWH
:DWHUORR0D\ KWWSZZZKFVFJFFDKFSVWREDFWDEDFUH-
VHDUFKUHFKHUFKHVWDWBVXUYH\VRQGDJHBUHVXOWHQJSKS
161 2WKHU LOOLFLWGUXJV LQFOXGHDPRQJRWKHUVKDOOXFLQRJHQV/6'3&3
DFLGPDJLFPXVKURRPVPHVF NHWDPLQH VSHFLDO N NLWNDW*+%
* OLTXLG;JRRS6DOYLD'LYLQH6DJH0DJLF0LQW6DOO\'-LP-
VRQZHHGORFRZHHGVWLQNZHHGPDGDSSOH&DQDGD+HDOWK&DQDGD
¶6XSSOHPHQWDU\ WDEOHV<RXWK6PRNLQJ6XUYH\·&RQWUROOHG
6XEVWDQFHV DQG7REDFFR'LUHFWRUDWH KWWSZZZ\VVXZDWHUORRFD
UHVXOWV<66BVXSSOHPHQWDU\BWDEOHVBHQSGI
162 &DQDGD +HDOWK &DQDGD ¶6XSSOHPHQWDU\ WDEOHV <RXWK 6PRNLQJ
6XUYH\ · &RQWUROOHG 6XEVWDQFHV DQG 7REDFFR 'LUHFWRUDWH
KWWSZZZ\VVXZDWHUORRFDUHVXOWV<66BVXSSOHPHQ-
WDU\BWDEOHVBHQSGI
163 ,UHODQGDQG1RUWKHUQ,UHODQG8QLWHG.LQJGRP1DWLRQDO$GYLVRU\
&RPPLWWHHRQ'UXJVDQG3XEOLF+HDOWK,QIRUPDWLRQDQG5HVHDUFK
%UDQFK ¶'UXJXVH LQ ,UHODQGDQG1RUWKHUQ,UHODQG'UXJ
3UHYDOHQFH6XUYH\5HJLRQDO'UXJ7DVN)RUFH ,UHODQG DQG+HDOWK
DQG6RFLDO&DUH7UXVW1RUWKHUQ,UHODQG5HVXOWV·
164 1HZ=HDODQG0LQLVWU\RI +HDOWK ¶'UXJXVH LQ1HZ=HDODQG NH\
UHVXOWV RI  WKH 1HZ=HDODQG $OFRKRO DQG'UXJ 8VH 6XU-
YH\· -DQXDU\  KWWSZZZKHDOWKJRYWQ]Q]KHDOWKVWDWLVWLFV
national-collections-and-surveys/surveys/current-recent-surveys/
DOFRKRODQGGUXJXVHVXUYH\
Source: data from the YSS 2010-11
Canada: last-year prevalence of drug and 
NPS use among secondary school students 
– Youth Smoking Survey, 2010 - 11
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more likely to be Maori. Moreover, hospital discharge 
data corresponding to 37 people discharged for cases 
involving NPS between 2009-2011, showed that users 
of NPS were reportedly younger compared with people 
discharged for cannabis use, less likely to be Maori (41% 
compared to 51% of cannabis users) and less likely to 
be living in an area of high deprivation (27% compared 
to 40% for cannabis users).165 Prevalence of use of NPS 
approved under the legislation that is being drafted will 
be monitored through national surveys.
 
In the United Kingdom, new measures of drug use were 
added to the 2010/11 British Crime Survey (BCS), 
with the inclusion of drugs recently classified under 
the Misuse of Drugs Act.166 According to the findings 
from the 2010/11 survey, an estimated 8.8% of adults 
in England and Wales had used an illicit drug in the 
last year (almost 2.9 million people). Last year use of 
mephedrone167 (1.4 %) for adults aged 16-59, was at a 
similar level as ecstasy use (1.4%), the third most preva-
lent drug for this age group. For younger adults (aged 
16-24), mephedrone use (4.4%) was at a similar level of 
use as cocaine (4.4%), the second most used drug in this 
age group. The use of synthetic cannabinoids, khat and 
BZP was only of 0.4%, 0.3%, and 0.2% respectively. 
Adults aged 16-24 showed higher rates of prevalence 
for both mephedrone (4.4%) and synthetic cannabi-
noids (0.4%) than adults aged 16-59 (0.6% and 0.1% 
respectively). Cannabis remained the most commonly 
used type of illicit drug with 6.8% of adults (aprox. 2.2. 
million people) having used this drug in the last year, 
followed by cocaine (2.1%, around 0.7 million adults) 
and ecstasy (1.4%, 0.5 million adults).168
In the United States, the ‘Monitoring the Future’ sur-
vey has been conducted annually since 1975 to gener-
ate national data on drug use of American adolescents, 
college students and adults through the age of 50. In 
2011, a question about the use of synthetic cannabi-
noids (‘spice’ and K2)169 was included for the first time 
in the survey, asking 12th graders about their use in the 
previous 12 months. The sample size of the 2011 survey 
encompassed about 46,700 secondary school students 
in 400 schools nationwide.170 According to the findings 
of the survey, synthetic cannabinoids ranked second 
only to natural cannabis in annual prevalence among 
12th graders. Some 11.4% of 12th graders reported 
having used synthetic cannabinoids in the previous 12 
months, while 5.9% of these users reported last year 
use of salvia divinorum. Overall, last-year use of NPS 
among 12th graders surpassed the use of other illicit 
drugs such as cocaine (2.9%) and heroin (0.80%) in 
2011. Among all young adults aged 19-30, the annual 
prevalence of synthetic cannabinoids was 6.5%, but 
there were considerable differences by age. With annual 
prevalence rates in 2011 between 2% and 5%, salvia 
divinorum seems to be more widespread among 19-24 
years olds than among those aged 25 to 30, where an-
nual prevalence was less than 1%.
165 1HZ=HDODQG0LQLVWU\RI +HDOWK¶5HJXODWRU\LPSDFWVWDWHPHQWQHZ
UHJXODWRU\UHJLPHIRUSV\FKRDFWLYHVXEVWDQFHV·WKH7UHDVXU\:HOOLQJ-
WRQ -XO\  KWWSZZZWUHDVXU\JRYWQ]SXEOLFDWLRQVLQIRUPD-
WLRQUHOHDVHVULVSGIVULVPRKUUSVMXOSGI
166 'HYHORSPHQWRI WKH%&6TXHVWLRQQDLUHWDNHVSODFHRQDQDQQXDOEDVLV
DQGDLPVWRUHÁHFWHPHUJLQJLVVXHV4XHVWLRQVDERXWWKHXVHRI NHW-
DPLQHZHUHDGGHGWRWKH%&6LQTXHVWLRQVDERXWV\QWKHWLF
FDQQDELQRLGV DQG EHQ]\OSLSHUD]LQH %=3 ZHUH DGGHG LQ 2FWREHU
2009, and questions about the use of  mephedrone were added to the 
%&6TXHVWLRQQDLUH6PLWK.DQG)ODWOH\ - ¶'UXJPLVXVH
GHFODUHGÀQGLQJV IURP WKH%ULWLVK&ULPH6XUYH\(QJODQG
DQG:DOHV·6WDWLVWLFDO%XOOHWLQ8QLWHG.LQJGRP+RPH2IÀFH
167 ,QPHSKHGURQHZDVFODVVLÀHGLQWKH8QLWHG.LQJGRPDVD&ODVV
%VXEVWDQFHXQGHUWKH0LVXVHRI 'UXJV$FW
168 6PLWK. DQG)ODWOH\ - ¶'UXJPLVXVH GHFODUHG ÀQGLQJV IURP WKH
%ULWLVK&ULPH6XUYH\(QJODQGDQG:DOHV·6WDWLVWLFDO%XOOHWLQ
8QLWHG.LQJGRP+RPH2IÀFH
169 In the survey, synthetic cannabinoids were understood as a substance 
WKDW´JRHVE\VXFKQDPHVDV ¶6SLFH·DQG.DQGLVDQKHUEDOGUXJ
mixture that usually contains designer chemicals that fall into the can-
QDELQRLGIDPLO\µ-RKQVWRQ/'2·0DOOH\30%DFKPDQ-*DQG
6FKXOHQEHUJ-(¶0RQLWRULQJWKH)XWXUHQDWLRQDOUHVXOWVRQDGROHV-
FHQW GUXJ XVH RYHUYLHZ RI  NH\ ÀQGLQJV · 7KH8QLYHUVLW\ RI 
0LFKLJDQVSRQVRUHGE\7KH1DWLRQDO,QVWLWXWHRQ'UXJ$EXVH1D-
tional Institutes of  Health, February 2012 (http://monitoringthefu-
WXUHRUJSXEVPRQRJUDSKVPWIRYHUYLHZSGI
170 -RKQVWRQ / ' 2·0DOOH\ 30 %DFKPDQ -* DQG 6FKXOHQEHUJ
-(¶0RQLWRULQJWKH)XWXUHQDWLRQDOUHVXOWVRQDGROHVFHQWGUXJXVH
RYHUYLHZRI NH\ÀQGLQJV·7KH8QLYHUVLW\RI 0LFKLJDQVSRQ-
VRUHGE\7KH1DWLRQDO,QVWLWXWHRQ'UXJ$EXVH1DWLRQDO,QVWLWXWHV
of  Health, February 2012 (http://monitoringthefuture.org/pubs/
PRQRJUDSKVPWIRYHUYLHZSGI
Source: data from the New Zealand Drug Use Survey 
2007-2008 
Base: all respondents %
New Zealand: prevalence of drug and NPS 
use in the adult population of New 
Zealand, 2007 - 08
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4.4.  National treatment data estimates 
Given their relatively recent emergence in the drug 
markets, treatment data on NPS is almost non-existent 
but some Governments have started to collect data on 
the impact of the use of NPS on public health systems. 
In the United Kingdom, treatment data on ketamine 
and mephedrone were included for the first time in the 
2012 report of the National Treatment Agency for Sub-
stances Misuse (NTA). The report showed that while 
the number of people entering treatment for ecstasy has 
halved from 2,138 in 2006-07 to 1,018 in 2011-12, 
ketamine and mephedrone cases have risen. Ketamine 
presentations continuously increased between 2005-06 
and 2010-11, from 114 to 845, falling back to 751 in 
2011-12. In 2012, 900 over-18s started treatment for 
mephedrone, compared to 839 in the previous year. 
The high numbers could indicate a potential strain 
on public health although it is not possible to predict 
long-term treatment demand on the basis of data for 
two years. In addition, many persons demanding treat-
ment for NPS were relatively young. In 2011, 56% of 
all over-18s treated for mephedrone were aged 18-24.171 
The 2011 annual report of the National Programme on 
Substance Abuse Deaths (np-SAD) of the United King-
dom revealed an increase in the number and range of 
NPS identified in post mortem toxicology results and/
or as cause of death of cases notified to the Programme. 
NPS include para-methoxyamphetamine (PMA) (an 
internationally controlled substance), fluoroamphet-
amine (4-FA), tryptamines (5-MeO-DALT) as well as 
mephedrone, MDPV and naphyrone. The number of 
cases where mephedrone and MDPV were mentioned 
increased significantly in 2010: according to post mor-
tem toxicology results, mephedrone rose to 46 reports 
(compared to 8 reports in 2009) and MDPV to 9 re-
ports in 2010 (compared to 0 in 2009). Cause of death 
cases notified to the Programme also registered an in-
crease in 2010 for both mephedrone (29) and MDPV 
(6) (compared to 5 and 0 cases in 2009, respectively).172
In the United States, the first report on synthetic can-
nabinoids from the Drug Abuse Warning Network re-
vealed that an estimated 11,406 visits of the approxi-
mately 2,300,000 emergency department visits that 
involved drug use in 2010 were specifically linked to 
synthetic cannabinoids. Three quarters of these emer-
gency department visits involved patients aged 12 to 
29 (75 percent or 8,557 visits), of which 78 percent 
were male, and in the majority (59 percent) of these 
cases, no other substances were involved. The average 
patient age for synthetic cannabinoids-related visits was 
24 years, while it was 30 years for cannabis. Overall, 
synthetic cannabinoid-related visits were concentrated 
in the younger age groups: 75 percent of the visits in-
volved patients aged 12 to 29, with 33 percent of the 
patients aged 12 to 17. In comparison, 58 percent of 
cannabis-related visits involved patients aged 12 to 29, 
with 12 percent in the 12 to 17 age group.173
171 1DWLRQDO 7UHDWPHQW $JHQF\ IRU 6XEVWDQFHV 0LVXVH ´&OXE GUXJV
HPHUJLQJ WUHQGV DQG ULVNVµ  KWWSZZZQWDQKVXNXSORDGV
FOXEGUXJVUHSRUW%'SGI DFFHVVHGLQ1RYHPEHU
172 8QLWHG.LQJGRP1DWLRQDO3URJUDPPHRQ6XEVWDQFH$EXVH'HDWKV
QS6$'¶'UXJUHODWHGGHDWKVLQWKH8.$QQXDOUHSRUW·
173 8QLWHG6WDWHV'UXJ$EXVH:DUQLQJ1HWZRUN ¶'UXJUHODWHG(PHU-
gency Department visits involving synthetic cannabinoids’, 2012 
United States: prevalence of drug and NPS use among 12th graders, 2010 - 2011
Source: data from the MTF Survey  2010-2011 
Base: 12th graders % 
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4.5. Internet surveys on the use of new 
psychoactive substances
Internet surveys have been conducted to assess the use 
of NPS. It should be noted that all known surveys on 
NPS have been conducted in Europe and that they are 
limited by the self-nominating nature of the sample 
and are therefore unrepresentative of the general popu-
lation. The use of an online method of data collection 
implies that those who respond are likely to be more ac-
tive online and that some populations with higher than 
average levels of drug use (e.g. the homeless and those 
in prison) as well as those with no access to the Internet 
are excluded. 
In Germany, an online survey on use experiences and 
use patterns of various NPS174 was conducted in 2011. 
The survey was addressed to those with drug use ex-
perience and invitations to participate were extended 
to them via social networks, internet shops that offer 
legal highs, online forums on drug-related topics and 
prevention websites. The survey was completed on-
line by 860 individuals (89% of the respondents were 
male and the average age was 24.2 years) from all over 
Germany. Reported lifetime prevalence of illegal drugs 
among the respondents was at 99%. Synthetic canna-
binoids were reportedly the most prevalent new psy-
choactive substance, with a lifetime prevalence of 86%. 
Lifetime prevalence of research chemicals175 was at 39% 
and at 35% for ‘other legal highs’.176 More than half of 
the respondents reported having used at least one NPS 
in the last month. The users of synthetic cannabinoids 
were reportedly older on average and more frequently 
living in small towns. Current users of research chemi-
cals were especially likely to be experienced and regular 
users of various illegal drugs. Overall, the respondents 
named more than 300 different substances which they 
had tried at least once. More than three out of five re-
spondents indicated the legal availability of NPS as a 
major motivation for use.187 
In the United Kingdom, the British electronic dance 
and clubbing magazine ‘MixMag’ has conducted two 
surveys on NPS, in 2009 and 2011. The survey had 
been traditionally addressed to young club goers, but 
over the last few years it has attempted to involve a 
wider segment of the population. The first survey, 
carried out in 2009 (results were published in Janu-
ary 2010), collected data of lifetime, last year and last 
month drug use on 29 substances, including NPS 
such as synthetic cannabinoids, synthetic cathinones 
(MDPV, mephedrone, methylone), phenethylamines 
(2C-I, and 2C-T-7), piperazines (BZP), salvia divi-
norum and ‘other new psychoactive substances’. Al-
though 3,500 responses had been received as of Feb-
ruary 2010, the analysis here presented is based on a 
subset of 2,295 UK respondents, the majority of them 
aged between 18-27.178 
The 2009 survey shows that lifetime and last-month 
prevalence of other NPS surpassed the use of illicit 
drugs such as heroin and methamphetamine. Last year 
prevalence showed ketamine as the most common new 
psychoactive substance (51%), followed by synthetic 
cathinones (mephedrone 37.3%), piperazines (BZP 
12.1%), and, to a lesser extent, plant-based substances 
(salvia divinorum 8.9%) and synthetic cannabinoids 
(‘spice’ 6.2%). 
The second Mixmag survey was carried out in 2010, 
with results published in March 2011. More than 
15,500 people worldwide took part in a similar Mix-
Mag/the Guardian Drugs Survey, which makes it “the 
biggest ever survey of drug use among clubbers”, ac-
cording to the organizers. Three quarters of the re-
spondents were aged between 18-27 and two-thirds 
were male (69%). Two NPS were added to the 2010 
174 1HZ SV\FKRDFWLYH VXEVWDQFHVZHUH EURNHQ GRZQ LQ KHUEDO EOHQGV
RWKHU OHJDO KLJKVEDWK VDOWV HWF DQG UHVHDUFK FKHPLFDOV:HUVH%
DQG0RUJHQVWHUQ&¶6KRUWUHSRUW2QOLQHVXUYH\RQWKHWRSLFRI ´ OH-
JDOKLJKVµ·&HQWUHIRU'UXJ5HVHDUFK*RHWKH8QLYHUVLW\)UDQNIXUW
am Main, 2011
175 Research chemicals refer to “new synthetic drugs that are (at least ac-
FRUGLQJWRWKHGHFODUDWLRQVROGLQSXUHIRUPXQGHUWKHLUDFWXDOFKHPL-
FDOQDPH7KHJHQHULFWHUPLVLQGHSHQGHQWRI WKHDFWLYLW\SURÀOHDQG
in principle, it considers the whole spectrum of  all the possible drug 
effects, even though there are focus areas. Research chemicals are, in 
VRPHFDVHV ODEHOOHGDV´RQO\IRUUHVHDUFKSXUSRVHVµ:HUVH%DQG
0RUJHQVWHUQ&¶6KRUWUHSRUWRQOLQHVXUYH\RQWKHWRSLFRI ´OHJDO
KLJKVµ·&HQWUHIRU'UXJ5HVHDUFK*RHWKH8QLYHUVLW\)UDQNIXUWDP
Main, 2011
176 2WKHU OHJDOKLJKV´LQFOXGHVDOOSURGXFWVH[FHSWFDQQDELVOLNHVPRN-
LQJEOHQGVZKLFKDUHPDLQO\GHOLEHUDWHO\ZURQJO\ODEHOOHGDV´EDWK
VDOWVµ´DLUIUHVKHQHUVµ´SODQWIRRGµHWFDQGFRQWDLQV\QWKHWLFSV\-
choactive substances. It mostly includes drugs which have stimulant 
and entactogenic / empathogenic effects, and are therefore substi-
tutes for popular party drugs’ such as amphetamine, ecstasy/ MDMA 
RUFRFDLQHµ:HUVH%DQG0RUJHQVWHUQ&¶6KRUWUHSRUWRQOLQHVXU-
YH\RQWKHWRSLFRI ´OHJDOKLJKVµ·&HQWUHIRU'UXJ5HVHDUFK*RHWKH
8QLYHUVLW\)UDQNIXUWDP0DLQ
177 /HJDO KLJKV UHIHU WR V\QWKHWLF FDQQDELQRLGV RWKHU OHJDO KLJKVEDWK
VDOWV HWF DQG UHVHDUFK FKHPLFDOV:HUVH % DQG0RUJHQVWHUQ &
¶6KRUWUHSRUWRQOLQHVXUYH\RQWKHWRSLFRI ´OHJDOKLJKVµ·&HQWUHIRU
'UXJ5HVHDUFK*RHWKH8QLYHUVLW\)UDQNIXUWDP0DLQ
178 :LQVWRFN$¶%ULHI VXPPDU\RI WKH0L[PDJ·VVXUYH\:LQ-
VWRFN DQG 0LWFKHVRQ IRU WKH (0&&'$ $QQXDO UHSRUW· KWWS
HZVGZLYLVSEH3XEOLFDWLRQVRQQHZSV\FKRDFWLYH
VXEVWDQFHV0HSKHGURQH%ULHIVXPPDU\RIWKH
BPL[PDJVXUYH\SGI
40
Global SMART Programme 2013
179 :LQVWRFN$¶%ULHI VXPPDU\RI WKH0L[PDJ·VVXUYH\:LQ-
VWRFN DQG 0LWFKHVRQ IRU WKH (0&&'$ $QQXDO UHSRUW· KWWS
HZVGZLYLVSEH3XEOLFDWLRQVRQQHZSV\FKRDFWLYH
VXEVWDQFHV0HSKHGURQH%ULHIVXPPDU\RIWKH
BPL[PDJVXUYH\SGI
180 :LQVWRFN$ ¶7KH 0L[0DJGUXJV VXUYH\·0L[0DJ/RQGRQ
KWWSLVVXXFRPPL[PDJIDVKLRQGRFVGUXJVXUYH\
Internet survey: prevalence of drug and NPS use – Mixmag, 2009
Source: data from the Mixmag Drug Survey, 2009.179 
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survey; aminoindane derivative 5,6-methylenedioxy-
2-aminoindane (MDAI) and phenethylamine deriva-
tive 6-APB (Benzofury). Although the results are not 
directly comparable from year to year as the composi-
tion of the sample is slightly altered, the 2010 survey 
findings showed a higher last year prevalence of me-
phedrone (51% in 2010 vs. 37% in 2009),181 and a 
fall in last year use of ketamine from 2009 to 2010 
(50.7% vs. 41.2%). All in all, in 2010 last year use of 
several NPS such as synthetic cannabinoids (‘spice’) 
(2.2%), MDPV (3%), or BZP (5%) remained higher 
than last year use of drugs such as heroin (1.2%) and 
methamphetamine (1.0%).182 
181 :LQVWRFN$ ¶7KH 0L[0DJGUXJV VXUYH\·0L[0DJ/RQGRQ
KWWSLVVXXFRPPL[PDJIDVKLRQGRFVGUXJVXUYH\
182 :LQVWRFN$ ¶7KH 0L[0DJGUXJV VXUYH\·0L[0DJ/RQGRQ
KWWSLVVXXFRPPL[PDJIDVKLRQGRFVGUXJVXUYH\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5. THE SOURCES* OF NEW 
PSYCHOACTIVE SUBSTANCES
183 Belgium, Bulgaria, Croatia, Finland, France, Germany, Ireland, Italy, 
Latvia, Netherlands, Norway, Poland, Romania, the Russian Federa-
tion, Spain, Switzerland, Turkey and the United Kingdom
5.1 Countries reporting seizures of new 
psychoactive substances
From a total of 80 countries and territories report-
ing, 61 (76%) stated having seized NPS, almost half 
of those respondents were European countries. Most 
countries and territories (45) reported having seized 
synthetic cannabinoids and ketamine (75%), followed 
by 42 having seized plant-based substances (68%) and 
39 having seized piperazines (65%).  
Twenty-four countries, 18 from Europe183, two each 
from the Americas (Canada and the United States), 
Asia (Japan and Singapore) and Oceania (Australia and 
New Zealand) reported having made seizures from each 
NPS group.  In Europe, seizures were made across the 
region, from Portugal to the Russian Federation and 
from Norway to Italy. 
In Africa and Europe, most NPS seizures concerned 
synthetic cannabinoids. Ketamine is the most widely 
seized NPS in the Americas and Asia. With regard to 
Oceania, all NPS groups of substances have been seized 
in Australia and New Zealand.  Africa is the only region 
in the world which did not report the emergence or 
seizures of synthetic cathinones and phenethylamines. 
* Sources are reported by respondents and have not been validated sci-
HQWLÀFDOO\DVPDQXIDFWXULQJSURGXFWLRQVLWHV
Number of countries reporting NPS seizures
Source: UNODC quesonnaire on NPS, 2012
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Synthetic cannabinoids
Synthetic cannabinoids are the most frequently seized 
NPS, with seizures reported from all regions. Over 
the last four years, seizures of synthetic cannabinoids 
have spread geographically. Whereas for 2009, only 
three countries (Finland, France and Germany) re-
ported seizures of more than 1 kg of synthetic canna-
binoids, that number had increased to 10 in 2010, 9 
from Europe as well as the United States. In 2011, 16 
countries reported seizures of synthetic cannabinoids, 
indicating a further spread to new regions, namely 
Oceania (New Zealand) and Asia (Saudi Arabia). 
Some countries reported particularly high increases, 
in the United States, for example, only 23 seizure 
cases were reported in 2009, rising to 22,000 cases 
in 2011. 
Several European countries reported significant sei-
zures of synthetic cannabinoids. In Germany, 261 kg 
Source: UNODC quesonnaire on NPS, 2012
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Seizures of more than 1 kg of synthetic cathi-
nones by country, 2009 - 2012
2009 2010 2011 2012
Bulgaria Ɣ Ɣ Ɣ
Croatia Ɣ
Finland Ɣ Ɣ Ɣ Ɣ
France Ɣ
Germany Ɣ Ɣ
Hungary Ɣ
Ireland Ɣ Ɣ Ɣ
Italy Ɣ
Latvia Ɣ Ɣ Ɣ
Malta Ɣ Ɣ
Netherlands Ɣ Ɣ Ɣ Ɣ
New Zealand Ɣ Ɣ
Norway Ɣ Ɣ
Poland Ɣ Ɣ Ɣ
Romania Ɣ Ɣ Ɣ
Russian Federation Ɣ Ɣ Ɣ
Spain Ɣ Ɣ
Source: UNODC questionnaire on NPS, 2012
of synthetic cannabinoids were seized in 2009. Cy-
prus, Hungary, Italy and Romania also reported sei-
zures of more than 10 kg. In 2011, the EMCDDA 
reported that 20,000 packages containing several syn-
thetic cannabinoids were seized at one facility in the 
Netherlands. 184
Various countries initiated special operations targeting 
NPS. The Drug Enforcement Administration of the 
United States, for example, conducted a nationwide 
operation in July 2012 which resulted in the seizures 
of  4.8 million packages of synthetic cannabinoids as 
well as large quantities of synthetic cathinones.
Synthetic cathinones
Seizure data of synthetic cathinones indicate the emer-
gence on a larger scale in 2010 and 2011. Whereas only 
Finland and the Netherlands, reported seizures of more 
than 1 kg of synthetic cathinones in 2009, 15 countries 
reported seizures in 2010 and 14 in 2011. In 2012, 9 
countries reported, however, as the questionnaire was 
circulated in July, data for that year is not complete. 
Mephedrone appears to be the most widely seized 
synthetic cathinone. Hungary reported mephedrone 
to be the most frequently seized synthetic substance 
in 2010 (ARQ data).  In the Netherlands, in October 
2009, more than 130 kg of mephedrone were seized 
from a pill-pressing site and four related storage loca-
Seizures of more than 1 kg of synthetic can-
nabinoids by country, 2009 - 2012
2009 2010 2011 2012
Belgium Ɣ
Bulgaria Ɣ Ɣ
 Croatia Ɣ
Cyprus Ɣ
Finland Ɣ Ɣ Ɣ Ɣ
France Ɣ
Germany Ɣ Ɣ Ɣ
Hungary Ɣ Ɣ
Ireland Ɣ Ɣ
Italy Ɣ Ɣ
Latvia Ɣ Ɣ Ɣ
Netherlands Ɣ Ɣ
New Zealand Ɣ Ɣ
Norway Ɣ Ɣ
Poland Ɣ
Romania Ɣ Ɣ
Russian Federation Ɣ Ɣ Ɣ
Saudi Arabia Ɣ
Slovakia Ɣ
Spain Ɣ Ɣ
Turkey Ɣ
United States Ɣ Ɣ Ɣ
Source: UNODC questionnaire on NPS, 2012
184 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶
$QQXDOUHSRUWRQWKHVWDWHRI WKHGUXJVSUREOHPLQ(XURSH·/LVERQ
2012
Source: UNODC quesonnaire on NPS, 2012
Seizures of more than 1 kg of  synthetic 
cathinones, 2009- 2012
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tions.185 Germany and the United Kingdom have also 
reported multi-kilo seizures of mephedrone.186 Seizures 
of MDPV and 4-methylethcathinone (4-MEC) were 
also reported from European countries. Canada and the 
United States reported numerous seizure cases of syn-
thetic cathinones.
 
Ketamine
Seizures of ketamine were stable, which might result 
from the fact that ketamine is a fairly established sub-
stance in ATS markets around the world. Sixteen coun-
tries reported more than 1 kg ketamine seizures in 2009, 
ten Asian countries and territories (Cambodia, China, 
India, Indonesia, Malaysia, Myanmar, Philippines, Sin-
gapore, Thailand and Hong Kong SAR), five European 
countries (France, Hungary, Italy, Netherlands and 
Spain) as well as Canada. In 2012, the year for which 
only partial data is available as the questionnaire was 
circulated in July, France, Malaysia, Singapore, Spain 
and Hong Kong SAR reported ketamine seizures.
The  most significant seizures of ketamine have been 
made in Asia, with multi-ton seizures made in China 
(5.3 mt ), India (1 mt) and Malaysia (1.1 mt) in 2009. 
Outside Asia, significant ketamine seizures are reported 
by Canada, where 2.3 mt were seized in 2010.  France, 
Hungary, Netherlands and the United States also re-
ported seizures. 
Phenethylamines
Most countries reporting more than 1 kg seizures 
of phenethylamines are from Europe. From 2009 to 
2012, phenethylamines were seized in nine different 
Seizures of more than 1 kg of ketamine by 
country, 2009 - 2012
2009 2010 2011 2012
Canada Ɣ Ɣ Ɣ
Cambodia Ɣ
China Ɣ Ɣ Ɣ
France Ɣ Ɣ Ɣ
Hong Kong SAR Ɣ Ɣ Ɣ Ɣ
Hungary Ɣ Ɣ Ɣ
India Ɣ Ɣ Ɣ
Indonesia Ɣ Ɣ
Italy Ɣ Ɣ Ɣ
Malaysia Ɣ Ɣ Ɣ Ɣ
Myanmar Ɣ Ɣ
Netherlands Ɣ Ɣ Ɣ
Philippines Ɣ
Singapore Ɣ Ɣ Ɣ Ɣ
Spain Ɣ Ɣ Ɣ Ɣ
Thailand Ɣ Ɣ Ɣ
United States Ɣ
6RXUFH812'&TXHVWLRQQDLUHRQ136$54DQG'$,1$3
Source: UNODC quesonnaire on NPS, 2012
Seizure of more than 1 kg of ketamine, 
2009-2012
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185 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJV DQG'UXJ$GGLFWLRQ ¶5H-
SRUWRQWKHULVNDVVHVVPHQWRI PHSKHGURQHLQWKHIUDPHZRUNRI WKH
&RXQFLO'HFLVLRQRQQHZSV\FKRDFWLYHVXEVWDQFHV·5LVN$VVHVVPHQWV
,VVXH/LVERQKWWSZZZHPFGGDHXURSDHXDWWDFKHPHQWV
FIPDWWBB(1B 7'$.(1&B:(%237,0,6('
),/(SGI
 (XURSHDQ 0RQLWRULQJ &HQWUH IRU 'UXJV DQG 'UXJ $GGLFWLRQ ¶5H-
SRUWRQWKHULVNDVVHVVPHQWRI PHSKHGURQHLQWKHIUDPHZRUNRI WKH
&RXQFLO'HFLVLRQRQQHZSV\FKRDFWLYHVXEVWDQFHV·5LVN$VVHVVPHQWV
,VVXH/LVERQKWWSZZZHPFGGDHXURSDHXDWWDFKHPHQWV
FIPDWWBB(1B 7'$.(1&B:(%237,0,6('
),/(SGI
Source: UNODC quesonnaire on NPS, 2012
Seizures of more than 1 kg of phenethyl-
amines, 2009-2012
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European countries as well as New Zealand. Whereas 
countries from the Americas and Asia reported smaller 
quantities, Romania reported the seizure of 77 kg of 
phenethylamines in 2010 and New Zealand reported 
having seized almost 6 kg in 2009. 
Piperazines
Given that piperazines have emerged in almost all re-
gions (Africa being the notable exception) before 2008, 
seizures during the last four years have been relatively 
constant, with a slightly decreasing trend in 2012. 
Almost all countries reporting seizures are in Europe. 
In 2010, ARQ data from Finland shows seizures of 56 
kg of mCPP pills. Romania also reported seizures of 7 
kg of unspecified “piperazines”. 
Seizures of more than 1 kg of phenethyl-
amines by country, 2009 - 2012
2009 2010 2011 2012
Belgium Ɣ Ɣ
Bulgaria Ɣ Ɣ
Finland Ɣ Ɣ
Ireland Ɣ
Netherlands Ɣ Ɣ Ɣ
New Zealand Ɣ
Norway Ɣ Ɣ Ɣ
Romania Ɣ
Russian Federation Ɣ Ɣ Ɣ Ɣ
Spain Ɣ
Source: UNODC questionnaire on NPS, 2012
187 .HOOHKHU&&KULVWLH5/DORU.)R[-%RZGHQ0DQG2·'RQQHOO
&¶$QRYHUYLHZRI QHZSV\FKRDFWLYHVXEVWDQFHVDQGWKHRXWOHWVVXS-
SO\LQJWKHP·1DWLRQDO$GYLVRU\&RPPLWWHHRQ'UXJV&HQWUHIRU6R-
FLDODQG(GXFDWLRQDO5HVHDUFK'XEOLQ,QVWLWXWHRI 7HFKQRORJ\'XE-
OLQ  KWWSZZZQDFGLHLPDJHVVWRULHVGRFVSXEOLFDWLRQD
KHDGBUHSRUWBRYHUYLHZSGI
188 (XURSHDQ 0RQLWRULQJ &HQWUH IRU 'UXJV DQG 'UXJ $GGLFWLRQ DQG
(XURSHDQ 3ROLFH 2IÀFH ¶(0&''$²(XURSRO  $QQXDO UHSRUW
RQ WKH LPSOHPHQWDWLRQ RI  &RXQFLO 'HFLVLRQ -+$· /LV-
ERQ   KWWSZZZHPFGGDHXURSDHXDWWDFKHPHQWVFIP
DWWBB(1B(0&''$BULVNBDVVHVVPHQWBSGI
Seizures of more than 1 kg of piperazines by 
country, 2009 - 2012
2009 2010 2011 2012
Bulgaria Ɣ Ɣ
Finland Ɣ Ɣ
Germany Ɣ
Hungary Ɣ
Ireland Ɣ Ɣ
Latvia Ɣ
Netherlands Ɣ Ɣ Ɣ Ɣ
New Zealand Ɣ Ɣ Ɣ Ɣ
Norway Ɣ Ɣ
Romania Ɣ
Russian Federation Ɣ Ɣ Ɣ
Spain Ɣ Ɣ Ɣ
Turkey Ɣ Ɣ
Source: UNODC questionnaire on NPS, 2012
In Ireland, BZP was often seized in combination with 
TFMPP.187 Norway has reported seizures of BZP in 
powder, capsules or pill form.188 
Plant-based substances
Seizures of plant based-substances have been reported 
from all regions and by most countries. Thirty-seven 
countries reported seizing more than 1 kg of a plant-
based substance over the past four years. The most 
significant general seizures of plant-based substances 
were reported by Italy for all four years with 386 kg in 
2009, 663 kg in 2010, 867 kg in 2011 and 161 kg in 
2012 (until 26th July). New Zealand seized 137 kg in 
2009 (65 seizure cases), 75 kg (40 cases) in 2011 and 
39 kg (21 cases) in 2012.
Khat was the most frequently reported plant-based 
substance by by respondents to the questionnaire. The 
highest seizures in 2010 were made in Saudi Arabia 
with 374 mt, followed by the United States with 90 
mt and Germany with 30.4 mt. ARQ data indicates 
further that multi-ton khat seizures were reported by 
Source: UNODC quesonnaire on NPS, 2012
Seizures of more than 1 kg of piperazines, 
2009-2012
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Denmark (2010: 5 mt), Sweden (2010: 14 mt) and 
United Republic of Tanzania (2010: 10 mt). Several 
countries experienced significant increases in seizures 
of khat between 2009 and 2010 such as Saudi Arabia 
(182 kg to 374 mt), Ireland (50 kg to 218 kg) and 
Norway (3 mt to 7 mt).
Significant seizures of kratom, a plant indigenous to 
South-East Asia, were also reported, mostly from that 
region. The largest kratom seizures were reported by 
Thailand with 29.9 mt in 2009, 44.2 mt in 2010 and 
189 6RXUFHV'$,1$321&%
190  6RXUFHV'$,1$3&&'$&
Seizures of more than 1 kg of plant-based 
substances by country, 2009 - 2012
2009 2010 2011 2012
Australia Ɣ
Bahrain Ɣ
Belgium Ɣ Ɣ
Bulgaria Ɣ
Canada Ɣ Ɣ Ɣ
Denmark Ɣ Ɣ
Egypt Ɣ Ɣ Ɣ Ɣ
Estonia Ɣ
Finland Ɣ Ɣ Ɣ Ɣ
France Ɣ Ɣ Ɣ Ɣ
Germany Ɣ Ɣ
Greece Ɣ
Hong Kong SAR Ɣ Ɣ Ɣ
Hungary Ɣ
Ireland Ɣ Ɣ Ɣ Ɣ
Italy Ɣ Ɣ Ɣ Ɣ
Latvia Ɣ
Lebanon Ɣ Ɣ
Malaysia Ɣ Ɣ Ɣ Ɣ
Malta Ɣ Ɣ Ɣ Ɣ
New Zealand Ɣ Ɣ Ɣ
Norway Ɣ Ɣ Ɣ Ɣ
Qatar Ɣ
Panama Ɣ Ɣ Ɣ Ɣ
Romania Ɣ
Saudi Arabia Ɣ Ɣ Ɣ
Spain Ɣ Ɣ
Sweeden Ɣ Ɣ
Switzerland Ɣ Ɣ Ɣ
Syrian Arab Republic Ɣ
Tanzania (United Re- 
public of ) Ɣ Ɣ
Thailand Ɣ Ɣ
Turkey Ɣ Ɣ
UAE Ɣ
United States Ɣ Ɣ
Yemen Ɣ
Zambia Ɣ Ɣ
6RXUFH812'&TXHVWLRQQDLUHRQ136DQG$54
Trend of NPS seizures, 2009 - 2012
NPS group 2009 2010 2011 2012
Synthetic cannabinoids Ĺ Ĺ Ĺ Ĺ
Synthetic cathinones Ĺ Ĺ Ĺ ļ
Ketamine ļ ļ ļ ļ
Phenethylamines ļ Ĺ ļ ļ
Piperazines Ĺ ļ ļ Ļ
Plant-based substances Ĺ Ĺ Ĺ ļ
Miscellaneous - Ĺ Ĺ Ĺ
ȹ ,QFUHDVLQJȻ 'HFUHDVLQJȼ 6WDEOHXQNQRZQ
Source: UNODC questionnaire on NPS,  2012 DQG$54
Source: UNODC quesonnaire on NPS, 2012
Seizures of more than 1 kg of plant-based 
substances, 2009-2012
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32.9 mt in 2011.189 Malaysia seized 2.2 mt in 2010 
(ARQ data) and Myanmar seized almost 600 kg in 
2009, 375 kg in 2010 and 970 kg in 2011.190
The third most widespread plant-based substance is 
salvia divinorum, a plant common to southern Mexico 
and Central and South America. Although salvia has 
been reported from every region, seizures remain rela-
tively low, with only Germany indicating to have seized 
1.3 kg in 2009. 
Seizure trends for new psychoactive substances
Trends for the seven NPS groups fluctuate. While sei-
zures of ketamine, phenethylamines and piperazines 
seem to be more or less stable over the past four years, 
expert perceptions indicate rising trends for synthetic 
cannabinoids, synthetic cathinones and plant-based 
substances.
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5.2 Number of new psychoactive sub-
stances in global markets
A total of 251 NPS (including ketamine) were re-
ported to UNODC by 40 countries and territories 
up to 2012. Most of the substances reported globally 
between 2009 and 2012 are synthetic cannabinoids 
(60 substances), followed by phenethylamines (58 
substances) and synthetic cathinones (44 substances).
At the global level, most reports pertaining to NPS 
concern synthetic cathinones, with 684 reports, fol-
lowed by synthetic cannabinoids with 665 reports. 
The highest number of reports in each NPS group 
were received in 2011. In terms of number of sub-
stances reported, 2012 ranks second, but it has to be 
taken into account that 2012 data is limited to the 
first 7 months or so, as the questionnaire was circu-
lated in the month of July. 
Number of NPS reported up to 2012   
Source: UNODC quesonnaire on NPS,  2012
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Source: UNODC quesonnaire on NPS,  2012
684 665 
437 
294 
200 
161 
134 
34 
6 
0 
100 
200 
300 
400 
500 
600 
700 
800 
Sy
nt
he
c
 
ca
th
in
on
es
 
Sy
nt
he
c
 
ca
nn
ab
in
oi
ds
 
Ph
en
et
hy
la
m
in
es
 
Pi
pe
ra
zin
es
 
Pl
an
t-
ba
se
d 
su
bs
ta
nc
es
 
O
th
er
s 
Tr
yp
ta
m
in
es
 
Am
in
oi
nd
an
es
 
Ph
en
cy
cl
id
in
e-
ty
pe
 
su
bs
ta
nc
es
 
50
Global SMART Programme 2013
In countries of the European Union, the emergence 
of NPS is monitored by the EMCDDA which review 
new substances reported by Member States of the 
European Union. The number of substances has con-
tinuously increased over the years, whereas in 2009 
only 24 substances were reported, 41 were formally 
notified in 2010, 49 in 2011 and 73 NPS reported 
in 2012.191,192 In 2010 and 2011, about two thirds of 
the newly notified substances reported were synthetic 
cannabinoids or synthetic cathinones.
Synthetic cannabinoids
Respondents to the UNODC questionnaire on NPS 
reported 60 different synthetic cannabinoids, the most 
frequently reported substance being JWH-018. 
The Republic of Korea reports that 74 per cent of all 
synthetic cannabinoids analysed by the Customs Labo-
ratory between January 2009 to August 2012 belonged 
to the JWH class.193 Similarly, data on synthetic canna-
binoids submitted through the National Forensic Lab-
oratory Information System (NFLIS)194 of the United 
195 8QLWHG 6WDWHV 'UXJ (QIRUFHPHQW $GPLQLVWUDWLRQ ¶6SHFLDO UHSRUW
synthetic cannabinoids and synthetic cathinones reported in NFLIS 
1DWLRQDO )RUHQVLF /DERUDWRU\ ,QIRUPDWLRQ 6\VWHP ·
'HSDUWPHQWRI -XVWLFH6SULQJÀHOGKWWSZZZGHDGLYHUVLRQ
XVGRMJRYQÁLVU[BV\QWKSGI
 8QLWHG 6WDWHV 'UXJ (QIRUFHPHQW $GPLQLVWUDWLRQ ¶6SHFLDO UHSRUW
synthetic cannabinoids and synthetic cathinones reported in NFLIS 
1DWLRQDO )RUHQVLF /DERUDWRU\ ,QIRUPDWLRQ 6\VWHP ·
'HSDUWPHQWRI -XVWLFH6SULQJÀHOGKWWSZZZGHDGLYHUVLRQ
XVGRMJRYQÁLVU[BV\QWKSGI
197 <XN6¶'HVLJQHUGUXJVLWXDWLRQDQGDFWLYLWLHVRI FXVWRPVODERUDWR-
ULHV LQ.RUHD·.RUHD&XVWRPV6HUYLFH SUHVHQWHG DW WKH*URXSRI 
European Customs Laboratories workshop on designer drugs, Berlin, 
²6HSWHPEHU
States, found that most belonged to the JHW class; in 
2010, 63 per cent of them were identified as JWH-018, 
followed by JWH-250 (14%) and JWH-073 (9%).195
Synthetic cathinones
Respondents to the UNODC questionnaire on NPS 
reported 44 different synthetic cathinones. The most 
frequently reported substance is mephedrone. 
Mephedrone and MDPV are the most widespread syn-
thetic cathinones. Analysis from NFLIS in the United 
States show the upsurge of these substances within a 
very short time. Whereas in 2009, only 34 reports of 
synthetic cathinones were received, this number in-
creased to 628 reports of synthetic cathinones in 2010. 
Most were mephedrone (48%), followed by MDPV 
(40%).196 At 29 per cent, MDPV is the most frequently 
detected synthetic cathinone analysed by the Customs 
Laboratory of the Republic of Korea.197
Source: EMCDDA 2012, 2013
NPS reported to EMCDDA, 2009 - 2012
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191 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶$Q-
QXDOUHSRUWRQWKHVWDWHRI WKHGUXJVSUREOHPLQ(XURSH·/LVERQ
192 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQDQG(X-
URSHDQ3ROLFH2IÀFH¶(8GUXJPDUNHWVUHSRUW$VWUDWHJLFDQDO\VLV·
7KH+DJXH
193 <XN6¶'HVLJQHUGUXJVLWXDWLRQDQGDFWLYLWLHVRI FXVWRPVODERUDWR-
ULHV LQ.RUHD·.RUHD&XVWRPV6HUYLFH SUHVHQWHG DW WKH*URXSRI 
European Customs Laboratories workshop on designer drugs, Berlin, 
²6HSWHPEHU
194 7KH1DWLRQDO)RUHQVLF/DERUDWRU\,QIRUPDWLRQ6\VWHP1)/,6LVD
SURJUDPPHRI WKH2IÀFHRI 'LYHUVLRQ&RQWURORI WKH'UXJ(QIRUFH-
PHQW$GPLQLVWUDWLRQ WKDW V\VWHPDWLFDOO\ FROOHFWV GUXJ LGHQWLÀFDWLRQ
UHVXOWVIURPGUXJFDVHVFRQGXFWHGE\VWDWHDQGORFDOIRUHQVLFODERUD-
WRULHVDFURVVWKH86
Source: UNODC quesonnaire on NPS, 2012
Top five synthetic cannabinoids reported 
to UNODC, up to 2012
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1.  JWH-018; (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone     70 
2.  JWH-073; (1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone    57 
3.  JWH-250; 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone   37 
4.  JWH-081; (4-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone    36 
5.  AM-2201; [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone    34 
5.  JWH-210; (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone    34 
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198 8QLWHG 6WDWHV 'UXJ (QIRUFHPHQW $GPLQLVWUDWLRQ ¶6SHFLDO UHSRUW
emerging 2C-phenethylamines, piperazines, and tryptamines in 
1)/,6 1DWLRQDO )RUHQVLF /DERUDWRU\ ,QIRUPDWLRQ 6\VWHP 
·'HSDUWPHQW RI  -XVWLFH 6SULQJÀHOG  KWWSVZZZQÁLV
GHDGLYHUVLRQXVGRMJRY 'HVNWRS0RGXOHV5HSRUW'RZQORDGV5H-
SRUWV1)/,6B65B(PHUJLQJB,,SGI
199 (XURSHDQ0RQLWRULQJ&HQWUHIRU'UXJVDQG'UXJ$GGLFWLRQ¶¶%=3
DQGRWKHUSLSHUD]LQHV·GUXJSURÀOHVKWWSZZZHPFGGDHXURSDHX
SXEOLFDWLRQVGUXJSURÀOHVE]S
Phenethylamines
Respondents to the UNODC questionnaire on NPS 
reported 58 different phenethylamines. The most fre-
quently reported substance is 4-Fluoroamphetamine. 
The 2C-phenethylamines are also widely reported 
from the United States. An estimated 580 reports 
of 2C-phenethylamines were submitted to State and 
local forensic laboratories in the United States from 
January 2006 through December 2010. In 2010, 2C-
phenethylamines were identified in 32 States; 33% as 
2C-E and 23% as 2C-I.198 
Piperazines
Respondents to the UNODC questionnaire on NPS 
reported 12 different piperazines. The most frequently 
reported substance is mCPP. 
The EMCDDA estimates that by 2006 almost 10% 
of illicit pills sold in the European Union, as part of 
the illicit ecstasy market contained mCPP. At the end 
of 2008 and beginning of 2009, this percentage seems 
to have increased up to 50% in some Member States 
of the European Union. Apart from mCPP, the next 
most commonly-found piperazine was 1-(3-trifluo-
romethyl-phenyl)piperazine (TFMPP), although it 
was nearly always seen in combination with BZP. 199 
Between 2006 to 2010, about 38,230 reports of pip-
erazines were submitted to the United States Nation-
al Forensic Laboratory Information System, reaching 
its peak in 2009 with 17,580 reports. In 2010, pip-
Source: UNODC quesonnaire on NPS, 2012
Top five synthetic cathinones reported to 
UNODC, up to 2012
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1.  4-MMC; Mephedrone (4-methylmethcathinone)    68 
2.  MDPV; 3,4-Methylenedioxypyrovalerone    61 
3.  bk-MDMA; Methylone   53 
4.  4-MEC; 4-Methylethcathinone    38 
5.  4-FMC; 4-Fluoromethcathinone (flephedrone )    35 
    
Source: UNODC quesonnaire on NPS, 2012
Top five phenethylamines reported to 
UNODC, up to 2012
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1.  4-FA; 4-Fluoroamphetamine    36 
2.  2C-E; 4-ethyl-2,5-dimethoxyphenethylamine     33
3.  2C-I; 4-iodo-2,5-dimethoxyphenethylamine   31 
4.  PMMA; p-Methoxymethamphetamine    29 
5.  2C-C; 4-Chloro-2,5-dimethoxyphenethylamine    18 
5.  4-FMA; 4-Fluoromethamphetamine   18 
Source: UNODC quesonnaire on NPS, 2012
Top five piperazines reported to UNODC, 
up to 2012
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1.  mCPP; 1-(3-Chlorophenyl)piperazine    70 
2.  BZP; 1-Benzylpiperazine    65 
3.  TFMPP; 1-(3-Trifluoromethylphenyl)piperazine   64 
4.  pFPP; 1-(4-Fluorophenyl)piperazine    27 
5.  MBZP; 1-Benzyl-4-methylpiperazine    22 
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erazines had been reported from 44 States, with BZP 
(80%) and TFMPP (18%) being the most common.200
Plant-based substances
Respondents to the UNODC reported 20 different 
substances of plant-based substances. The most fre-
quently reported substance is salvia divinorum. The 
multitude of other plant-based substances, that were 
reported by the respondents were country-specific, 
with only up to four countries reporting them.
5.3 Perceived sources* of new psycho-
active substances and the role of the In-
ternet
The primary region from where NPS originate was 
identified to be Asia, followed by Europe, the Ameri-
cas, Africa and Oceania.  In Asia, China and India are 
frequently named as sources of NPS whereas in Europe, 
various countries were named (Czech Republic, Hun-
gary, Netherlands, Portugal, Spain, Ukraine and United 
Kingdom). Domestic manufacture was reported by sev-
eral countries from the Americas, Asia and Europe. 
*  Sources are reported by the respondents and have not been validated 
VFLHQWLÀFDOO\DVPDQXIDFWXULQJSURGXFWLRQVLWHV
200 8QLWHG 6WDWHV 'UXJ (QIRUFHPHQW $GPLQLVWUDWLRQ ¶6SHFLDO UHSRUW
emerging 2C-phenethylamines, piperazines, and tryptamines in 
1)/,6 1DWLRQDO )RUHQVLF /DERUDWRU\ ,QIRUPDWLRQ 6\VWHP 
·'HSDUWPHQW RI  -XVWLFH 6SULQJÀHOG  KWWSVZZZQÁLV
GHDGLYHUVLRQXVGRMJRY'HVNWRS0RGXOHV 5HSRUW'RZQORDGV5H-
SRUWV1)/,6B65B(PHUJLQJB,,SGI
Source: UNODC quesonnaire on NPS, 2012
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1.  DMAA; 1,3-Dimethylamylamine (Others)    23 
2.  MDAI; 5,6-Methylenedioxy-2-aminoindane (Aminoindane)   21 
3.  Dimethocaine; 3-(Diethylamino)2,2-dimethylpropyl4-aminobenzoate (Others)   19 
4.  2-DPMP; 2-(Diphenylmethyl)piperidine (Others)    18 
5.  5-MeO-DPT; 5-Methoxy-N,N-dipropyltryptamine (Tryptamine)    15 
    
Miscellaneous substances
Respondents to the UNODC questionnaire on NPS 
reported 56 different substances of miscellaneous sub-
stances, mostly tryptamines (27). The most frequent-
ly reported substance is DMAA (1,3-dimethylam-
ylamine). 
Source: UNODC quesonnaire on NPS, 2012
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Sources are reported by the respondents and have not 
been validated scientifically as manufacturing/produc-
tion sites.
The mode of trafficking named by most respondents 
was trafficking by air (30 countries) followed by traf-
ficking by mail (24 countries), without any regional 
variations. 
The Internet was named as a source of NPS from all 
regions. The significant informational, promotional 
and distributional capacity of the Internet plays an im-
portant role in the NPS market and global web-based 
marketing and distribution distinct from illegal street 
markets has developed in past years.201
The Internet offers many advantages to NPS suppliers 
as it provides access to a vast number of potential us-
ers, suppliers do not need large up-front investments 
and can retain some level of anonymity. In addition, 
suppliers may be able to bypass the laws of different 
countries, thus making enforcement or legal action 
in response to their activities very difficult.  Products 
sold on the Internet may also stay under the radar for 
some time as illustrated in the case of ‘spice’, a prod-
uct containing synthetic cannabinoids. Initially sold 
largely over the Internet and specialized shops, its dis-
tribution took place in a ‘grey zone’ where the poten-
tially responsible institutions (public health authori-
ties, consumer protection agencies or the competent 
authorities for  medicinal products) did not assume 
direct responsibility.202
201 :LQVWRFN$DQG:LONLQV& ¶´/HJDOKLJKVµ7KHFKDOOHQJHRI QHZ
SV\FKRDFWLYHVXEVWDQFHV·7UDQVQDWLRQDO,QVWLWXWH6HULHVRQ/HJLVODWLYH
5HIRUPRI 'UXJ3ROLFLHVKWWSZZZWQLRUJVLWHV
ZZZWQLRUJÀOHVGRZQORDGGOUSGI
202 (XURSHDQ0RQLWRULQJ&HQWUH IRU'UXJV DQG'UXJ$GGLFWLRQ ¶8Q-
GHUVWDQGLQJ WKH ¶6SLFH· SKHQRPHQRQ· (0&''$ 7KHPDWLF 3DSHU
Lisbon, 2009
203 6FKPLGW006KDUPD$6FKLIDQR)DQG)HLQPDQQ& ¶´/HJDO
KLJKVµ RQ WKH QHW(YDOXDWLRQ RI 8.EDVHGZHEVLWHV SURGXFWV DQG
SURGXFW LQIRUPDWLRQ· )RUHQVLF 6FLHQFH ,QWHUQDWLRQDO   
²
204.HOOHKHU&&KULVWLH5/DORU.)R[-%RZGHQ0DQG2·'RQQHOO
&¶$QRYHUYLHZRI QHZSV\FKRDFWLYHVXEVWDQFHVDQGWKHRXWOHWVVXS-
SO\LQJWKHP·1DWLRQDO$GYLVRU\&RPPLWWHHRQ'UXJV&HQWUHIRU6R-
FLDODQG(GXFDWLRQDO5HVHDUFK'XEOLQ,QVWLWXWHRI 7HFKQRORJ\'XE-
OLQ  KWWSZZZQDFGLHLPDJHVVWRULHVGRFVSXEOLFDWLRQD
KHDGBUHSRUWBRYHUYLHZSGI
The significant distributional capacity of the Internet 
is evidenced in studies which have estimated online 
NPS availability. Internet snapshots produced by EM-
CDDA have shown an increase in the online availabil-
ity of NPS over the years, with the number of online 
shops increasing from 170 in January 2010, to 314 
shops in January 2011 and 690 online shops in Jan-
uary 2012. Little information is provided to users on 
the type of substance that is being bought. A 2011 
review of UK-based websites selling NPS showed that, 
in many cases, sellers fail to list ingredients, side effects 
or drug interactions of the advertised product.203
The Internet serves as a repository of information for 
several groups of people. Drug users can obtain infor-
mation through online forums, chat rooms and blogs 
and find out about new products. They can also com-
municate with other users on their experiences, the 
effects of the substances as well as the recommended 
sources and avenues of delivery. 204 On the other hand, 
the Internet is also used frequently by health and law 
enforcement authorities to expand their knowledge on 
the subject. Respondents from 62 countries and ter-
ritories (out of 71) to the UNODC questionnaire on 
NPS indicated, for example, that their level of knowl-
edge on the manufacturing process for NPS is low and 
that the Internet is frequently used to learn about syn-
thesis routes and other fact pertaining to NPS. 
,GHQWL¿FDWLRQRI QHZSV\FKRDFWLYH
substances
Respondents from 60 countries and territories pro-
vided information on the methods used in the iden-
tification of NPS. Most respondents indicated using 
chemical analysis techniques (49), followed by refer-
ence standards (33) and online databases (19). 
Chemical analysis techniques
A variety of chemical analysis techniques can be used 
to identify NPS and most respondents to the UNO-
DC questionnaire on NPS reported using gas chro-
Source: UNODC quesonnaire on NPS, 2012
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matography - mass spectrometry (GC-MS), which 
enables the separation of mixtures of molecules into 
individual components, followed by identification 
and quantification individually. The data collected 
from electron ionization mass spectrometry is checked 
against fragmentation libraries. Liquid chromatogra-
phy–mass spectrometry (LC–MS) also has been used 
to analyse NPS. Other analytical techniques reported 
by laboratories are high performance liquid chro-
matography (HPLC) and fourier transform infrared 
spectroscopy (FTIR). Nuclear magnetic resonance 
(NMR) spectrometry has been employed by the labo-
ratories for identification as well as elucidation of the 
chemical structure of substances. All of these methods 
have their limitations, with GC-MS, for example,  it 
is not always possible to distinguish between different 
synthetic cannabinoids from the JWH class. Various 
difficulties are encountered in identifying the active 
ingredients of NPS due to the presence of isomers and 
possible similarities between certain compounds of 
the same class. 
Reference standards
Reference standards are a useful tool in the identifica-
tion of drugs and NPS. These standards are certified 
samples of NPS with the highest quality and purity 
205 .HOOHKHU & &KULVWLH 5 /DORU . )R[ - %RZGHQ 0 DQG
2·'RQQHOO & ¶$Q RYHUYLHZ RI  QHZ SV\FKRDFWLYH VXEVWDQFHV DQG
WKHRXWOHWVVXSSO\LQJWKHP·1DWLRQDO$GYLVRU\&RPPLWWHHRQ'UXJV
&HQWUHIRU6RFLDODQG(GXFDWLRQDO5HVHDUFK'XEOLQ,QVWLWXWHRI 7HFK-
QRORJ\'XEOLQKWWSZZZQDFGLHLPDJHVVWRULHVGRFV
SXEOLFDWLRQDKHDGBUHSRUWBRYHUYLHZSGI
which serve as a measurement base for similar sub-
stances. The results of NPS identification are based on 
matches achieved through mass spectra libraries and 
mass spectra sourced from other agencies.205 Reference 
standards can be obtained from commercial sources. 
It may also be possible to make reference materials 
from internal sources, e.g. from seized materials. Most 
respondents indicated that their main source of refer-
ence standards were commercial sources.
However, even the availability of commercial refer-
ence standards is limited. In addition, with the high 
number of NPS circulating in the market, a large 
stock is required to keep up to date with the latest 
emergent substances. The cost is high, to stock up on 
the top 10 substances costs several thousand dollars 
which may be beyond the financial resources avail-
able to many drug analysis laboratories in developed 
and developing countries alike. Obtaining reference 
standards from internal sources such as seizures, on 
the other hand, may present further challenges, as 
NPS identification methods
Source: UNODC quesonnaire on NPS,  2012
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they have to be validated. In some countries, the use 
of seized materials may be impeded by legal issues. 
Many respondents to the UNODC questionnaire on 
NPS addressed the issue of the lack of availability and 
difficulty of obtaining reference standards for NPS. 
Online database
Various online databases offer mass spectral libraries 
for NPS to assist laboratories in their drug identifica-
tion work and to offer a platform for the exchange of 
information within the forensic science community. 
However, in the case of mass spectral libraries, various 
different formats (NIST, Agilent) are used and these 
may or may not be searchable. The fact that the mass 
spectra are not validated represents another challenge. 
Physical appearance
Physical appearance also plays an important role in the 
NPS identification process. Information gained from 
the physical examination of goods, including their la-
belling, packaging and presumptive testing results, all 
contribute to the judgment of authorities with regards 
to a substance being a NPS. However, in many cases 
the only way to identify the active ingredient of a sus-
pected NPS is to refer the substance for full forensic 
analysis.
Source: UNODC quesonnaire on NPS, 2012
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ABBREVIATIONS 
The following abbreviations have been used in the list: 
ALB     Albania
AUS      Australia 
BGR      Bulgaria     
BHR      Bahrain     
BRA      Brazil       
CAN     Canada       
CHE      Switzerland      
CHL     Chile       
CRI      Costa Rica      
EGY      Egypt       
ESP      Spain       
FIN     Finland      
GBR      United Kingdom of Great Britain and Northern Ireland 
HKG      China, Hong Kong Special Administrative Region          
HRV     Croatia       
HUN      Hungary      
IDN      Indonesia      
IRL      Ireland      
ISR      Israel       
ITA     Italy     
LVT      Latvia       
MDA      Republic of Moldova     
MYS      Malaysia      
NLD      Netherlands      
NOR      Norway       
NZL      New Zealand      
OMN      Oman       
POL      Poland       
PRT      Portugal     
ROU      Romania      
RUS      Russian Federation     
SGP      Singapore      
SVK      Slovakia
FYROM    The former Yugoslav Republic of Macedonia  
TGO      Togo       
TUR      Turkey       
USA      United States of America 
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Annex 3. Synthetic cathinones
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Annex 3. Synthetic cathinones
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Annex 4. Ketamine
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Annex 5. Phenethylamines
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Annex 8. Aminoindanes
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Annex 9. Phencyclidine-type substances
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Annex 10. Tryptamines
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